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Preamble 
It is important hat the medical profession play a significant 
role in critically evaluating the use of diagnostic procedures 
and therapies in the management or prevention of disease. 
Rigorous and expert analysis of the available data document- 
ing relative benefits and risks of those procedures and thera- 
pies can produce helpful guidelines that improve the effective- 
ness of care, optimize patient outcomes, and impact he overall 
cost of care favorably by focusing resources on the most 
effective strategies. 
The American College of Cardiology (ACC) and the Amer- 
ican Heart Association (AHA) have jointly engaged in the 
preparation of such guidelines in the area of cardiovascular 
disease since 1980. This effort is directed by the ACC/AHA 
Task Force on Practice Guidelines, which is charged with 
developing and revising practice guidelines for important 
cardiovascular diseases and procedures. Experts in the subject 
under consideration are selected from both organizations to 
examine subject-specific data and write guidelines. The process 
includes additional representatives from other medical pro- 
vider and specialty groups when appropriate. Writing groups 
are specifically charged to perform a formal literature review, 
weigh the strength of evidence for or against a particular 
treatment or procedure, and include estimates of expected- 
health outcomes in areas where data exist. Patient-specific 
modifiers, comorbidities, and issues of patient preference that 
might influence the choice of particular tests or therapies are 
considered, along with frequency of follow-up and cost- 
effectiveness. 
These practice guidelines are intended to assist physicians 
and other healthcare providers in clinical decision making by 
describing a range of generally acceptable approaches for the 
diagnosis, management, or prevention of specific diseases or 
conditions. These guidelines attempt o define practices that 
meet the needs of most patients in most circumstances. The 
ultimate judgment regarding care of a particular patient must 
be made by the physician and patient in light of circumstances 
specific to that patient. 
These guidelines have been officially endorsed by the 
American Society of Echocardiography, the American College 
of Emergency Physicians, and the American Association of 
Critical-Care Nurses. 
James L. Ritchie, MD, FACC 
Chair, ACC/AHA Task Force on Practice Guidelines 
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Executive Summary 
Purpose 
These guidelines are intended for physicians, nurses, and 
allied healthcare personnel who care for patients with sus- 
pected or established acute myocardial infarction (MI). 
This executive summary of the guidelines, plus a definition 
of the classes and a summary of recommendations, appears in 
the November 1, 1996, issue of Circulation. The guidelines in 
their entirety, including the ACC/AHA Class I, II, and III 
recommendations, are published in the November 1996 issue 
of the Journal of the American College of Cardiology. Beginning 
with these guidelines, the full text of ACC/AHA guidelines will 
be published in one journal and the executive summary and 
summary of recommendations i  the other. Reprints of both 
the full text and the executive summary and summary of 
recommendations are available from both organizations. 
Prehospital Issues 
Each year 900 000 people in the United States experience 
acute myocardial infarction (MI). Of these, roughly 225 000 
die, including 125 000 who die "in the field" before obtaining 
medical care. Most of these deaths are arrhythmic in etiology. 
Because arly reperfusion treatment of patients with acute MI 
improves left ventricular (LV) systolic function and survival, 
every effort must be made to minimize prehospital delay. 
Indeed, efforts are ongoing to promote rapid identification and 
treatment of patients with acute MI, including (1) patient 
education about the symptoms of acute MI and appropriate 
actions to take and (2) prompt initial care of the patient by the 
community emergency medical system. In treating the patient 
with chest pain, emergency medical system personnel must act 
with a sense of urgency. 
Initial Recognition and Management in the 
Emergency Department 
When the patient with suspected acute MI reaches the 
emergency department (ED), evaluation and initial manage- 
ment should take place promptly, because the benefit of 
reperfusion therapy is greatest if therapy is initiated early. The 
initial evaluation of the patient ideally should be accomplished 
within 10 minutes of his or her arrival in the ED; certainly no 
more than 20 minutes hould elapse before an assessment is 
made. On arrival in the ED the patient with suspected acute 
MI should immediately receive (1) oxygen by nasal prongs; (2) 
sublingual nitroglycerin (unless ystolic arterial pressure is less 
than 90 mm Hg or heart rate is less than 50 or greater than 100 
beats per minute [bpm]); (3) adequate analgesia (with mor- 
phine sulfate or meperidine); and (4) aspirin, 160 to 325 mg 
orally. A 12-lead electrocardiogram (ECG) should also be 
performed. ST-segment elevation (equal to or greater than 
1 mV) in contiguous leads provides trong evidence of throm- 
botic coronary arterial occlusion and makes the patient a 
candidate for immediate reperfusion therapy, either by fibri- 
nolysis or primary percutaneous transluminal coronary angio- 
plasty (PTCA). Symptoms consistent with acute MI and left 
bundle branch block (LBBB) should be managed like ST- 
segment elevation. In contrast, he patient without ST-segment 
elevation should not receive thrombolytic therapy. The benefit 
of primary PTCA in these patients remains uncertain. 
In comparison with standard medical therapy, thrombolytic 
therapy exerts a highly significant 21% proportional reduction 
in 35-day mortality among patients with acute MI and ST 
elevation, corresponding to an overall reduction of 21 deaths 
per 1000 patients treated. A powerful time-dependent effect on 
mortality has been observed in the administration of thrombo- 
lytic agents. The greatest benefit occurs when thrombolysis 
initiated within 6 hours of the onset of symptoms, although it 
exerts definite benefit when begun within 12 hours. An esti- 
mated 35 lives per 1000 patients treated are saved when 
thrombolysis used within the first hour of symptom onset, 
compared with 16 lives saved per 1000 treated when given 7 to 
12 hours after symptom onset. Thrombolysis benefits the 
patient irrespective of age and gender and the presence of 
comorbid conditions uch as diabetes mellitus, although the 
degree of benefit varies among patient groups. Thrombolytic 
therapy is associated with a slightly increased risk of intracra- 
nial hemorrhage (ICH) that usually occurs within the first day 
of therapy. Variables that appear to predict an increased risk 
of 1CH include age greater than 65 years, body weight less than 
70 kg, systemic arterial hypertension, and administration of 
tissue plasminogen activator (TPA). 
Primary PTCA may be performed as an alternative to 
thrombolytic therapy, provided that it can be accomplished in 
a timely fashion by persons skilled in the procedure and 
supported by experienced personnel. Prompt access to emer- 
gency coronary artery bypass graft (CABG) surgery must also 
be available if primary PTCA is to be undertaken. 
Once reperfusion therapy is initiated, the patient with 
suspected acute MI should be hospitalized. Subsequent short- 
and long-term management is similar, irrespective of the 
appearance of the initial ECG. Thus, following the initial 
triage decision regarding reperfusion therapy, treatment of the 
patient whose ECG initially showed ST-segment elevation or 
presumably new LBBB and who received reperfusion therapy 
is similar to that for the patient whose initial ECG failed to 
show ST-segment elevation or LBBB and who did not receive 
reperfusion therapy. 
Hospital Management 
The First 24 Hours 
Once hospitalized, the patient with acute MI should be 
continuously monitored by electrocardiography and the diag- 
nosis of acute MI confirmed by serial ECGs and measurements 
of serum cardiac markers of myocyte necrosis, such as creatine 
kinase isoenzymes or cardiac specific troponin T or I. The 
patient should be monitored closely for adverse lectrical or 
mechanical events because reinfarction and death occur most 
frequently within the first 24 hours. The patient's physical 
activities should be limited for at least 12 hours, and pain 
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and/or anxiety should be minimized with appropriate analge- 
sics. Although the use of prophylactic antiarrhythmic agents in 
the first 24 hours of hospitalization is not recommended, 
atropine, lidocaine, transcutaneous pacing patches or a trans- 
venous pacemaker, a defibrillator, and epinephrine should be 
immediately available. 
Patients who survive a large anterior MI or who have a LV 
mural thrombus een on echocardiography are at high risk of 
having an embolic stroke. Some data suggest hat this risk is 
reduced by early administration of intravenous heparin. For 
the patient without a large anterior MI or LV mural thrombus 
who did not receive reperfusion therapy, there are few data on 
the benefit of heparin beyond that of aspirin,/3-adrenoceptor 
blocking agents, nitrates, and angiotensin converting enzyme 
(ACE) inhibitors. For the patient given thrombolytic therapy, 
the recommendations for subsequent heparin administration 
are based more on current practice than on evidence and 
depend on the specific thrombolytic agent. There is only 
limited evidence that heparin (given intravenously or subcuta- 
neously) is beneficial in the patient who receives a nonspecific 
fibrinolytic agent such as streptokinase, anisoylated plasmino- 
gen streptokinase activator complex (APSAC), or urokinase. 
When TPA (alteplase) is administered, intravenous heparin 
increases the likelihood of patency in the infarct-related artery 
(assessed angiographically), but this may not necessarily ead 
to improved clinical outcome. Considering the superior per- 
formance of accelerated TPA plus intravenous heparin in the 
Global Utilization of Streptokinase and TPA for Occluded 
Arteries (GUSTO) trial, it seems judicious to give heparin 
intravenously for at least 48 hours after alteplase is given. 
When primary PTCA is performed, high-dose intravenous 
heparin is recommended. Aspirin, 160 to 325 mg daily, initially 
given in the ED, should be continued indefinitely. 
Despite the absence of definitive outcome data, it is rea- 
sonable to treat the patient with acute MI and without 
hypotension, bradycardia, or excessive tachycardia with intra- 
venous nitroglycerin for 24 to 48 hours after hospitalization. 
Concern exists about oral nitrate preparations in the patient 
with acute MI because of inability to titrate the dose to effect 
in an acutely evolving hemodynamic situation, whereas intra- 
venous infusion of nitroglycerin can be titrated successfully 
with frequent measurement of heart rate and cuff blood 
pressure. Nitroglycerin should not be used as a substitute for 
narcotic analgesics that are often required in the patient with 
acute MI. 
The patient with evolving acute MI should receive early 
intravenous /Ladrenergic blocker therapy, followed by oral 
therapy, provided that there is no contraindication. /3- 
Adrenoceptor blocker therapy should be initiated regardless of 
whether eperfusion therapy was given, because several studies 
in the prethrombolytic aswell as the thrombolytic era showed 
that/3-adrenoceptor blockers diminish morbidity and mortal- 
ity. Calcium channel blockers have not been shown to reduce 
mortality in patients with acute MI, and in certain persons with 
cardiovascular disease they appear to be harmful. In the 
patient without ST-segment elevation or LBBB in whom 
pulmonary congestion is absent, diltiazem may reduce the 
incidence of recurrent ischemic events, but its benefit beyond 
that of 13-adrenoceptor blockers and aspirin is unclear. 
Immediate-release dihydropyridines (eg, nifedipine) are con- 
traindicated in the patient with acute MI. 
In the patient with evolving acute MI with ST-segment 
elevation or LBBB, an ACE inhibitor should be initiated 
within hours of hospitalization, provided that the patient does 
not have hypotension or a contraindication. Subsequently, the 
ACE inhibitor should be continued indefinitely in the patient 
with impaired LV systolic function (ejection fraction less than 
40%) or clinical congestive heart failure (CHF). In patients 
without complications and no evidence of symptomatic or 
asymptomatic LV dysfunction by 6 weeks, ACE inhibitors can 
be stopped. On admission to the hospital, a lipid profile and 
serum electrolyte concentration (including magnesium) should 
be measured in all patients. 
After the First 24 Hours 
After the first day in the hospital, the patient with acute MI 
should continue to receive aspirin 160 to 325 mg/d indefinitely 
with a /3-adrenergic blocker; an ACE inhibitor should be 
administered for at least 6 weeks. Nitroglycerin should be 
infused intravenously for 24 to 48 hours, and magnesium 
sulfate should be given as needed to replete magnesium 
deficits for 24 hours. For the patient receiving alteplase, it is 
current practice to give intravenous heparin for an additional 
48 hours. 
Patients with myocardial ischemia that is spontaneous or 
provoked in the days to weeks after acute MI, irrespective of 
whether they received thrombolytic therapy, ordinarily should 
undergo elective angiographic evaluation, with subsequent 
consideration of percutaneous or surgical revascularization. 
There is considerable variability in the use of coronary angiog- 
raphy and catheter interventions among survivors of uncom- 
plicated acute MI with preserved LV systolic function. Al- 
though some practitioners outinely perform angiography and 
PTCA during the days after acute MI in virtually all patients, 
the available data suggest hat such a management s rategy 
does not salvage myocardium nor reduce the incidence of 
reinfarction or death. Accordingly, coronary angiography and 
subsequent revascularization should be reserved for survivors 
of acute MI who have preserved LV systolic function and 
spontaneous or provoked ischemia. 
During hospitalization the patient with acute MI should be 
closely observed for prompt recognition and management of
complications. The patient with recurrent chest pain believed 
due to pericarditis hould receive high-dose aspirin (650 mg 
every 4 to 6 hours). Recurrent chest discomfort thought o be 
caused by myocardial ischemia should be treated with intrave- 
nous nitroglycerin, analgesics, and antithrombotic medications 
(aspirin, heparin). Coronary angiography with subsequent re- 
vascularization therapy should be considered. The patient with 
heart failure should receive a diuretic (usually intravenous 
furosemide) and an afterload-reducing a ent. For the patient 
in cardiogenic shock, consideration should be given to inser- 
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tion of an intra-aortic balloon pump and emergency coronary 
angiography, followed by PTCA or CABG. The patient with 
right ventricular infarction and dysfunction should be treated 
vigorously with intravascular volume expansion (using normal 
saline) and inotropic agents if hypotension persists. 
In the patient with acute MI, the appearance of atrial 
fibrillation is often a manifestation of extensive LV systolic 
dysfunction. If its occurrence causes hemodynamic compro- 
mise or ongoing ischemia, direct-current cardioversion should 
be performed. In the absence of these,/3-adrenoceptor bl ck- 
ing agents or digitalis should be given to slow the ventricular 
response. Episodes of ventricular fibrillation should be treated 
with immediate direct-current countershock; the same is true 
for episodes of monomorphic ventricular tachycardia ssoci- 
ated with angina, pulmonary congestion, or hypotension. If
monomorphic ventricular tachycardia is not accompanied by 
chest pain, pulmonary congestion, or hypotension, it should be 
treated with intravenous lidocaine, procainamide, or amioda- 
tone .  
The patient with acute MI and symptomatic sinus brady- 
cardia or atrioventricular block should receive atropine. Tem- 
porary pacing should be performed in the patient with (1) sinus 
bradycardia unresponsive to drug therapy, (2) Mobitz type II 
second-degree atrioventricular block, (3) third-degree heart 
block, (4) bilateral bundle branch block (BBB), (5) newly 
acquired BBB, and (6) right or left BBB in conjunction with 
first-degree atrioventricular block. 
Immediate surgical intervention is often required for the 
patient with (1) failed PTCA with persistent chest pain or 
hemodynamic instability; (2) persistent or recurrent ischemia 
refractory to medical therapy who is not a candidate for 
catheter intervention; (3) cardiogenic shock and coronary 
anatomy not amenable to PTCA; or (4) a mechanical abnor- 
mality leading to severe pulmonary congestion or hypotension, 
such as papillary muscle rupture (with resultant mitral regur- 
gitation) or ventricular septal defect (VSD). 
Preparation for Discharge From the Hospital 
Before hospital discharge or shortly thereafter, the patient 
with recent acute MI should undergo standard exercise testing 
(submaximal t 4 to 7 days or symptom limited at 10 to 14 
days). This is done to (1) assess the patient's functional 
capacity and ability to perform tasks at home and work, (2) 
evaluate the efficacy of the patient's current medical regimen, 
and (3) stratify risk for a subsequent cardiac event. The 
incremental value of radionuclide imaging or echocardiogra- 
play during exercise is uncertain. Although markers of electri- 
cal instability such as abnormal baroreftex stimulation or the 
presence of late potentials on a signal-averaged ECG are 
associated with increased risk of death, their positive predictive 
value is low, and appropriate therapy when these findings are 
observed is yet to be determined. 
Long-Term Management 
For an indefinite period after acute MI, the patient should 
continue to receive aspirin, a/3-adrenoceptor blocker, and a 
selected dose of an ACE inhibitor. The patient should be 
instructed to achieve an ideal weight and educated about a diet 
low in saturated fat and cholesterol. The patient with a 
low-density lipoprotein (LDL) cholesterol measurement 
greater than 130 mg/dL despite diet should be given drug 
therapy with the goal of reducing LDL to less than 100 rag/alL. 
Smoking cessation is essential. Finally, the patient should be 
encouraged to participate in a formal rehabilitation program 
and ultimately to plan to engage in 20 minutes of exercise at 
the level of brisk walking at least three times a week. 
1336 RYAN ET AL. JACC Vol. 28, No. 5 
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION November 1, 1996:1328-428 
Guidelines for the Management 
of Patients With Acute 
Myocardial Infarction 
I. In t roduct ion  
The ACC/AHA statement "Guidelines for the Early Man- 
agement of Patients with Acute Myocardial Infarction" was 
introduced in 1990,1 following a time during which advances in 
cardiovascular knowledge and therapies proceeded at a pace 
and scope remarkable even for this century. A substantial body 
of knowledge and considerable clinical experience was gained 
in the last decade, and ACC/AHA leaders believed there was 
a compelling need to summarize this experience and provide 
guidelines for appropriate management of patients with acute 
MI. At that time the authors of the guidelines tated that 
although they believed they were "shooting at a moving 
target," enough ad been established to develop appropriate 
guidelines. The guidelines were not intended as a rigid pre- 
scription but rather as a guide to be modified by clinical 
judgment, individual patient needs, and the findings of new 
studies. Revision of the original guidelines was clearly envi- 
sioned. 
The current committee was convened by the ACC/AHA 
Task Force on Practice Guidelines and charged at its first 
meeting, held November 12, 1994, "to review a critical body of 
knowledge that has accumulated since 1990 and recommend 
whatever changes or revisions of the original guidelines that 
seem appropriate." The committee held seven 2-day meetings, 
convened 11 conference calls, and concluded its business at a 
final meeting held March 24, 1996. Pertinent medical literature 
in the English language was identified by a search of standard 
library databases for the 5 years preceding uideline develop- 
ment. An estimated 5000 publications were reviewed by com- 
mittee members during the course of their deliberations. The 
committee r viewed many documents on the management or 
aspects of management of patients with acute MI published by 
other organizations, uch as the American College of Chest 
Physicians, the American College of Physicians, the Canadian 
Cardiovascular Society, and the European Society of Cardiol- 
ogy; in addition, the committee made every effort to adhere to 
well-established guidelines uch as those for advanced cardiac 
life support (ACLS) and use of automatic defibrillation. 
The committee compiled and ranked the evidence, with the 
weight of evidence ranked highest (A) if the data were derived 
from multiple randomized clinical trials involving large num- 
bers of individuals. An intermediate rank (B) was given when 
the data were derived from a limited number of trials involving 
comparatively small numbers of patients or from well- 
conceived ata analyses of nonrandomized studies or observa- 
tional data registries. A lower rank (C) was given when 
consensus opinion of experts was the primary source of a 
recommendation. In the interest of ease of use, these vidence 
ranks are not published in the final document but are available 
upon request. The analysis of the available vidence, as well as 
its quality, was critical in making final recommendations a d is 
developed inthe text in detail. Similarly, when no evidence was 
available, this is noted in the text. 
The final recommendations for indications for a diagnostic 
procedure, a particular therapy, or an intervention summarize 
both the evidence and expert opinion and are expressed in the 
ACC/AHA format as follows: 
Class I: Conditions for which there is evidence and/or 
general agreement hat a given procedure or treatment is 
beneficial, useful, and effective. 
Class II: Conditions for which there is conflicting evidence 
and/or a divergence of opinion about the usefulness/efficacy of 
a procedure or treatment. 
Class IIa: Weight of evidence/opinion is in favor 
of usefulness/efficacy. 
Class lib: Usefulness/efficacy is less well estab- 
lished by evidence/opinion. 
Class III" Conditions for which there is evidence and/or 
general agreement hat a procedure/treatment is not useful/ 
effective and in some cases may be harmful. 
Literature citations were generally restricted to published 
manuscripts appearing in journals listed in Index Medicus. 
Because of the scope and importance of certain ongoing 
clinical trials and other emerging information, published ab- 
stracts (previously refereed) were cited when they were the 
only published information available. 
The emphasis of the committee's review reflected the 
current rend in the practice of medicine, which is making a 
transition from practice patterns driven by pathophysiological 
and nonquantitative reasoning to a broad belief in "evidence- 
based medicine." Nowhere has this concept been more firmly 
embraced than in the treatment ofcardiovascular disease, and 
it was greatly influenced by the recent demonstration in clinical 
trials that concepts eemingly quite rational and widely ac- 
cepted have been associated with substantial dverse ffects on 
mortality. 2 Despite the recognized importance of empirical 
evidence to guide therapeutic decisions, it has been only since 
the advent of computers that computational nd organiza- 
tional capabilities have begun to meet the need. As a conse- 
quence, the medical community is in the rapid growth phase of 
learning bow to assimilate and interpret clinical trials and 
observational databases. 
Although these guidelines have been shaped largely within 
the context of evidence-based medical practice, the committee 
clearly understands that variations in inclusion and exclusion 
criteria from one randomized trial to another impose some 
limitation on the generalizability of their findings. Likewise, in its 
efforts to reconcile conflicting data, the committee mphasized 
the importance of properly characterizing the population under 
study. Not all patients diagnosed with acute MI are alike. For 
example, those diagnosed with acute MI on entry into the medical 
care system differ considerably from those whose diagnosis be- 
comes evident late after admission and appears not as the 
admission diagnosis but only as the discharge diagnosis. In the 
former, thrombolytic therapy is feasible, whereas in the latter it is 
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not. Studies examining "processes of care" in acute MI will be 
greatly influenced by such considerations. 
In the first half of this decade rapid changes in the natural 
history of patients with acute MI have continued, and the 
committee r cognizes the establishment of he reperfusion era. 
In this era a constellation of therapies in the management of 
patients with acute MI has been introduced, and therapy isnot 
limited just to the widespread use of thrombolytic agents, 
PTCA, and emergency CABG surgery in suitable patients. The 
reperfusion era also embraces the extensive use of aspirin, 
/3-adrenoceptor blocking agents, vasodilator therapy, and the 
common use of ACE inhibitors. In addition, this era has 
witnessed far more aggressive use of cardiac catheterization 
and revascularization techniques inpatients with clinical mark- 
ers of a poor prognosis (eg, hypotension, CHF, and continuing 
ischemia). The combined use of all these therapies has resulted 
in an impressive reduction in early and l-year mortality for 
patients with acute MI. 
As a consequence of this improved survival rate, patients 
now under observation, such as those enrolled in recent 
thrombolysis trials, have low rates for subsequent cardiac 
events. This substantially reduces the predictive accuracy of 
many tests previously used in risk stratification. Therefore, 
many gains have resulted in the need to rethink some diagnos- 
tic and therapeutic strategies. 
It is the aim of these revised guidelines to reflect what the 
committee has identified as the most important changes to be 
made in thinking about patients with acute MI. Many therapies 
and procedures incurrent use are not based on sound scientific 
evidence. The committee proposes the abandonment of such 
therapies and procedures that can be identified with confi- 
dence. On the other hand, new information suggests that a 
practical division of all patients with acute MI is to classify 
them as those with ST-segment elevation and those without it. 
Evidence now shows a distinction in pathoanatomy between 
the two that demands different therapeutic approaches. Ample 
evidence exists that persons with suspected MI and ST- 
segment elevation or BBB should undergo immediate reper- 
fusion, and those without hese findings hould not. 
Committee members were selected from cardiovascular 
specialists with broad geographical representation a d com- 
bined involvement inacademic medicine and primary practice. 
The Committee on Management ofAcute Myocardial Infarc- 
tion was also broadened by members of the American Acad- 
emy of Family Physicians, the American College of Emergency 
Physicians, the AHA Council on Cardiovascular Nursing, and 
the American Association of Critical-Care Nurses. 
The committee was chaired by Thomas J. Ryan, MD, and 
included the following members: Jeffrey L. Anderson, MD; 
Elliott M. Antman, MD; Blaine A. Braniff, MD; Nell H. 
Brooks, MD; Robert M. Califf, MD; L. David Hillis, MD; 
Loren F. Hiratzka, MD; Elliot Rapaport, MD; Barbara J. 
Riegel, DNSc; Richard O. Russell, MD; Earl E. Smith IlI, 
MD; and W. Douglas Weaver, MD. 
This document was reviewed by three outside reviewers 
nominated by the ACC and three outside reviewers nominated 
by the AHA, as well as individuals from the American Acad- 
emy of Family Physicians, the American College of Emergency 
Physicians, the American Association of Critical-Care Nurses, 
the AHA Council on Cardiovascular Nursing, the American 
Society of Echocardiography, and the American Society of 
Nuclear Cardiology. 
"ACC/AHA Guidelines for the Management of Patients 
With Acute Myocardial Infarction" was approved for publica- 
tion by the governing bodies of the American College of 
Cardiology and the American Heart Association. These guide- 
lines will be reviewed 2 years after publication and yearly 
thereafter and considered current unless the task force revises 
or withdraws them from distribution. 
II. P rehosp i ta l  I ssues  
Recommendations 
Class I 
1. Availability of 911 access. 
2. Availability of an emergency medical services (EMS) 
system staffed by persons trained to treat cardiac arrest with 
defibrillation if indicated and to triage patients with ischemic- 
type chest discomfort. 
Class Ila 
1. Availability of a first-responder defibrillation program 
in a tiered response system. 
2. Heaithcare providers educate patients/families about 
signs and symptoms of acute MI, accessing EMS, and medi- 
cations. 
Class lib 
1. Twelve-lead telemetry. 
2. Prehospital thrombolysis in special circumstances (eg, 
transport time greater than 90 minutes). 
Each year approximately 900 000 persons in the United 
States experience acute MI, and about 225 000 of them die. At 
least one half of these persons die within 1 hour of onset of 
symptoms and before reaching a hospital emergency depart- 
ment. 3-4 It has been recognized for more than 3 decades that 
the majority of these sudden cardiac deaths are the result of 
fatal arrhythmias that often can be stopped by emergency 
cardiopulmonary esuscitation (CPR), defibrillation, and 
prompt ACLS. More recent data regarding the time- 
dependent benefits of thrombolytic therapy provide added 
stimulus to develop more effective means of expediting deliv- 
ery of medical care to persons with acute MI. It has been 
shown that early treatment results in reductions in mortality, 
infarct size, and improved LV function? -7Clearly, delay in 
treating patients with suspected acute MI is a critical factor in 
decreasing the overall survival rate. For these reasons the 
National Heart, Lung, and Blood Institute (NHLBI) has 
initiated the National Heart Attack Alert Program (NHAAP), 
a coordinated national program that extends the ACC/AHA 
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recommendations promoting rapid identification and treat- 
ment of patients with acute MI. s,9 
Recognition and Management 
It has been demonstrated that most patients do not seek 
medical care for 2 hours or more after symptom onset. A 
sizable proportion wait 12 hours or more. In general, reperfu- 
sion therapy beyond 12 hours may offer little benefit. 8,9 The 
components ofdelay from symptom onset o treatment are (1) 
patient related (ie, failure to recognize the seriousness of the 
problem and delay in seeking emergency care); (2) prehospital 
evaluation, treatment, and transport imes; and (3) time re- 
quired for diagnosis and initiation of treatment in the hospital. 
In most cases, patient-related delay is the longest, but each 
component moves the patient further away from the golden 
first hour to a time when the effect of treatment is lessened. 
Effective early intervention cannot occur without appropriate 
patient and family action early after symptom onset. 
Intervention Strategies 
Interventions to minimize patient delay are primarily edu- 
cational in nature and focus on what to do when ischemic-type 
chest discomfort occurs. Patients with known heart disease or 
those at high risk of acute MI should be educated by physi- 
cians, nurses, and staff about common symptoms of acute MI 
and appropriate actions to take after symptom onset. Patients 
should be given an action plan that covers (1) prompt use of 
aspirin and nitroglycerin if available, (2) how to access EMS, 
and (3) location of the nearest hospital that offers 24-hour 
emergency ardiac are. Ideally patients hould be given a copy 
of their resting ECG as a baseline to aid physicians in the 
emergency department. Because chest discomfort is the most 
common symptom of infarction,~° patients need simple instruc- 
tions to respond effectively. In addition to being made aware 
that chest discomfort may be more of a pressure sensation than 
actual pain, they should understand that the discomfort can be 
referred to the arm, throat, and lower jaw and can be accom- 
panied by breathing difficulty, diaphoresis, or a feeling of 
impending doom. 11.lz Reviewing the description of possible 
symptoms and the action plan in simple, understandable terms 
at each visit is extremely important, because studies have 
indicated that many patients minimize the importance of their 
symptoms or deny the possibility of acute MI. 12,13 Discussions 
with patients should emphasize the importance of acting 
promptly. Family members hould be included in these discus- 
sions and enlisted as advocates for action when symptoms of 
infarction are apparent. 8 H 
The role of medications to be taken at onset of symptoms 
must be tailored to each individual. Current advice is to take 1 
nitroglycerin tablet sublingually at the onset of ischemic-type 
chest discomfort and another every 5 minutes for a total of 3 
doses. If symptoms persist, the patient should call 911 emer- 
gency services or obtain other emergency transportation tothe 
hospital--not he physician's office. The hospital should be 
staffed round-the-clock by physicians and nurses competent in
(1) performing an initial evaluation, including an ECG, (2) 
providing cardiac monitoring and ACLS, and (3) providing 
reperfusion therapy. Patients who can be identified in the field 
as being at high risk with signs of shock, pulmonary congestion, 
heart rate greater than 100 bpm, and systolic blood pressure 
less than 100 mm Hg ideally should be triaged to facilities 
capable of cardiac catheterization and revascularization. Al- 
though it has not yet been demonstrated that initial triage of 
such patients to tertiary centers results in improved outcome 
compared with initial management in primary facilities, this 
approach has the desirable effect of obviating the need of 
emergency transfer of a critically ill patient from one hospital 
to another, interrupting intensive nursing care and possibly 
delaying diagnosis and treatment. 
Use of the EMS system almost always decreases delays in 
initiation of definitive care/Accordingly, the physician should 
discuss the use of 911 or other local emergency numbers with 
the patient and should also be aware of the nature and 
capability of the care that will be rendered. The physician 
should know whether or not the local EMS system can provide 
defibrillation and other lifesaving care and should also be 
familiar with the triage strategy for patients with suspected MI. 
Emergency Medical Services Systems 
Each community prehospital EMS system should develop a
plan to triage and provide rapid initial medical care to patients 
with ischemic-type chest discomfort. In most cities in the 
United States trained emergency medical technicians (EMTs) 
work in several different healthcare settings: (1) the emergency 
medical section of the fire department, (2) hospital-based 
ambulance systems, and (3) department of health services. To 
minimize time to treatment, particularly for cardiopulmonary 
arrest, many systems incorporate professional first responders 
to provide CPR and defibrillation. Ideally there should be a 
sufficient number of trained personnel so that a first responder 
can be at the victim's side within 5 minutes. Public service 
personnel such as police, firefighters, public works employees, 
and other first-aid providers have frequently been trained 
successfully as first responders. A sense of urgency in managing 
patients with ischemic-type chest discomfort must be imparted 
to EMS personnel. Rapid identification and treatment of the 
acute MI patient is imperative. 
Early access to EMS is promoted by a 911 system currently 
available to 80% of the United States population. 8,9 Enhanced 
911 systems provide the caller's location, permitting rapid 
dispatch of prehospital personnel to locations even if the caller 
is not capable of verbalizing or the dispatcher cannot under- 
stand the location of the emergency. Unfortunately the capa- 
bilities of EMS systems vary considerably among communities, 
some providing little beyond first aid, whereas others have 
formal, advanced protocols for the management of patients 
with suspected MI or ischemic-type chest discomfort. The 
latter offers promise in favorably influencing outcomes in such 
patients. Because patients with acute MI are at relatively high 
risk of sudden death during the first hour after onset of 
symptoms, a prehospital EMS system that can provide defibril- 
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Table 1. Chest Pain Checklist for Use by EMT/Paramedic for 
Diagnosis of Acute Myocardial Infarction and Thrombolytic 
Therapy Screening 
Check each finding below. If all [yes] boxes are checked and ECG indicates 
ST elevation or new BBB, reperfusion therapy with thrombolysis or primary. 
PTCA may be indicated. Thrombolysis generally not indicated unless all 
[no] boxes are checked and BP <-180/110 mm Hg. 
Ongoing chest discomfort (->20 rain and <12 h) 
Oriented, can cooperate 
Age >35 y (>40 if female) 
Histo~, of stroke or TIA 
Known bleeding disorder 
Active internal bleeding in past 2 weeks 
Surge~' or trauma in past 2 weeks 
Terminal illness 
Jaundice, hepatitis, kidney failure 




Systolic/diastolic blood pressure 
Right arm: , ~  
Left arm: / 
Yes No 
ECG done 21 
High-risk profile * Yes No 
Heart rate ->100 bpm 7_1 
BP -<100 mm Hg ~1 
Pulmona~' edema (rales greater than one half way' up) 21 __  
Shock j 
• Transport to hospital capable of angiography and revascularization if needed. 
Pain began AM/PM 
Arrival time AM/PM 
Begin transport AM/PM 
Hospital arrival AM/PM 
EMT indicates emergency medical technician: ECG, electrocardiogram; 
BBB, bundle branch block; PTCA, percutaneous transluminal coronary, anglo- 
plash; BP, blood pressure; TIA, transient ischemic attack. Adapted from the 
Seattle/King County. EMS Medical Record. 
lation is mandatory. ~,~a The survival of patients who develop 
ischemia-induced ventricular fibrillation (VF) depends on 
rapid deployment ofdefibrillation. The survival rate of prehos- 
pital treatment for all patients with cardiac arrest (those with 
and without acute MI) varies from 1% to 25%fl 5d9 If VF 
occurs under observation and immediate defibrillation is suc- 
cessful, almost all such patients urvive and recover complete- 
ly. 2° Therefore, the AHA has recommended that every ambu- 
lance that transports cardiac arrest victims should be equipped 
with a defibrillator. 2~ However, this goal is yet to be realized. 
Automated external defibrillators (AEDs) have been shown 
to be effective and safe. 18,19.21-23 They can be used by first 
responders with a minimum of training to quickly and accu- 
rately analyze rhythms and deliver defibrillation shocks to 
patients in VF. Systems that incorporate AEDs to shorten 
response times are highly desirable. Prehospital providers 
trained and capable of providing ACLS with drugs, intubation, 
and other therapy further improve the patient's chances for 
survival. 
Undirected prehospital assessments of patients with 
ischemic-type chest discomfort can lead to excessive valuation 
times and can impede rapid delivery of appropriate therapy. 24 
Procedures need to be in place for each EMS system so that a 
targeted history, physical examination, prehospital ECG, and 
initial treatment take place in 20 minutes or less. Recently, 
highly skilled prehospital healthcare providers have been 
trained and equipped to evaluate patients with ischemic-type 
chest discomfort by using a checklist and performing 12-lead 
ECGs in the prehospital setting (Table 1). The checklist should 
be designed to determine the likelihood of MI and the 
presence or absence of comorbid conditions and underlying 
conditions in which thrombolytic therapy may be hazardous. 
The checklist should facilitate detection of patients with sus- 
pected MI who are at especially high risk, including those with 
tachycardia (_>100 bpm), hypotension (-<100 mm Hg), or signs 
of shock or pulmonary edema. If available, prehospital ECGs 
should be obtained in all patients with ischemic-type chest 
discomfort and transmitted to the ED physician for interpre- 
tation and instructions. Such advances accelerate the initial 
diagnosis and administration of thrombolytic agents after the 
patient's arrival in the ED. 5,25,26 Active involvement of local 
healthcare providers--particularly cardiologists and emer- 
gency physicians--is needed to formulate local EMS protocols 
for patients with suspected MI, provide training, and secure 
equipment. Virtually all states have regulations and standards 
for emergency personnel, training, and equipment. It is useful 
for those involved in the emergency care of patients with acute 
MI to be familiar with these regulations. 
Prehospital-Initiated Thrombolysis 
Randomized controlled trials of fibrinolytic therapy have 
demonstrated the benefit of initiating thrombolytic therapy as 
early as possible after onset of ischemic-type chest 
discomfort. 27-29 It seems rational therefore to expect hat if 
thrombolytic therapy could be started at the time of prehospi- 
tal evaluation, a greater number of lives could be saved. The 
value of reducing delay until treatment depends not only on 
the amount of time saved but when it occurs. Available data 
suggest that time saved within the first 1 to 2 hours has greater 
biological importance than time saved during the later stages 
of acute MI. 5,7,27,28,3° Several randomized trials of prehospital- 
initiated thrombolysis have advanced our understanding of the 
impact of early treatment. 5,31-34 Acquisition of ECGs in the 
field and use of a chest-pain checklist (Table 1) leads to more 
rapid prehospital and hospital care. 5,26 Although none of the 
individual trials showed a reduction in mortality with 
prehospital-initiated thrombolytic therapy, a meta-analysis of
all available trials demonstrated a 17% relative improvement 
in outcome associated with prehospital therapy (95% confi- 
dence interval [CI], 2% to 29%). 34 The greatest improvement 
in outcome is observed when treatment can be initiated in the 
field 60 to 90 minutes earlier than in the hospital. 5,33-35 
Although prehospital-initiated thrombolytic therapy results 
in earlier treatment, he time savings can be offset in most 
cases by an improved hospital triage with resultant "door-to- 
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needle time" reduced to 30 minutes or less. 4 However, only a 
small percentage (5% to 10%) of patients with chest pain in 
the prehospital setting have acute MI and are eligible for 
thrombolytic therapy. 5 2s,3~' Ensuring proper selection of pa- 
tients for therapy can be dill]cult, and avoiding therapy when it 
is contraindicated has important medical, legal, and economic 
implications. For these reasons, a general national policy of 
prehospital thrombolytic therapy cannot currently be advo- 
cated. However, in special settings in which physicians are 
present in the ambulance or prehospital transport times are 90 
minutes or longer, this therapeutic strategy should be consid- 
ered. Observations from prehospital trials suggest that prehos- 
pital systems should focus on early diagnosis (a relatively minor 
augmentation i prehospital services) instead of delivery of 
therapy. 
I I l .  Init ial  Recogni t ion  and Management  in 
the Emergency  Depar tment  
Recommendation 
Class I 
1. Emergency department acute MI protocol that yields a 
targeted clinical examination and a 12-lead ECG within 10 
minutes and a door-to-needle time that is less than 30 
minutes. 
Detection~Quantification and Risk Assessment 
Physicians evaluating patients in the ED for possible admis- 
sion to the coronary care unit (CCU) face the difficult task of 
avoiding unnecessary admissions but also minimizing the num- 
ber of patients discharged home inappropriately. Certain sub- 
groups of patients are known to present with unusual symp- 
toms of acute MI. Women often experience atypical ischemic- 
type chest discomforts while the elderly may complain of 
shortness of breath more frequently than ischemic-type chest 
discomfortY In addition, with the advent of reperfusion 
therapy and the desire to minimize door-to-needle time for 
administration of thrombolytic agents or rapid triage to the 
catheterization laboratory for primary PTCA, there is a clear 
need for better methods of prompt identification of patients 
experiencing a true acute MI as accurately and as soon as 
possible. The ECG and a history of ischemic-type chest 
discomfort remain the primary methods for screening patients 
for myocardial ischemia and infarction. The 12-lead ECG in 
the ED is at the center of the decision pathway because of the 
strong evidence that ST-segment elevation identifies patients 
who benefit from reperfusion therapy. In patients with 
ischemic-type chest discomfort, ST-segment elevation on the 
ECG has a specificity of 91% and a sensitivity of 46% for 
diagnosing acute MI? s Mortality increases with the number of 
ECG leads showing ST elevation. > Current data do not 
support administration of thrombolytic agents to patients 
without ST elevation or BBB, and the benefit of primary PTCA 
remains uncertain in this population. However, it remains 
important o admit such patients to the hospital for medical 
therapy and possible cardiac catheterization (Fig 1). 
Initial errors in ECG interpretation can result in up to 12% 
of patients being categorized inappropriately (ST elevation 
versus no elevation), demonstrating a potential benefit of 
accurate computer-interpreted electrocardiography and fac- 
simile transmission to an expert. Other decision aids such as 
high-risk clinical indicators, 4°,41 rapid determination of car- 
diac serum markers, 42,43 two-dimensional echocardiographic 
screening for regional wall motion abnormalities, 44 myocardial 
perfusion imaging, 45 and computer-based diagnostic aids 46,47 
are of greatest importance in patients in whom the ECG is 
nondiagnostic. Two-dimensional echocardiography (trans- 
thoracic and transesophageal) is of particular value for rapid 
triage decisions in patients suspected of having an aortic 
dissection. Because lethal ventricular arrhythmias may develop 
abruptly in patients with an acute coronary syndrome, all 
patients hould be monitored electrocardiographically on ar- 
rival in the ED. It is important o examine serial tracings 
during evaluation in the ED for development of ST elevation, 
an event hat may be detected by intermittent visual inspection 
of the oscilloscope or auditory alarms in systems with contin- 
uous ST-monitoring capability. 
All patients with complicated infarctions (eg, cardiogenic 
shock) and/or those requiring sophisticated, labor-intensive 
treatments (eg, intra-aortic balloon counterpulsation) should 
be admitted to the CCU. In many hospitals physicians admit 
low-risk MI patients to a coronary observation unit or tele- 
metry unit where electrocardiographic monitoring and defibril- 
lation equipment are available, but other forms of monitoring 
are not, and staffing is reduced. 
According to the World Health Organization (WHO) def- 
inition, the diagnosis of MI is based on the presence of at least 
two of the following three criteria: (1) a clinical history of 
ischemic-type chest discomfort, (2) changes on serially ob- 
tained electrocardiographic tracings, and (3) a rise and fall in 
serum cardiac markers. 1°,4s Approximately 70% to 80% of 
patients with MI present with ischemic-type chest discom- 
fort. 49,5o Conversely, less than 25% of patients admitted to the 
hospital with ischemic-type chest discomfort are subsequently 
diagnosed as having had an acute MI. 51,52 Although ST- 
segment elevation and/or Q waves on the ECG are highly 
indicative of MI, about 50% of patients with MI do not exhibit 
ST elevation 53 but display other or nondiagnostic ECG 
changes, 4Thus, for the majority of patients, the laboratory plays 
an essential role in establishing the diagnosis of MI (Fig 2). 
An ideal serum marker of MI should be present early and 
in high concentration i  the myocardium and should be absent 
from nonmyocardial tissue and serum. 55.56 It should be rapidly 
released into the blood after myocardial injury, and there 
should be a stoichiometric relation between the plasma level of 
the marker and the extent of myocardial injury. The marker 
should persist in blood for a sufficient length of time to provide 
a convenient diagnostic time window. Finally, measurement 
should be easy, inexpensive, and rapid. 57 
Creatine kinase-MB (CK-MB) is the current standard 
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laboratory test for confirmation of MI, although it is by no 
means perfect. 55-57 Its drawbacks include lack of specificity for 
cardiac muscle, resulting in false-positive r sults and inability 
to detect MI with sufficient sensitivity in the first 6 to 8 
hours, sS,ss There is also uncertainty regarding the meaning of 
increased levels of CK-MB in the presence of normal total CK 
levels. In addition, CK-MB is excreted rapidly and usually does 
not remain elevated in the blood more than 72 hours, s6 
CK-MB exists in only one form in myocardial tissue but in 
different isoforms (or subforms) in the plasma. An absolute 
level of CK-MB 2 greater than 1 U/L or a ratio of CK-MB 2 to 
CK-MB1 of 1.5 has improved sensitivity and specificity for 
diagnosis of MI within the first 6 hours as compared with 
conventional ssays for CK-MB. 5~ Cardiac specific troponin T
(cTnT) and I (cTnI) are new markers for acute MI. 5s,6°.6~ Rapid 
whole blood bedside assays are now available, and increases in 
serum levels of cTnT and cTnI may therefore occur relatively 
early after muscle damage and may be present for several days 
after MI (up to 7 days for cTnI and up to 10 to 14 days for 
cTnT). 6~ An elevated cTnT level (greater than 0.1 ng/mL) on 
admission in a patient with an acute coronary syndrome is an 
important indicator of subsequent cardiac events. ~2,63 
Myoglobin, a low molecular weight heme protein found in 
cardiac and skeletal muscle, is released more rapidly from 
infarcted myocardium than CK-MB but is also excreted rapidly 
by renal clearance. Although myoglobin elevations may be 
seen as early as 2 hours after infarction, the lack of cardiac 
specificity suggests a need for confirmation of the cardiac 
Figure I. Algorithm for management of patients with suspected acute 
myocardial nfarction i the emergency department (ED). All patients 
with ischemic-type chest discomfort should be evaluated rapidly and 
receive aspirin. The initial 12-lead electrocardiogram (ECG) is used to 
define the acute management strategy. Patients with ST-segment eleva- 
tion or new or presumably new bundle branch block (BBB) should be 
considered candidates forreperfusion; those without ST-segment eleva- 
tion but with an ECG and clinical history that are strongly suspicious for 
ischemia should be admitted for initiation of anti-ischemic therapy (see 
Fig 4). Patients with a normal or nondiagnostic ECG should undergo 
further evaluation i  the ED or short-term observation u til results of 
serial serum cardiac marker levels are obtained. The following routine 
blood tests hould be obtained inall patients admitted: a complete blood 
count (CBC), lipid profile, and electrol~e levels. Tw indicates Y wave; 
PTCA, percutaneous transluminal coronary angioplasty. Adapted from 
Antman EM, Braunwald E.Acute myocardial nfarction. In: Braunwald 
EB, ed. Heart Disease: A Textbook of Cardiovascular Medicine, 1996, 
Philadelphia, Pa: WB Saunders. 
source of myoglobin by supplementary tests uch as CK-MB or 
cardiac specific troponin (Table 2). 64,65 
Assays for biochemical markers of myocardial necrosis must 
be interpreted in the context of the time-dependent process of 
MI. Some markers may be more efficient at detecting MI in 
patients presenting early (eg, myoglobin), while others are useful 
for detecting patients who present late (eg, cardiac specific 
troponin T and troponin I). A major difficulty in interpreting the 
results of clinical trials with biochemical markers is the lack of a 
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Figure 2. Nomenclature of acute coronary syndromes. Patients with 
ischemic discomfort may present with or without ST-segment elevation 
on the electrocardiogram. The majority (large arrow) of patients with 
ST-segment elevation ultimately develop a Q wave acute myocardial 
infarction (AMI), while a minority (small arrow) develop a non-Q 
wave AMI. Of patients who present without ST-segment elevation, the 
majority (large arrows) are ultimately diagnosed as either unstable 
angina or non-Q wave AMI based on the presence or absence of a 
cardiac marker such as CK-MB detected in the serum; a minority of 
such patients ultimately develop a Q wave AMI. The spectrum of 
clinical conditions ranging from unstable angina to non-Q wave AMI 
and Q wave AMI is referred to as acute coronary syndromes. *Positive 
serum cardiac marker. Adapted from Antman EM, Braunwald E. 
Acute myocardial infarction. In: Braunwald EB, ed. Heart Disease: A
Textbook of Cardiovascular Medicine, 1996, Philadelphia, Pa: WB 
Saunders. 
clear gold standard. The WHO criteria are inadequate for many 
cases of MI, especially when CK and CK-MB values are only 
minimally elevated above the normal range. 
Routine Measures (Oxygen, Nitroglycerin, Aspirin) 
Recommendations 
Class I 
1. Supplemental oxygen, intravenous access, and continu- 
ous electrocardiographic monitoring should be established in 
all patients with acute ischemic-type chest discomfort. 
2. An ECG should be obtained and interpreted within 10 
minutes of arrival in the ED in all patients with suspected 
acute ischemic-type chest discomfort. 
Although the specific diagnosis of acute MI can be made 
with absolute certainty only occasionally at the time of a 
patient's entry into the healthcare system, the immediate 
management of all acute coronary syndromes i generally the 
same. All patients uspected of having an acute MI should have 
a clinical and electrocardiographic evaluation that is prompt 
and targeted to estimate the likelihood that the presenting 
condition is an acute MI as opposed to one of its potentially 
lethal mimics: aortic dissection, acute pericarditis, acute myo- 
carditis, spontaneous pneumothorax, or pulmonary embolism. 
Although local settings vary widely, the entry process 
should be completed by a health team member (or members) 
with the competency to make such an assessment within a very 
short time of the patient's presentation, ideally within the first 
10 minutes and certainly no more than 20 minutes from presen- 
tation. Only then should specific procedures or therapies be given, 
except for securing peripheral venous access. At this entry stage it 
is important that all members of the healthcare team interact with 
the patient and family in a warm and caring fashion while 




1. Overt pulmonary congestion. 
2. Arterial oxygen desaturation (SaO 2 less than 90%). 
Class lla 
1. Routine administration to all patients with uncompli- 
cated MI during the first 2 to 3 hours. 
Class Ilb 
1. Routine administration of supplemental oxygen to pa- 
tients with uncomplicated MI beyond 3 to 6 hours. 
It has become universal practice to administer oxygen, 
usually by nasal prongs, to virtually all patients uspected of 
having acute ischemic-type chest discomfort, although it is not 
known whether this therapy limits myocardial damage or 
reduces morbidity or mortality. If oxygen saturation monitor- 
ing is used, therapy with supplemental oxygen is indicated if 
the saturation is less than 90%. Experimental results indicate 
that breathing oxygen may limit ischemic myocardial injury, 66 
Table 2. Serum Markers of Acute Myocardial Infarction 
Cardiac Troponins 
Myoglobin cTnI cTnT CK-MB MB-Isoforms 
Molecular weight (kD) 17 23 33 86 86 
First detectable (h) 1-2 2-4 3-4 2-4 
100% sensitivity (h) 4-8 8-12 8-12 6-10 
Peak (h) 4-8 10-24 10-24 6-12 
Duration (d) (0.5-1.0) 5-10 5-14 2-4 0.5-1.0 
cTnI indicates cardiac specific troponin I; cTnT, cardiac specific troponin T. Adapted with permission from Adams 
J, Abendschein D, Jaffe A. Biochemical markers ofmyocardial njury: is MB creatine kinase the choice for the 1990s? 
Circulation. 1993;88:750-763. 
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and there is evidence oxygen administration reduces ST- 
segment elevation in patients with MI as wells The rationale 
for use of oxygen is based on the observation that even with 
uncomplicated MI, some patients are modestly hypoxemic 
initially, presumably because of ventilation-perfusion mis- 
match and excessive lung water. 68 
In patients with severe CHF, pulmonary edema, or a 
mechanical complication of acute MI, significant hypoxemia 
may not be corrected with supplemental oxygen alone. Con- 
tinuous positive-pressure breathing or endotracheal intubation 
and mechanical ventilation are often required in such cases 
and should not be unnecessarily delayed. 69 A variety of me- 
chanical ventilators are available, and multiple modes are 
possible. For patients who do not have a depressed sensorium 
and are capable of initiating spontaneous ventilation, the 
preferred modes to use include intermittent mandatory venti- 
lation, assist control, or pressure-support ventilation. 7o 
For patients without complications, it should be recalled 
that excess administration of oxygen can lead to systemic 
vasoconstriction, and high flow rates can be harmful to patients 
with chronic obstructive airway disease. On the other hand, 
because administration of nitroglycerin dilates the pulmonary 
vascular bed and increases ventilation-perfusion abnormalities, 
it is reasonable to provide supplemental oxygen, at least in the 
initial hours, for all patients uspected of having an acute MI. 
In the absence of compelling evidence for established benefit 
in uncomplicated cases and in view of its expense, there 
appears to be little justification for continuing its routine use 
beyond 2 to 3 hours. 
Nitroglycerin 
Recommendations for Intravenous Nitroglycerin 
Class I 
1. For the first 24 to 48 hours in patients with acute MI and 
CHF, large anterior infarction, persistent ischemia, or hyper- 
tension. 
2. Continued use (beyond 48 hours) in patients with recur. 




1. For the first 24 to 48 hours in all patients with acute MI 
who do not have hypotension, bradycardia, or tachycardia. 
2. Continued use (beyond 48 hours)* in patients with a 
large or complicated infarction. 
Class III 
1. Patients with systolic pressure less than 90 mm Hg or 
severe bradycardia (less than 50 bpm). 
Considering that the use of nitrates in acute MI was 
believed to be contraindicated until the early 1970s, 71 it is 
*Oral or topical preparations may be substituted. 
rather striking that today, with the exception of hypotensive 
patients, virtually all patients with acute ischemic syndromes 
will receive at least 1 sublingual nitroglycerin tablet before 
admission to the hospital. Aside from its known clinical benefit 
in alleviating ischemic myocardial pain, nitroglycerin is now 
appreciated as having a dilatory effect on the vascular smooth 
muscle in vessels throughout the body. Thus, vasodilation of 
the coronary arteries themselves (especially at or adjacent o 
sites of recent plaque disruption), the peripheral arteries, and 
the venous capacitance vessels is particularly beneficial to the 
patient with acute infarction. However, inadvertent systemic 
hypotension with resulting worsening of myocardial ischemia is 
the most serious potential complication of nitroglycerin ther- 
apy. Thus, patients with ischemic-type chest discomfort should 
receive sublingual nitroglycerin unless the initial systolic blood 
pressure is less than 90 mm Hg. It should be avoided in the 
presence of marked bradycardia (less than 50 bpm) or tachycar- 
dia 72 and used with extreme caution, if at all, in patients with 
suspected right ventricular infarction. Patients with right ventric- 
ular infarction are especially dependent on adequate right ven- 
tricular preload to maintain cardiac output and can experience 
profound hypotension during administration of nitrates. 73 
Long-acting oral nitrate preparations should be avoided in 
the early management of acute MI. Sublingual or transdermal 
nitroglycerin can be used, but intravenous infusion of nitroglyc- 
erin allows for more precise minute-to-minute control of this 
agent. Intravenous nitroglycerin can be successfully titrated by 
frequent measurement of cuff blood pressure and heart rate. 
Although invasive hemodynamic monitoring is not mandatory, it
may be preferable if high doses of vasodilating agents are 
required, blood pressure instability ensues, or there is clinical 
doubt about he adequacy of LV filling pressure. Although quite 
effective in relieving ischemic-type chest discomfort due to acute 
coronary syndromes, nitroglycerin should not be used as a sub- 
stitute for narcotic analgesia that is usually required to manage 
pain associated with acute MI. For a detailed discussion of the 
pharmacotherapy and relevant clinical studies pertaining to the 
use of nitroglycerin i  acute MI, see "Rationale and Approach to 
Pharmacotherapy." 
Analgesia 
The clinical observation ofrapid and complete relief of pain 
after early reperfusion with thrombolytic therapy reinforces 
the concept hat the pain of acute MI is due to continuing 
ischemia of viable but jeopardized myocardium rather than the 
effects of completed myocardial necrosis. Efforts to control 
pain therefore may reasonably involve use of anti-ischemic 
interventions, including, in addition to reperfusion, oxygen, 
nitrates,/3-adrenoceptor bl cking agents, and, in some circum- 
stances, intra-aortic balloon counterpulsation. Effective anal- 
gesia (eg, intravenous morphine) should be administered 
promptly at the time of diagnosis and should not be delayed on 
the premise that to do so will obscure ability to evaluate the 
results of anti-ischemic therapy. See "Hospital Management" 
for more detailed discussion of proper analgesia. 
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1. A dose of 160 to 325 mg should be given on day 1 of acute 
MI and continued indefinitely on a daily basis thereafter. 
Class lib 
1. Other antiplatelet agents such as dipyridamole or ticlo- 
pidine may be substituted if true aspirin allergy is present. 
The Second International Study of Infarct Survival (ISIS-2) 
has shown conclusively the efficacy of aspirin alone for treat- 
ment of evolving acute MI with a 35-day mortality reduction of 
23%. 29 When combined with streptokinase, the reduction in 
mortality was 42%. A meta-analysis demonstrated that aspirin 
reduced coronary reocclusion and recurrent ischemic events 
after thrombolytic therapy with either streptokinase or alte- 
plase. TM In a dose of 160 mg or more, aspirin produces a rapid 
clinical antithrombotie effect caused by immediate and near- 
total inhibition of thromboxane A2 production. Accordingly, 
aspirin now forms part of the early management of all patients 
with suspected acute MI and should be given promptly and 
certainly within the first 24 hours at a dose between 160 and 
325 nag and continued aily indefinitely. 
Unlike fibrinolytic agents, there is little evidence for a time- 
dependent effect of aspirin on early mortality. However, data do 
support he contention that a chewable aspirin is absorbed more 
quickly than one swallowed in the early hours after infarction, 
particularly after opiate therapy. The use of aspirin is contraindi- 
cated in those with a hypersensitivity to salicylate and should be 
used with caution in patients with active ulcer disease. Aspirin 
suppositories (325 rag) can be used safely and are the recom- 
mended route of administration for patients with severe nausea 
and vomiting or known upper-gastrointestinal disorders. There is 
currently no evidence that other antiplatelet agents such as 
dipyridamole, ticlopidine, or sulfinpyrazone have any advantage 
over aspirin for mortality reduction after acute MI. See "Ratio- 
nale and Approach to Pharmacotherapy" for additional discus- 
sion on the use of aspirin in the management of acute MI, and 
"Preparation for Discharge From the Hospital." 
Atropine 
Recommendations 
The following recommendations are applicable from early 
after onset of acute MI to 6 or 8 hours afterward: 
Class I 
1. Sinus bradycardia with evidence of low cardiac output 
and peripheral hypoperfusion or frequent premature ventric- 
ular complexes at onset of symptoms of acute MI. 
2. Acute inferior infarction with type I second, or third- 
degree atrioventricular (AV) block associated with symptoms of 
hypotension, ischemic discomfort, or ventricular arrhythmias. 
3. Sustained bradycardia and hypotension after adminis- 
tration of nitroglycerin. 
4. For nausea and vomiting associated with administration 
of morphine. 
5. Ventricular asystole. 
Class lla 
1. Symptomatic patients with inferior infarction and type I 
second- or third.degree heart block at the level of the AV node 
(ie, with narrow QRS complex or with known existing BBB). 
Class lib 
1. Administration concomitant with (before or after) admin- 
istration of morphine in the presence of sinus bradycardia. 
2. Asymptomatic patients with inferior infarction and type 
I second-degree heart block or third-degree heart block at the 
level of the AV node. 
3. Second- or third-degree AV block of uncertain mecha- 
nism when pacing is not available. 
Class I I I  
1. Sinus bradycardia greater than 40 bpm without signs or 
symptoms of hypoperfusion or frequent premature ventricular 
contractions. 
2. Type II AV block and third-degree AV block and third- 
degree AV block with new wide QRS complex presumed ue to 
acute MI. 
By its parasympatholytic (anticholinergic) activity, atropine 
sulfate reduces vagal tone, enhances the rate of discharge of 
the sinus node, and facilitates AV conduction. 75It may be 
given as an adjunct o morphine administration when nausea 
and vomiting occur. During the early moments to hours of 
acute ischemia or acute MI, atropine is particularly useful in 
treating sinus bradycardia ssociated with reduced cardiac 
output and signs of peripheral hypoperfusion, including arte- 
rial hypotension, confusion, faintness, or frequent premature 
ventricular complexes. 76 In this setting, leg elevation and 
intravenous administration of atropine may be lifesaving. 
Atropine for Atrioventricular Block, Sinus Bradycardia, or 
Ventricular Asystole 
Atropine is the drug of choice for the occasional treatment 
of type I second-degree AV block, especially when complicat- 
ing inferior MI. It is occasionally useful in third-degree AV 
block at the AV node level in either restoring AV conduction 
or enhancing the junctional response. When AV block or sinus 
bradycardia is associated with CHF, hypotension, or frequent 
and complex ventricular arrhythmias, atropine may improve 
AV conduction, increase the sinus rate, and avoid the need for 
immediate insertion of a transvenous pacemaker, v7 As a rule, 
however, in the absence of hemodynamic compromise, treat- 
ment of sinus bradycardia or first- or second-degree AV block 
is not indicated. Similarly, atropine is rarely, if ever, the drug of 
choice for management of type II second-degree AV block. On 
occasion, while failing to improve AV block, atropine may 
increase the sinus rate, and, in fact, enhance the block. 
The recommended dosage of atropine for bradycardia s 0.5 
to 1.0 mg intravenously (IV), repeated if needed every 3 to 5 
minutes to a total dose of no more than 2.5 mg (0.03 to 
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0.04 mg/kg), the amount hat produces complete vagal block- 
ade. Atropine may also be therapeutic n ventricular asystole, 
for which the recommended dose is 1 mg IV, to be repeated 
every 3 to 5 minutes (while CPR continues) if asystole persists. 
The total cumulative dose should not exceed 2.5 mg over 2.5 
hours. The peak action of atropine given intravenously is
observed within 3 minutes. 1 
Side Effects 
When administered in doses of less than 0.5 mg or other than 
intravenously, atropine may produce a paradoxic effect (namely, 
bradycardia nd depression of AV conduction), 7s which is due 
either to central reflex stimulation of the vagus or a peripheral 
parasympathomimetic ffect on the heart. Urinary retention isnot 
uncommon following administration of atropine and can be 
deleterious tothe patient with acute MI. Repeated administration 
of atropine may produce adverse central nervous ystem effects, 
including hallucinations and fever. Careful dosing and observa- 
tion after administration of atropine is necessary because the 
sinus tachycardia that follows may increase ischemia. Rarely, 
ventricular tachycardia nd fibrillation occur after intravenous 
administration of atropine. 79 
Pacing is the treatment of choice for symptomatic brady- 
cardia not responding promptly to atropine administration. 
Risk Stratification and Management of ST-Segment 
Elevation/Bundle Branch Block Cohort 
Newer Concepts 
The spectrum of myocardial ischemia consists of patients 
with clinical presentations that cover the following range of 
diagnoses: stable angina, unstable angina, MI without ST 
elevation, and MI with ST elevation. Clinical discrimination 
among unstable angina, Q wave, and non-Q wave MI can only 
Figure 3. Recommendations for management of patients with ST 
elevation. All patients with ST-segment elevation on the electrocardio- 
gram should receive aspirin (ASA), /3-adrenoceptor blockers (in the 
absence of contraindications), andan antithrombin (particularly if tissue- 
type plasminogen activator [t-PA] is used for thrombolytic therapy). 
Whether heparin is required in patients receiving streptokinase (SK) 
remains amatter of controversy; the small additional risk for intracranial 
hemorrhage may not be offset by the survival benefit afforded by adding 
heparin to SK therapy. Patients treated within 12 hours who are eligible 
for thrombolytics should expeditiously receive ither frontloaded TPA or 
SK or be considered for primary percutaneous transluminal coronary 
angioplasty (PTCA). Primary PTCA is also to be considered when 
thrombolytic therapy is absolutely contraindicated. Coronary artery by- 
pass graft (CABG) may be considered if the patient is less than 6 hours 
from onset of symptoms. Individuals treated after 12 hours hould receive 
the initial medical therapy noted above and, on an individual basis, may be 
candidates for reperfusion therapy or angiotensin-converting enzyme 
(ACE) inhibitors (particularly if left ventricular function is impaired). 
Modified from Antman EM. Medical therapy for acute coronary syn- 
dromes: an overview. In: Califf RM, ed. Atlas of Heart Diseases, Vlll. 
Philadelphia, Pa: Current Medicine; 1996. 
be made retrospectively after serial ECGs and serum cardiac 
markers have been obtained (Fig 2). Patients with ST-segment 
elevation have a high likelihood of a coronary thrombus 
occluding the infarct-related artery, so,s1 However, not every 
ST-elevation MI evolves into a Q wave MI. Angiographic 
evidence of occlusive coronary thrombus formation may be 
seen in more than 90% of patients with ST-elevation MI but in 
only 1% of patients with stable angina and about 35% to 75% 
of patients with unstable angina or non-Q wave MI. 8°-s3 
Commonly indicated treatment regimens for all acute coronary 
ischemic syndromes include aspirin, heparin,/3-adrenoceptor 
blockers, and nitrates. Thrombolytic therapy is highly effective 
in patients with ST elevation or presumably new LBBB (which 
obscures the electrocardiographic d agnosis of MI) 27 (Fig 3). 
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Figure 4. Recommendations for management of patients with acute 
myocardial infarction (MI) without ST elevation. All patients without 
ST elevation should be treated with an antithrombin and aspirin 
(ASA). Nitrates should be administered for recurrent episodes of 
angina. Adequate /3-adrenoceptor blockade should then be estab- 
lished; when this is not possible or contraindications exist, a calcium 
antagonist can be considered. High-risk patients hould be triaged to 
cardiac catheterization with plans for revascularization if they are 
clinically suitable; patients who are clinically stable can be treated 
more conservatively, with continued observation in the hospital and 
consideration of a stress test to screen for myocardial ischemia that 
can be provoked. LV indicates left ventricular; ECG, electrocardio- 
graphic; PTCA, percutaneous transluminal coronary angioplasty; 
CABG, coronary artery bypass graft. Modified from Antman EM. 
Medical therapy for acute coronary syndromes: an overview. In: Califf 
RM, ed. Atlas of Heart Diseases, VIII. Philadelphia, Pa: Current 
Medicine; 1996. 
At the same time, evidence now suggests that thrombolytic 
therapy is ineffective (for normal or nonspecific electrocardio- 
graphic presentations) and possibly even harmful (for ST- 
depression presentation) in unstable angina and non-ST- 
elevation MI subgroups.Z7, 84Fig 4 presents a suggested schema 
for management of acute MI without ST-segment elevation. 
Noninvasive Imaging in the Emergency Department 
Screening patients who present with ischemic-type chest dis- 
comfort in the ED is an area of clinical and economic importance. 
Because only 25% or less of patients admitted to the hospital to 
"rule out" MI actually suffer an MI, accurate screening tech- 
niques to identify patients with ongoing necrosis is an important 
goal. The usefulness of echocardiography in the ED as a means of 
screening for MI has been validated, but small areas of infarction 
can be missed, and the age of a regional wall motion abnormality 
cannot be determined. 85-s7a Thallium and sestamibi imaging in 
the ED are both very good radioisotope screening tech- 
niques 85,sS.s9 and appear to be quite sensitive. However, their use 
in the ED is still viewed as experimental nd is not recommended. 
In time, the value of noninvasive imaging may further diminish as 
rapid assays of specific, earlier, and more sensitive serum markers 
of myocardial necrosis are developed. 56,5s,~°,6~ 
Thrombolysis 
Recommendations 
The constellation of clinical features that must be present 
(although not necessarily at the same time) to serve as 
standard indications for administration of thrombolytic ther- 
apy to patients with acute MI are as follows: (selection of 
specific thrombolytic agents or regimens is discussed in "Ra- 
tionale and Approach to Pharmacotherapy.") 
Class I 
1. ST elevation (greater than 0.1 mV, two or more contig- 
uous leads),* time to therapy 12 hours or less,t age less than 
75 years. 
2. Bundle branch block (obscuring ST-segment analysis) 
and history suggesting acute MI. 
Comment: Treatment benefit is present regardless of gender, 
presence of diabetes, blood pressure (if less than 180 mm Hg 
systolic), heart rate, or history of previous MI. 27 Benefit is greater in 
the setting of anterior MI, diabetes, low blood pressure (less than 
100 mm Hg systolic), or high heart rate (greater than I00 bpm). The 
earlier therapy begins, the better the outcome, with the greatest benefit 
decidedly occurring when therapy is given within the first 3 hours; 
proven benefit occurs, however, up to at least within 12 hours of the 
onset of symptoms. Benefit is less with inferior acute MI, except for 
the subgroup with associated right ventricular infarction (ST eleva- 
tion RV-4) or anterior-segment depression. 
Class lla 
1. ST elevation,* age 75 years or older. 
Comment: In persons older than 75 years, the overall risk of 
mortality from infarction is high without and with therapy. 
Although the proportionate r duction in mortality is less than in 
patients younger than 75, the absolute reduction results in I0 lives 
*Repeat ECGs recommended during medical observation in suggestive 
clinical settings when initial ECG is nondiagnostic of ST elevation. 
tTime of symptom onset is defined as the beginning ofcontinuous, persistent 
discomfort that brought the patient to the hospital. 
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saved per I000 patients treated in those over 75. The relative 
benefit of therapy is reduced. T 
Class lib 
1. ST elevation,* time to therapy greater than 12 to 24 
hours.? 
2. Blood pressure on presentation greater than 180 mm Hg 
systolic and/or greater than 110 mm Hg diastolic associated 
with high-risk MI. 
Comment: Generally there is only a small trend for benefit of 
therapy' after a delay of more than 12 to 24 hours, but thrombol- 
ysis may be considered for selected patients with ongoing ischemic 
pain and extensive ST elevation. Risk of ICH is greater when 
presenting blood pressure is greater than 180/110 mm Hg, and in 
this situation the potential benefit of therapy must be weighed 
carefully against he risk of hemorrhagic stroke. Risk of cardiac 
rupture appeared to increase with prolonged time to therapy in an 
earlier meta-analysis 9° but was not associated with increased risk 
of rupture in a later, larger study. 9j Generally patients presenting 
more than 12 hours after symptom onset were excluded from 
some but not all trials. An attempt to lower blood pressure first 
(with nitrates, f3-adrenoceptor blockers, etc) is recommended but 
is not of proven benefit in lowering the risk of ICH. Primary 
PTCA or CABG may be considered if available. 
Class III 
1. ST elevation,* time to therapy greater than 24 hours,? 
ischemie pain resolved. 
2. ST-segment depression only. 
Comment: In the absence of ST elevation, there is no evidence 
of benefit for patients with normal electrocardiographic or non- 
specific hanges, and, using current hrombolytic regimens, there 
is some suggestion of harm (including increased bleeding r~k) for 
patients with ST-segment depression only.2Z 92 When marked 
ST-segment depression is confined to leads V l through V4, there 
is a likelihood that this reflects a posterior current of injury and 
suggests a circumflex artery occlusion for which thrombolytic 
therapy would be considered appropriate. Very recent retrospective 
analysis of the Late Assessment ofThrombolytic E ficacy ( LA TE ) 
Trial 93,94 also casts some uncertainties about withholding throm- 
bolytic therapy from this heterogenous group of patients. 
A collaborative overview from nine trials of thrombolytic 
therapy (versus control) for acute MI has shown a highly 
significant (P<.00001) 18% proportional reduction in 35-day 
mortality (9.6% fibrinolysis versus 11.5% control) correspond- 
ing to a reduction of 18 deaths per 1000 patients treated when 
data from all patient groups are pooled. 2v In patients with ST 
elevation, aproportional mortaliV reduction of 21% occurred. 
It is now known that this survival benefit can be maintained 
long term (6 months to at least 4 years). 27.95 
Fig 5 summarizes the number of lives saved per 1000 
*Repeat ECGs recommended during medical observation in suggestive 
clinical settings when initial ECG is nondiagnostic of ST elevation. 
?Time of symptom onset is defined as the beginning of continuous, persistent 







Figure 5. Effect of thrombolytic herapy on mortality according to 
admission electrocardiogram. Patients with bundle branch block 
(BBB) and anterior ST-segment elevation (ANT ST I' ) derive the 
most benefit from thrombolytic therapy. Effects in patients with 
inferior ST-segment elevation (INF ST ~' ) are much less, while pa- 
tients with ST-segment depression (ST DEP) do not benefit. Adapted 
from Fibrinolytic Therapy Trialists' (FTI") Collaborative Group. Indi- 
cations for fibrinolytic therapy in suspected acute myocardial infarc- 
tion: collaborative overview of early mortality and major morbidity 
results from all randomised trials of more than 1000 patients. Lancet 
Ltd. 1994;343:311-322. Reprinted from Management of Acute Myocar- 
dial Infarction (Julian D, Braunwald E,eds). Martin GV, Kennedy JW. 
Choice of thrombolytic agent, p 90, 1994, by permission of the 
publisher, WB Saunders Co Ltd, London. 
patients treated based on the presenting ECG pattern. 96 In 
general, thrombolytic agents hould be administered only to 
patients with ST-segment elevation greater than 0.1 mV or 
presumably new LBBB on the ECG. 27,97 However, in the very 
early phase of acute infarction, giant, hyperacute T waves may 
be present with no ST-segment elevation. Similarly, direct 
posterior infarction can result in ST-segment depressions in 
leads V1 through V4, and in both situations it is appropriate o
administer thrombolytic therapy. Thus, it should be clear that 
certain cases require experienced interpretation f the ECG 
before withholding reperfusion therapy. Unquestionably, pa- 
tients with LBBB and anterior ST elevation are at greater 
inherent risk from MI but also achieve greater benefit with 
thrombolytic therapy. Although one study 39 suggested that the 
amount of ST elevation might also predict greater inherent risk 
and therefore greater benefit, it did not take into account the 
increased amount of ST elevation seen in patients with ante- 
rior infarction. Other factors uch as collateral flow 98 clearly 
influence the amount of ST elevation, which may limit its value 
for predicting therapeutic benefit. 
Additional factors that influence the decision to administer 
thrombolytic therapy include time since onset of symptoms, 
patient's age, hemodynamic status, and coexisting medical 
illnesses (Figs 6 and 7). Myocardial salvage increases with 
progressively earlier administration f thrombolytic therapy, 
although a reduction in mortality may still be seen in patients 
treated up to at least 12 hours from onset of definitive 
symptoms. 27,99.1°° Some patients presenting atmore than 12 to 
24 hours with persistent ischemic symptoms and ST elevation 
also may benefit from treatment. Although younger patients 
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Figure 6. Effect of thrombolytic herapy on mortality according totime 
from symptom onset. Patients treated early derive the most benefit. 
Adapted from Fibrinolytic Therapy Trialists' (FIT) Collaborative 
Group. Indications for fibrinolytic therapy insuspected acute myocar- 
dial infarction: collaborative overview of early mortality and major 
morbidity results from all randomised trials of more than 1000 
patients. Lancet Ltd. 1994;343:311-322. Reprinted from Management 
of Acute Myocardial Infarction (Julian D, Braunwald E, eds). Martin 
GV, Kennedy JW. Choice of thrombolytic agent, p 90, 1994, by 
permission ofthe publisher, WB Saunders Co Ltd, London. 
achieve agreater relative reduction i  mortality compared with 
older patients, the increasing absolute mortality rates with 
advancing age result in progressively greater absolute mortality 
reductions up to age 75. Benefit may also be achieved after age 
75 but is less certain than at younger ages. 27,1ol Advanced age 
does increase risk of stroke after acute MI, both without and 
with thrombolytic therapy. Given the much greater mortality 
risk of MI, the elderly should be considered candidates for 
thrombolytic therapy after careful screening for exclusions. 
Patients hould be considered at higher isk if they have any of 
the following: female gender, advanced age (greater than 70 
years), history of previous infarction, atrial fibrillation, anterior 
infarction, tales in more than one third of the lung fields, 
hypotension, and sinus tachycardia or diabetes mellitus.27, w2
Indeed, certain subgroups of patients with an especially high 
likelihood of benefiting from successful reperfusion include 
those with hypotension, tachycardia, nd a history of diabetes 
mellitus or prior MI. 
Early placebo-controlled trials of thrombolysis for MI 
raised concern about a paradoxical increase in mortality during 
the first 24 hours after thrombolysis that was later offset by a 
greater eduction in mortality in the thrombolytic groupsY 
More recently conducted thrombolytic trials have confirmed a 
"high density" of mortality, inthe first 24 hours but suggest that 
this may be attributed primarily to pump failure from unsuc- 
cessful reperfusion rather than an early hazard of thromboly- 
sis.l°3 
Risk of Stroke 
Thrombolytic therapy isassociated with a slight but definite 
excess risk of stroke that occurs predominantly within the first 
day of therapy. 27 Clinical variables that can be ascertained in
the ED that predict an increased risk of ICH are advanced age 
(older than 65 years, odds ratio 2.2, 95% CI, 1.4 to 3.5), low 
body weight* (less than 70 kg, odds ratio 2.1, CI 1.3 to 3.2), 
hypertension on presentation (odds ratio 2.0, CI 1.2 to 3.2), 
and use of alteplase (odds ratio 1.6, CI 1.0 to 2.5). l°4-1°6 The 
number of risk factors at presentation may be used to estimate 
the probability of ICH and is shown in Fig 8.* Although no 
firm guidelines have been established, ICH rates less than 1% 
have generally been regarded as acceptable in clinical trials, 
considering the overall favorable benefit-risk profiles, whereas 
rates greater than 1.5% or higher have been viewed as 
unacceptably high3 °7 
Net Clinical Benefit 
Clinicians must carefully weigh the risk-benefit ratio of 
thrombolysis for individual patients. Hesitancy to prescribe 
thrombolytic therapy arises from concern about intracranial 
bleeding and uncertainty about eligibility criteria. The gener- 
ally higher mortality rate among MI patients who do not 
undergo thrombolysis underscores the need for heightened 
awareness of current indications for thrombolysis through such 
projects as the NHAAP. 1°8 Decision analysis methods suggest 
that appropriate use of thrombolytic therapy in eligible pa- 
tients would save many additional lives annually in the United 
States? o9 
Contraindications / Cautions 
Hemorrhage r presents he most important risk of throm- 
bolytic therapy, especially ICH, which may be fatal in one half 
to two thirds of patients. Contraindications and cautions to 
thrombolytic use are given in Table 3. 
Summary of Initial Diagnostic and 
Treatment Strategy 
A summary of initial diagnostic and treatment s rategies for 
patients with acute MI with ST elevation or BBB, focusing on 
emergency management, is provided in Table 4. 




1. As an alternative to thrombolytie therapy only if per- 
formed in a timely fashion by individuals skilled in the proce- 
duret and supported by experienced personnel in high-volume 
centers.~ 
*To reduce risk, the dose of 90-minute alteplase hould be adjusted 
downward for low body weight (less than 67 kg). Similarly, the 180-minute 
regimen should be adjusted downward for patients who weigh less than 65 kg. 
tlndividuals who perform ore than 75 PTCA procedures per year.H" 
~Centers that perform ore than 200 PTCA procedures per year. H° 
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Presentation Percent of patients dead Stratified 
features Flbrinolyti¢ Control statistics 
O-E Variance 
ECG 
Bee 1 8 .7% 23  . 60/o - 24 .5  63 .3  
ST elev, anterior 13.2% 16 .9% * 122 .0  420 .6  
ST elev, inferior 7.5% 8 ,4% - 27 , 1 237 .4  
ST elev, other 10.6° /o  13.4% -42 .1  159 ,6  
ST depCe=elon 15.2° /o  13 ,8% 12 .9  108 .7  
Other abnormality 5.20 /o  5 . 8% - 9 . 6 103 . 2 
Normal 3 .0% 2 .3% 3 4 12.9 
Hours from onset 
0-1 9 .5% 13 .0% -29,3 83.3 
2-3 6,2°~ 10 .7% -100,2 364.8 
4-6 9.7=/0 11 ,5% -78 ,5  387.6 
7-12 11 .  I% 12 .7% -51  ,5 336 ,7  
13-24 10 .0% 10 .5% -11.1 212,6 
Age (years) 
<66 3 ,4% 4 ,6% -45.9 155.6 
s.~s4 7 .20 /0  6 .9% - 86 .3  360 .0  
66-74 13 .5% 16 .1% -113.7 533,0 
75+ 24.3=/0 25 .3% -12.6 266.6 
Gender 
Male 8 ,2% 10,1% -206.1 928.0 
Female 14.  1% 16 .0% -62 ,2  436 ,8  
Systolic BP (ram Hg) 
<100 28 .9% 35 .  1% -38 .7  132 .2  
lOO-t49 9 .6% 11 .5% -168.9 860.o 
150-174 7 ,  2% 8 .7% - 59 .2  290 .0  
176+ 7 .2% 8 .2% -10.8 74.1 
Heart rate 
<80 7 .2% 6 ,5% -83 ,2  464 ,9  
60-99 9.2% 11.3% - 65.8 287 . 2 
IO0+ 17.4% 20,7=/o -51.7 238.6 
Prior MI 
yes 12.5% 14.1% -43.7 322.4 
No 6 .90  10,9% -228.5 1001 .g 
Diabetes 
Yes 13.6% 17 .3% -41 .4 145 .7  
NO 8 .70 /o  10 ,2° /o  -142 ,6  830 ,4  
IALLPAT IENTS 2820/2931E 3357/29285 -269 .5  1377,4  
9 .6% 11 .5% 
i 
0.5  
Odds ratio & CIs 
a:  
! ,  
: t  
,.= 
i - 






• I - -  
1.0  
Chi-square test of odds ratios 
In different patient categories: 
Heterogeneity Trend 
21.28 on 6 df 
(P< .01) 
9.69 on 4 df 9,55 on 1 df 
(P < .05) (ZP = O.OO2) 
8.27 on 3 df 6.58 on 1 dt 
(P < .05) (2P = 0.01) 
1.99 on 1 df 
(NS} 
1.31 on 3 df 0.68 on 1 df 
(NS) (NS) 
0.51 on 2 df 0.31 on 1 dt 
(NS} (NS) 
2.09 on 1 df 
INS) 
1.57 on 1 df 
(NS} 
18% SD 2 odds reduction 




1. As a repeffusion strategy in patients who are candidates 
for repeffusion but who have a risk of bleeding contraindication 
to thrombolytic therapy (Table 3). 
2. Patients in eardiogenic shock. 
Class Ilb 
1. As a repeffusion strategy in patients who fail to qualify 
for thrombolytic therapy for reasons other than a risk of 
bleeding contraindication. 
Comment: There is serious concern that a routine policy of 
primary PTCA for patients with acute MI will result in unaccept- 
able delays in achieving reperfusion in a substantial number of 
cases and less than optimal outcomes if performed by less 
experienced operators. Strict performance criteria must be man- 
dated for primary angioplasty programs o that such delays in 
revascularization and performance by low-volume operators/ 
centers do not occur. Interventional cardiologists and centers 
must operate within a specified "corridor of outcomes" toinclude 
(1) balloon dilation within 60 to 90 minutes" of diagnosis of acute 
MI; (2) a documented clinical success rate with Thrombolysis n
Myocardial Infarction (TIMI) II through III flow attained in 
more than 90% of patients without emergency CABG, stroke, or 
death; (3) emergency CABG rate less than 5% among all patients 
undergoing the procedure," (4) actual performance of angioplasty 
in a high percentage of patients (85%) brought o the laboratory; 
Figure 7. Mortality differences during days 0 through 35 subdivided by 
presentation features in a collaborative overview of results from nine 
trials of thrombolytic therapy. At center absolute mortality rates are 
shown for fibrinolytic and control groups for each clinical feature at 
presentation listed at left. The odds ratio of death in fibrinolytic group 
to that in control group is shown for each subdivision (black square) 
along with 95% confidence interval (horizontal ine). The summary 
odds ratio at bottom corresponds to an 18% proportional reduction in 
35-day mortality and is highly statistically significant. This translates to 
a reduction of 18 deaths per 1000 patients treated with thrombolytic 
agents. O-E indicates observed versus expected ratio; CIs, confidence 
intervals; ECG, electrocardiogram; BBB, bundle branch block; ST 
elev, ST-segment elevation; df, degrees of freedom; BP, blood pres- 
sure; MI, myocardial infarction; SD, standard eviation. Adapted from 
Fibrinolytic Therapy Trialists' (FTI') Collaborative Group. Indications 
for fibrinolytic therapy in suspected acute myocardial infarction: 
collaborative overview of early mortality and major morbidity results 
from all randomised trials of more than 1000 patients. Lancet Ltd. 
1994;343:311-322. Reprinted from Management of Acute Myocardial 
Infarction (Julian D, Braunwald E, eds). Antman EM. General hospi- 
tal management, pp 42-44, 1994, by permission of the publisher, WB 
Saunders Co Ltd, London. 
and (5) mortality rate less than 12%. Otherwise, the focus of 
treatment should be the early use of thrombolytic therapy. 
Since publication of the original report of primary (direct) 
PTCA as an alternative to thrombolytic therapy in patients 
with acute MI, 111 its merits have been debated. 112,113 There are 
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Figure 8. Risk of intracranial hemorrhage (ICH) during 
thrombolytic therapy. At bottom is estimated incidence of 
frequency of one or more of the following risk factors: age 
>65 y, weight <70 kg, hypertension  admission, and use 
of tissue plasminogen activator (TPA) in patients with acute 
MI who are potential candidates for thrombolytic therapy. 
The likelihood ratio describes the probability of finding the 
risk profile among patients with intracranial bleeding di- 
vided by the probability of finding the same risk profile 
among patients without intracranial b eeding. Curves depict 
estimated probability of ICH assuming an overall incidence 
of 0.5% and 0.75% (bottom and top curves respectively). 
Adapted from data in Simoons ML, Maggioni AP, Knat- 
terud G, et al. Individual risk assessment for intracranial 
hemorrhage during thrombolytic therapy. Lancet Ltd. 1993; 
342:1523-1528. 
no randomized controlled trials of primary PTCA versus no 
reperfusion. Thus, the recommendations are based on findings 
from small and moderately sized comparative trials of primary 
PTCA and thrombolysis and from indirect evidence. 
Initial assessments showed that PTCA restored antegrade 
flow in the occluded infarct-related artery in more than 90% of 
patients and was associated with a 1-year survival rate of 90% 
to 96%. ]14-117 Subsequently several randomized trials com- 
pared PTCA and thrombolytic therapy in patients with acute 
MI. 118-j2° In these studies PTCA was reported to successfully 
restore antegrade coronary flow in approximately 88% to 95% 
Table 3. Contraindications and Cautions for Thrombolytic Use in 
Myocardial Infarction* 
Contraindications 
• Previous hemorrhagic stroke at any time; other strokes or cerebrovascular 
events within 1 year 
• Known intracranial neoplasm 
• Active internal bleeding (does not include menses) 
• Suspected aortic dissection 
Cautions/relative contraindications 
• Severe uncontrolled hypertension on presentation (blood pressure 
>180/110 mm Hg)t 
• History of prior cerebrovascular accident or known intraeerebral p thology. 
not covered in contraindications 
• Current use of anticoagulants i  therapeutic doses (INR >-2-3); known 
bleeding diathesis 
• Recent trauma (within 2-4 weeks), including head trauma or traumatic or
prolonged (>10 min) CPR or major surgery (<3 wk) 
• Noncompressible vascular punctures 
• Recent (within 2-4 weeks) internal bleeding 
• For streptokinase/anistreplase: prior xposure ( specially within 5 d-2 y) or 
prior allergic reaction 
• Pregnancy 
• Active peptic ulcer 
• History of chronic severe hypertension 
INR indicates International Normalized Ratio; CPR, cardiopulmonary 
resuscitation. *Viewed as advisory for clinical decision making and may not be 
all-inclusive or definitive, tCould be an absolute contraindication n low-risk 
patients with myocardial nfarction (see text). 
of attempts. In the study of Zijlstra et al, ]]8 follow-up angiog- 
raphy weeks after infarction showed that the infarct-related 
artery was patent in 91% of those who had primary PTCA and 
in 68% of those who received streptokinase (P=.001), and the 
residual infarct-related artery stenosis was less in those who 
underwent PTCA. Those in whom primary PTCA was per- 
formed also had fewer in-hospital adverse events (nonfatal 
reinfarction or death) and were less likely to have recurrent 
ischemia or to require coronary revascularization over the 
period of follow-up. 
Table 4. Diagnostic and Treatment Measures in Patients With ST 
Elevation or Bundle Branch Block 
Initial diagnostic measures 
1. Use continuous ECG, automated BP, HR monitoring 
2. Take targeted history (for AMI inclusions, thrombolysis exclusions), 
check vital signs, perform focused examination 
3. Start IV(s), draw blood for serum cardiac markers, hematology, 
chemistry, lipid profile 
4. Obtain 12-lead ECG 
5. Obtain chest x-ray (preferably upright) 
General treatment measures 
1. Aspirin, 160-325 mg (chew and swallow) 
2. Nitroglycerin, sublingual: test for Prinzmetal's angina, reversible spasm; 
anti-ischemic, antihypertensive eff cts 
3. Oxygen: sparse data; probably indicated, first 2-3 h in all; continue if low 
arterial oxygen saturation (<90%). 
4. Adequate analgesia: small doses of morphine (2-4 mg) as needed 
Specific treatment measures 
1. Reperfusion therapy: goal--door-to-needle time <30 min; door-to- 
dilatation time <60 min 
2. Conjunctive antithrombotics: aspirin, heparin (especially with TPA) 
3. Adjunctive therapies:/3-adrenoceptor blockade if eligible, intravenous 
nitroglycerin (for anti-ischemic or antihypertensive eff cts), ACE 
inhibitor (especially with large or anterior AMI, heart failure without 
hypotension [SBP >100 mm Hg], previous MI). 
ECG indicates lectrocardiogram; BP, blood pressure; HR, heart rate; AMI, 
acute myocardial infarction; IVs, intravenous administrations; TPA, tissue 
plasminogen activator; ACE, angiotensin converting en~me; SBP, systolic blood 
pressure. 
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Similarly, Gibbons et a1119 found that those who underwent 
primary PTCA were less likely to require coronary revascular- 
ization for recurrent ischemia over a 6-month follow-up period 
than those treated with alteplase. In this study the two groups 
had similar myocardial salvage (the primary end point), LV 
ejection fraction, incidence of recurrent MI, and survival. The 
Primary Angioplasty in Myocardial Infarction (PAMI) Inves- 
tigators 12o found a significant difference in their primary end 
point (combined death and nonfatal reinfarction) between 
patients receiving PTCA (5.1%) or alteplase (12.0%, P = .02) 
but no significant differences in LV function or mortality. In a 
post hoc analysis of high-risk patients (ie, older than 70 years, 
with anterior infarction or tachycardia on presentation), mor- 
tality was only 2% for those who had primary PTCA and 10% 
for those who received thrombolysis (P=.01). The survival 
benefit of PTCA was at least partly due to the fact that those 
who received thrombolytic therapy had an excessive incidence 
of cerebrovascular hemorrhage with death; in fact, cardiac- 
related deaths were similar in the two groups. 
A meta-analysis suggests that, in comparison with throm- 
bolytic therapy, primary PTCA reduces the incidence of sub- 
sequent hospital morbidity, readmission, and follow-up costs 
largely by reducing recurrent ischemia following inter- 
vention, j21 However, this benefit comes at the cost of per- 
forming PTCA on all patients presenting with infarction 
(rather than the 20% to 40% who require revascularization for 
clinical indications following thrombolytic therapy in these 
trials). 118-120 
Before considering PTCA as the preferred therapy for 
acute MI, several caveats hould be kept in mind. Because only 
about 20% of hospitals in the United States have cardiac 
catheterization laboratories and even less have the capability 
of performing emergency PTCA, its applicability as a primary 
therapy for acute MI is limited. Although transfer of the 
patient with MI to a facility that can perform PTCA is possible, 
the necessary, time delay in achieving reperfusion may out- 
weigh any added benefit. 
The excellent results attained in the limited number of 
patients studied in the randomized trials to date can be 
attributed to several factors, including (1) the extensive xpe- 
rience of these investigators in performing PTCA in the setting 
of acute MI; (2) their enthusiastic commitment toall details of 
the protocol; (3) the resulting dedication of their institutions 
and support personnel to the project; and (4) the capability to 
perform PTCA within a short time frame (by 60 to 90 minutes 
of arrival at hospital). These important considerations may not 
be reproducible in the community setting and for all acute MI 
patients not enrolled in specific protocols. For example, there 
are now several reports from community-based registries in 
both the United States and Europe showing a greater time 
delay to primary PTCA (door-to-balloon i flation) compared 
with thrombolytic therapy (door-to-needle). 122-~26 In these 
registries in-hospital mortality of patients treated with primary 
angioplasty ranged from 5% to 10% and was similar to that of 
patients treated with thrombolysis at the same hospitals. 
In the recently completed GUSTO-lib trial results pre- 
sented at the 45th Annual Scientific Session of the American 
College of Cardiology, held in Orlando, Fla, in March 1996, 
1138 patients were randomly selected to receive either direct 
angioplasty or thrombolytic therapy with accelerated alte- 
plase. 127 Although the mortality (5.7% versus 7.0%) and the 
composite of death, reinfarction, and disabling stroke (9.6% 
versus 13.1%) showed a trend toward favoring direct angio- 
plasty, the magnitude of the effect was less than that observed 
in the previous mall trials, and the cost of each therapy was 
within several hundred ollars of the other. It is also important 
to recognize that the results of the randomized trials were 
achieved only in patients who were eligible for thrombolytic 
therapy, and the findings do not necessarily apply to persons 
who are not eligible. In addition, 2% to 5% of patients initially 
referred for PTCA will require emergency CABG surgery, 
either because the artery is not suitable for PTCA or failed 
angioplasty requires further surgical intervention. Accordingly, 
primary PTCA should be performed in centers with cardiac 
surgical capability or in those institutions with a proven plan 
for rapid access to cardiac surgery in a nearby facility. 
Recommendations for Early Coronary Angiography in 
the ST-Segment Elevation or Bundle Branch Block 
Cohort Not Undergoing Primary Percutaneous 




1. Patients with cardiogenic shock or persistent hemody- 
namic instability. 
Class IIb 
1. Patients with evolving large or anterior infarcts treated 
with thrombolytic agents in whom it is believed that the artery 
is not patent and adjuvant PTCA is planned. 
Class II I  
1. Routine use of angiography and subsequent PTCA 
within 24 hours of administration of thrombolytic agents. 
Recommendations for Emergency or Urgent Coronary 
Artery Bypass Graft Surgery 
Class I 
1. Failed angioplasty with persistent pain or hemodynamic 
instability in patients with coronary anatomy suitable for 
surgery. 
2. Acute MI with persistent or recurrent ischemia refrac- 
tory to medical therapy in patients with coronary anatomy 
suitable for surgery who are not candidates for catheter 
intervention. 
3. At the time of surgical repair of postinfarction VSD or 
mitral valve insufficiency. 
Class IIa 
1. Cardiogenic shock with coronary anatomy suitable for 
surgery. 
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Class lib 
1. Failed PTCA and small area of myocardium at risk; 
hemodynamically stable. 
Class III 
1. When the expected surgical mortality rate equals or 
exceeds the mortality rate associated with appropriate medical 
therapy. 
Comment: These recommendations are supplementary to
those published recently in a more complete set of general 
guidelines and indications for CABG by another ACC/AHA 
subcommittee 12~ and are restricted in general to patients with 
acute MI and associated complications. The basis for recom- 
mending surgery in emergency ircumstances is based on the 
documented benefits of CABG for severe multivessel disease or 
left main coronary artery stenosis, particularly with reduced LV 
function, leS ~Sl with the realization that risk of emergency CABG 
is greater than that for elective operation. 
Previous studies 13~--134 suggested that emergency CABG 
improved survival and salvaged more myocardium than 
matched retrospective control groups developed before the 
widespread use of thrombolytic therapy and primary PTCA. 
More recently, emergency CABG has been used for acute MI 
patients when other interventional therapies have failed or 
have not been indicated. 
Risk Stratification and Management in 
Non-ST-Segment Elevation Cohort 
Recommendations for Early Coronary Angiography 
and/or Interventionai Therapy 
Class I 
1. Patients with recurrent (stuttering) episodes of sponta- 
neous or induced ischemia or evidence of shock, pulmonary 
congestion, or LV dysfunction. 
Class IIa 
1. Patients with persistent ischemic-type discomfort de- 
spite medical therapy and an abnormal ECG or two or more 
risk factors for coronary artery disease. 
2. Patients with chest discomfort, hemodynamic instabil- 
ity, and an abnormal ECG. 
Class lib 
1. Patients with chest discomfort and an unchanged ECG. 
2. Patients with ischemic.type chest discomfort and a 
normal ECG and more than two risk factors for coronary 
artery disease. 
Patient Characteristics 
Ischemic-type chest discomfort in the setting of nondiag- 
nostic electrocardiographic findings (no ST elevation) repre- 
sents a continuum between chronic stable angina and typical 
acute MI. Unstable angina and MI without ST elevation 
represent two of the most common cardiac emergencies re- 
quiring hospitalization and account for over 650 000 discharges 
per year in the United States. While the optimal treatment 
regimen or strategy for such patients is under investigation, a
proposed schema is presented in Fig 4. 
It is believed that acute MI accompanied by nondiagnostic 
ECG changes is related to acute disruption of an atheroscle- 
rotic plaque. 82,135-137 Although there are few angiographic and 
clinical correlations with the syndrome, studies to date have 
suggested that, unlike MI with ST elevation, total coronary 
occlusion is much less common, sz,~3s-14° In the initial study by 
DeWood et al, s2 total coronary occlusion occurred in only 32% 
of patients tudied early by angiography, a greater than 70% 
stenosis was present in more than 70%, and a few had normal 
coronary arteries. When total occlusion is present, it most 
commonly occurs in the circumflex distribution, which is 
electrocardiographically silent, or in a vessel that is well 
collateralized.S:. 141 
The earlier descriptions of MI patient populations often 
differ from more contemporary descriptions. Patients with 
suspected MI are best classified in terms of the initial electro- 
cardiographic finding: ST-segment elevation and BBB versus 
other electrocardiographic findings at the time of ischemic- 
type chest discomfort and admission. Earlier studies of non-Q 
wave MI described a heterogeneous population that included 
patients with both ST-segment elevation and nondiagnostic 
electrocardiographic abnormalities at the time of presenta- 
tion.142 Many of these studies howed that patients with non-Q 
wave infarction had a relatively low in-hospital mortality 
rate. 143,144 Recurrent ischemia, recurrent MI, and death in the 
weeks after discharge, however, occurred frequently. 145-148 
Findings from more recent registries of consecutive patients 
with acute MI show that nondiagnostic ECGs at the time of 
admission are more common in the elderly and those with 
prior MI. 25,149 One study showed that ST elevation occurred in 
54% of patients older than 75 years compared with 63% of 
patients under 55. Fewer elderly patients were eligible for 
thrombolytic therapy, and invasive means of reperfusion 
such as primary PTCA were also performed less frequently 
in this group. 25 The overall incidence of non-Q wave MI 
may be increasing with the advancing age of the population 
and the greater use of thrombolytic therapy, aspirin, and 
/3-adrenoceptor blockers. 
Most randomized trials in patients with MI have been 
conducted in those with ST-segment elevation, although a few 
early studies were less restrictive and provide some insight into 
the effect of thrombolysis on outcome in patients with nondi- 
agnostic electrocardiographic changes. In the first GISSI study 
(Gruppo Italiano per lo Studio della Streptochinasi 
nell'Infarto Miocardico) of streptokinase for acute MI, no 
benefit was associated with thrombolytic therapy in patients 
with ST-segment depression at the time of admission. Mortal- 
ity rates in patients with ST-segment depression were in fact 
higher in those treated with streptokinase (20.5 % versus 16.2% 
in the control group). 28 Patients with less abnormal or unde- 
fined electrocardiographic abnormalities had a lower overall 
mortality rate, averaging about 8%. Again, there was no 
treatment benefit of thrombolytic therapy. 28 It is important to 
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realize, however, that only about 10% of all patients randomly 
assigned in the trial had nondiagnostic electrocardiographic 
findings. Thus, they likely represent a very select group of 
patients with nondiagnostic electrocardiographic changes who 
were deemed eligible and appropriate for thrombolytic ther- 
apy. In the ISIS-2 trial there was a relatively high mortality rate 
in patients with MI and ST-segment depression and no treat- 
ment benefit from thrombolytic therapy. 29 In patients with MI 
who had only T-wave abnormalities, mortality rates were low 
(about 5%); in patients with normal ECGs, the mortality rate 
was 1% to 2%. In a recent overview of the early, large 
randomized placebo-controlled trials of thrombolytic therapy, 
3.6% of the entire group had ST-segment depression. 27The 
mortality rate for those receiving thrombolysis was 15.2%, 
compared with 13.8% for control subjects, a higher ate than in 
those with ST elevation. Furthermore, two randomized trials of 
thrombolytic therapy in patients with unstable angina or MI 
with nondiagnostic electrocardiographic findings showed no 
benefit of alteplase compared with treatment with aspirin and 
heparin alone. 92,~5° In summary, the available data do not 
support he routine use of thrombolytic therapy as a form of 
reperfusion in patients admitted with ischemic-type chest 
discomfort and nondiagnostic ECGs. 
It should be recognized that relatively few patients with 
nondiagnostic electrocardiographic findings have been studied 
to date, and the possibility of benefit, particularly in some 
subsets of patients, cannot be excluded on the basis of the 
available data. In the retrospective subgroup analysis of pa- 
tients enrolled in the LATE study, 93 1-year mortality was 
significantly reduced by alteplase in patients presenting initially 
with ST depression greater than 2 mm (20.1% versus 31.9%, 
P=.006). Thus, although the available data do not support he 
routine use of thrombolytic therapy in patients with ischemic- 
type chest discomfort and nondiagnostic ECGs, future pro- 
spective trials are warranted to better define the role of 
thrombolytic therapy in such patients. 94 
Although few patients with nondiagnostic electrocardio- 
graphic findings have been treated in trials, it is important o 
realize that this presentation is not unusual. It was estimated in
one consecutive series of patients that almost half of patients 
with MI were ineligible for acute reperfusion because of a 
nondiagnostic ECG at the time of admission, yet the mortality 
rate for this subset was high (14%). s4,151 
Pharmacological Therapy in Patients in the 
Non-ST-Segment Elevation Cohort 
Despite the recent realization that at least half of patients 
with enzymatic evidence of myocardial necrosis do not have 
ST-segment elevation on the ECG, little is known about the 
specific response of these patients to pharmacological therapy 
other than their lack of mortality reduction with thrombolytic 
therapy as discussed above. On presentation these patients 
cannot be distinguished from those with unstable angina 
without myocardial necrosis. The initial pharmacological ther- 
apy, other than avoidance of thrombolytic therapy, is the same 
as for all patients with unstable angina or infarction with 
ST-segment elevation (Fig 2). It is important o recognize, 
however, that these recommendations are made in the absence 
of information specific to this very large group of patients. In 
patients with recurrent episodes of pain, serial ECGs should be 
repeated frequently. The development of sustained ST eleva- 
tion is an indication for thrombolysis or primary PTCA. If the 
ECG remains nondiagnostic but stuttering symptoms continue, 
urgent angiography is recommended. 
Interventional Therapy 
There is considerable variation in use of acute catheteriza- 
tion, angiography, and catheter or surgical interventions in the 
management of patients with suspected acute MI and non- 
diagnostic ECGs. The approach of acute catheterization has 
been promoted to quickly identify the problem and offer 
reperfusion therapy and expedite hospital discharge. Although 
PTCA for non-Q wave MI has been shown to have high 
success rates and improve myocardial function within the 
infarct zone, few data exist regarding its effect on clinical 
outcome. 92.152 To elucidate this issue, the TIMI-IIIB study was 
undertaken. 
T1MI-II1B was the largest (1473 patients) randomized, 
controlled trial of early intervention versus a conservative 
strategy in patients with unstable angina/MI and nondiagnostic 
electrocardiographic changes. 92 Results showed no significant 
difference in the primary outcome (death, MI, or a positive 
exercise test at 42 days) in patients receiving early angiography 
and revascularization versus the conservative approach (16.2% 
versus 18.1%), 92 although the trend favored PTCA. Hospital 
mortality rates in the population selected for this trial were low 
(less than 3%) and considerably ower than the rate observed 
for patients with nondiagnostic electrocardiographic changes 
in the large trials. The rate of death and recurrent MI in 
patients with documented MI and nondiagnostic ECGs treated 
by early intervention versus conservative therapy was 7.2% 
versus 9.9%. Similarly, in the subset of patients with unstable 
angina, these event rates (7.2% versus 6.9%) were not signif- 
icantly different. In those with ST-segment depression, death 
and MI occurred in 10.5% in the early intervention group 
versus 11.8% in the conservative group. All patients were 
treated with/3-adrenoceptor blockers, calcium channel block- 
ers, nitrates, heparin, and aspirin. By 42 days, 64% of the 
conservative-treatment group had received coronary angiogra- 
phy because of either spontaneous or induced ischemia on 
provocative testing. Fifty-five percent of the angiograms were 
done before hospital discharge. The greatest difference be- 
tween the two treatment strategies was the need for rehospi- 
talization, which was less in patients undergoing early inter- 
vention (7.8% versus 14.1%, respectively.) The initial 
hospitalization was statistically shorter, but the average time 
saved was only 15 hours and the lengths of hospital stay were 
much longer than the national average (10 days). There were 
no economic omparisons of the two strategies, and thus it is 
not known whether the cost of routine angiography and 
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intervention was offset by the reduced need for rehospitaliza- 
tion. 
Many physicians in hospitals with full cardiac facilities 
routinely perform delayed coronary angiography within 2 to 3 
days of admission and then revascularization if appropriate, 
even if the patient remains asymptomatic, ls3 Other physicians 
treat such patients conservatively and perform angiography 
and revascularization ly in those with spontaneous or in- 
duced ischemia during provocative testing in the recovery 
phase of hospitalization. Proponents for the routine use of 
coronary angiography soon after admission for patients with 
suspected MI and nondiagnostic electrocardiographic findings 
argue that (1) a definitive anatomic diagnosis can be made and 
prognosis can be stratified, based on the extent of coronary 
disease and LV dysfunction; (2) a therapeutic plan can be 
executed early in the hospital, possibly reducing length of stay; 
and (3) patients with critical coronary obstructions can un- 
dergo revascularization in the hope that outcome improves and 
the subsequent need for antianginal medications lessens. ~53 
However, there are no trials or empiric data substantiating 
better outcome using this approach. A conservative strategy of 
risk stratification and a more selective use of procedures may 
be more cost-effective with revascularization less frequently 
performed and targeted to those who would most benefit from 
it. 
More recent data from the TIMI-IIIB study ~54 suggest that 
patients with unstable angina or non-Q wave MI who have 
elevations of cTnI on admission have an increased risk of death 
or nonfatal MI at 6 weeks. Clearly more studies are needed in 
this area before a guideline for optimal care can be suggested. 
In general the outcome of patients with ischemic-type chest 
discomfort and isolated T wave or other minor abnormalities is 
favorable, and the relative role of interventions in this group is 
much less clear. 
IV. Hosp i ta l  Management  
Early, General Measures 
Recommendations 
Class I 
1. Selection of electrocardiographic monitoring leads 
based on infarct location and rhythm. 
2. Bed rest with bedside commode privileges for initial 12 
hours in hemodynamically stable patients free of ischemic- 
type chest discomfort. 
3. Avoidance of Yalsalva. 
4. Careful attention to maximum pain relief. 
Class lib 
1. Routine use of anxiolytics. 
Class III 
1. Prolonged bed rest (more than 12 to 24 hours) in stable 
patients without complications. 
Monitoring for Adverse Events 
Early general measures focus on monitoring for adverse 
events, preventing such events through protective measures, 
and treating adverse vents when they do occur. Electrocar- 
diographic monitoring is an essential role of CCU staff, who 
must be adept at rhythm interpretation, lead selection based 
on infarct location and rhythm, 82 as well as lead placement for 
detection of right ventricular involvement. 155 Computer algo- 
rithms have proved superior to medical personnel for detec- 
tion of arrhythmias. 156 However, the choice of lead placement 
and application technique (ie, skin preparation and use of 
conducting els) remain essential human skills. 
Blood pressure should be measured repeatedly; actual 
frequency will depend on the severity of the illness. Although 
invasive arterial monitoring (discussed in "Hospital Manage- 
ment") is preferred in the hypotensive patient, noninvasive 
monitoring is adequate for most patients. Monitoring with an 
automatic device that inflates and deflates at programmed 
intervals is useful, but it must be recognized that measure- 
ments may be inaccurate because of inappropriate cuff size or 
muscle contractions; marked peripheral vasoconstriction can 
result in falsely low readings. Furthermore, many patients 
report that the device is irritating and disrupts rest. Pulse 
oximetry is now routine for continuous monitoring of oxygen 
saturation and extremely helpful for providing early warning of 
hypoxemia. 
I~vel of Activity 
Protection against adverse events involves a variety of 
measures aimed at minimizing myocardial damage by main- 
taining a balance of oxygen supply and demand. If oxygen and 
aspirin therapy have not been initiated in the ED, they should 
be administered immediately (see "Initial Recognition and 
Management in the Emergency Department" for dosing), and 
the need for nitroglycerin should be determined (see "Ratio- 
nale and Approach to Pharmacotherapy" for dosing). All 
healthcare providers hould communicate quiet confidence. 
Limiting early physical exertion and minimizing sympa- 
thetic stimulation (eg, acute ischemic-type chest discomfort 
and anxiety) are methods of minimizing myocardial oxygen 
demand that increases the area of myocardial damage when 
coronary, blood flow is limited, a57 In an earlier era the duration 
of bed rest was extended to several weeks until it was known 
that prolonged immobility is harmful because of the physio- 
logical deconditioning that occurs after even 6 hours in the 
supine position. 15s Preload decreases because of plasma vol- 
ume losses that occur early in the bed rest period. Shifts in 
ventricular filling activate the body's compensatory mecha- 
nisms to buffer pressure and volume alterations. Cardiovascu- 
lar dysfunction after bed rest may be more a function of these 
fluid shifts than deconditioning from physical inactivity?59 
A short period (about 12 hours) of bed rest seems prudent 
for most patients with acute MI with allowances for bedside 
commode use. Prolonged bed rest is unnecessary except for 
patients with acute MI who are hemodynamically unstable. 
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NS or DsW to keep vein open 
q~'.~ h until stable, then q 4 h and p.r.n. Notify if HR <60 
or >110; BP <90 or >150; RR <8 or >22. Pulse 
oximetry x24 h. 
Bed rest with bedside commode and progress as tolerated 
after approximately 12 h 
NPO until pain free, then clear liquids. Progress to a 
heart-healthy diet (complex carbohydrates=50-55% of 
kilocalories, monounsaturated an  unsaturated fats 
-<30% of kilocalories), including foods high in 
potassium (eg, fruits, vegetables, whole grains, dairy 
products), magnesium (eg, green leafy vegetables, whole 
grains, beans, seafood), and fiber (eg, fresh fruits and 
vegetables, whole-grain breads, cereals). 
,. Nasal 02 2 L/min × 3 h 
• Enteric-coated ASA daily (165 rag) 
• Stool softener daily 
• /3-adrenoceptor blockers? 
• Consider need for analgesics, nitroglycerin, anxiolytics 
Low-level activities uch as toileting, assisted bathing, and light 
ambulation should be used to prevent physiological decondi- 
tioning. Sample admitting orders are presented in Table 5. 
"Coronary precautions," designed to limit physical exertion 
and sympathetic stimulation, became the standard of care in 
the 1960s. Iced and hot fluids were restricted as were stimulant 
beverages, rectal temperature measurements and examina- 
tions, and vigorous back rubs; assistance with eating was 
common, and enforced bed rest was the norm. A recent 
national survey demonstrates that coronary precautions are 
still in practice across the United States despite the fact that 
research does not support heir use. ~6° 
Avoidance of the Valsalva maneuver is the only coronary 
precaution of universal significance. Forced expiration against 
a closed glottis causes udden and intense changes in systolic 
blood pressure and heart rate. Changes in ventricular loading 
during the Valsalva maneuver may influence regional endocar- 
dial repolarization and predispose the patient o ventricular 
arrhythmias. L61.~62 Age attenuates autonomic ardiovascular 
responsiveness/6L163-~65 so avoiding use of the Valsalva ma- 
neuver may be especially important inpersons younger than 45 
years. Stool softeners hould be prescribed routinely, and a 
bedside commode rather than a bedpan should be used by all 
but the most unstable patients. 
Blood pressure increases after caffeine intake, t66 but the 
increase is not clinically significant until 400 mg of caffeine (ie, 
2 to 4 cups of coffee, depending on strength and brewing 
method) isingested.167 People who drink caffeinated beverages 
regularly develop a tolerance after 1 to 4 days] 68,t69 regardless 
of dose. Withdrawal of caffeine is associated with head- 
ache 17°,171 and increases in heart rate/72 Routine caffeine 
drinkers can safely drink several cups of coffee daily even while 
in the CCU. 173 
Proper Analgesia (Use of Morphine, Anxiolytics, and 
the Role of Education) 
Patients with acute MI typically exhibit overactivity of the 
sympathetic nervous system, which adversely increases myo- 
cardial oxygen demands through acceleration of heart rate, 
elevation of arterial pressure, augmentation f cardiac ontrac- 
tility, and a heightened tendency to occurrence of ventricular 
tachyarrhythmias. 97.174 Because this sympathetic drive arises 
from a combination of ischemic-type chest discomfort and 
anxiety, a primary objective of therapy is administration f
sufficient doses of an analgesic such as morphine sulfate to 
relieve what many patients have described as a feeling of 
impending doom. Morphine sulfate can be administered intra- 
venously at a rate of 2 to 4 mg every 5 minutes, with some 
patients requiring as much as 25 to 30 mg before pain relief is 
adequate?V,175 The current practice of administering morphine 
in small increments o avoid paradoxic augmentation f sym- 
pathetic nervous ystem tone and respiratory depression may 
have a tendency to result in too low a cumulative dose being 
administered. Fear of inducing hypotension also tends to 
restrict the amount of morphine sulfate administered. It is 
important to realize that morphine-induced hypotension typi- 
cally occurs in volume-depleted, orthostatic patients and is not 
a particular threat o supine patients. 97 It may be more prudent 
to avoid concomitant use of other vasodilators such as intra- 
venous nitroglycerin in patients with severe unremitting pain. 
Patients hould be instructed to noti~ the nurse immediately 
when discomfort occurs and describe its severity using a 
numeric scale (eg, 1 to 10). 
The depressant effect of morphine on ventilation is cen- 
trally mediated and widely appreciated. Fortunately, in the 
setting of acute MI respiratory depression is usually not a 
significant clinical problem because of the sympathetic dis- 
charge associated with severe ischemic-type chest discomfort 
or pulmonary edema. Administration f0.4 mg naloxone IV at 
up to 3-minute intervals to a maximum of 3 doses may be used 
to relieve morphine-induced respiratory depression, should it 
Occur. 
Patient education effectively decreases emotional dis- 
tress, ~76 increases knowledge, 177 and changes behavior 17s fol- 
lowing acute MI. Patients want information about risk fac- 
tors ~78 and self-management techniques (eg, how to treat 
ischemic-type chest discomfort) rather than information about 
disease pathophysiology (eg, causes of ischemic-type chest 
discomfort)/79 Effective educational techniques focus on con- 
crete, objective information before procedures are per- 
formed/8° Following are some examples of sensory informa- 
tion that are helpful to patients before they undergo cardiac 
catheterization: 
• "The room will be dimly lit and may feel cool." 
• "You will hear us tell you to take a deep breath and hold 
it." 
• "The dye will make you feel hot and flushed for about 15 
seconds." 
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Materials written at a sixth-grade reading level or below are 
best.t81 
The decreasing length of hospital stays has raised concern 
about adequate opportunity for appropriate patient educa- 
tion, ls2 although short educational sequences have been shown 
to produce outcomes comparable to lengthy sessions. 178 Inno- 
vative presentation styles (eg, programmed instruction, audio- 
visual techniques, health education television programs) can 
produce benefits comparable to individual educational ses- 
sions. 177A83 All patients may not be ready to learn during 
hospitalization, and methods of accommodating them until 
they are ready are greatly needed. Responsibility for some 
education can be delegated to healthcare professionals who 
see the patient after discharge (eg, cardiac rehabilitation, 
home health, or office nurse). Use of a single repository for all 
educational materials (eg, a binder that travels with the 
patient) may provide consistency, document material taught, 
and identify goals that remain. Self-education through per- 
sonal computer software or videotapes warrants further study. 
Inclusion of spouses in teaching also increases learning and 
retention over time. 184 
It is important to note that 80% of all sudden cardiac deaths 
occur in persons with known cardiovascular disease. 185 Accord- 
ingly, family members of acute MI patients hould be taught 
CPR, 186 because most episodes of cardiac arrest occur within 
18 months of hospital discharge. ~87 
Symptoms of nicotine withdrawal, anxiety, insomnia, de- 
pression, difficulty concentrating, irritability, anger, restless- 
ness, and slowed heart rate ~s8 may occur in hospitalized 
smokers. Pharmacological therapy can be of benefit o patients 
experiencing nicotine withdrawal. The proper use of anxiolyt- 
ics, however, is dependent on a thorough understanding of
their pharmacokinetics and pharmacodynamic properties. 29
Agitation and delirium are not uncommon in the CCU, 
particularly in patients with complicated acute MI and pro- 
tracted stays in the intensive care setting. In addition, a number 
of drugs frequently used in the CCU, such as lidocaine, 
mexiletine, procainamide, atropine, cimetidine, and meperi- 
dine, are capable of inducing delirium. Intravenous haloperi- 
dol is a rapidly acting neuroleptic that can be given safely and 
effectively to cardiac patients with agitation. It rarely produces 
hypotension or requires assisted ventilation. In selected pa- 
tients the use of anxiolytics may prove beneficial. 
Usually, however, routine use of pharmacological anxiolyt- 
ics is neither necessary nor recommended. Dixon and col- 
leagues ~s9 have demonstrated that anxiety, blood pressure, 
heart rate, and ischemic-type chest discomfort were no differ- 
ent in patients treated with diazepam compared with those 
treated with placebo. Conversely, psychological support pro- 
vided during hospitalization has been shown to decrease 
anxiety and depression immediately and for up to 6 months 
after acute MI. 184 Liberalized visiting rules for patients in 
critical care can be helpful; several studies have demonstrated 
no harmful physiological effects attributable to unrestricted 
visiting policies, w°,191 
Treatment of Adverse Events 
Although the use of prophylactic antiarrhythmic agents in 
the first 24 hours after MI is not recommended, the availability 
of atropine, lidocaine, pacing paddles or a pacemaker, a
defibrillator, and epinephrine remains prudent for treating 
important rhythm disorders.* Lidocaine in a dose of 1.0 to 
1.5 mg/kg IV may be used for first-line treatment of sustained 
ventricular tachycardia (VT) associated with hemodynamic 
instability. See "Rationale and Approach to Pharmacology" 
for further recommendations. 
Epinephrine plays a prominent role in advanced life sup- 
port following a circulatory arrest associated with VF, asystole, 
or electromechanical dissociation. 192 Although it is known to 
have an adverse ffect on cardiac rhythm and increases myo- 
cardial oxygen demand, it does support he peripheral vascular 
tree and thus enhances circulation during external chest com- 
pression. 
Identification and Treatment of the Patient at 
Low Risk 
Several methods have been proposed to reduce the cost of 
caring for acute MI patients: (1) identify true infarcts early; (2) 
provide early aggressive reperfusion; and (3) streamline the 
in-hospital phase of management using clinical guidelines and 
critical pathways, tratifying patients based on risk, and reduc- 
ing length of CCU stay and total length of stay in hospital. 
The ready availability of serum cardiac marker measure- 
ments in most hospitals, coupled with significant advances in 
techniques for rapidly measuring markers that rise into the 
abnormal range in less than 6 hours (eg, myoglobin, 64,65 
CK-MB isoforms, 59 cardiac specific troponin T and 156,61) now 
enable clinicians to diagnose or exclude MI in uncertain cases 
within 8 to 12 hours from onset of chest discomfort. Use of 
such rapid biochemical techniques has been shown to reduce 
length of stay in CCUs, and clinicians are encouraged toassess 
their current laboratory testing protocols with a goal of more 
accelerated decision making? 93 
Several reports in the literature suggest hat reperfusion 
protocols with thrombolytic agents or PTCA can significantly 
reduce hospital stay. 194-197 Important independent predictors 
of freedom from late major complications include absence of 
early sustained VT or VF, absence of early sustained hypoten- 
sion or cardiogenic shock, the presence of only one or two 
coronary arteries with significant (75%) stenosis, and a pre- 
served LV ejection fraction (greater than 40%). 196 
Using clinical variables at presentation, clinicians can esti- 
mate a patient's risk of mortality before administering throm- 
bolytic therapy, l°2,tgs Although considerable controversy cen- 
ters around the relative merits of one thrombolytic agent over 
another, it is important to realize that several clinical variables 
*The committee strongly recommends that physicians and nurses maintain 
expertise in the correct differentiation of accelerated i ioventricular hythm, 
bundle branch block, and monomorphic and polymorphic ventricular tachycar- 
dia. 
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Figure 9. Influence of clinical characteristics on 30-day mortality after 
myocardial infarction in patients treated with thrombolytic agents 
based on experience from the GUSTO (Global Utilization of Strep- 
tokinase and TPA for Occluded Arteries) trial. Although considerable 
attention has been paid to optimizing thrombolytic regimens--indeed, 
the small absolute differences in mortality observed with different 
thrombolytic regimens are controversial--it should be emphasized that 
the choice of the agent is far less important than are certain clinical 
variables with respect to mortality. This pyramid epicts the impor- 
tance of such clinical characteristics as calculated from a regression 
analysis in the GUSTO trial. Numbers in parentheses indicate the 
proportion of risk of 30-day mortality associated with particular 
characteristics; shaded blocks indicate variables that constitute 90% of 
mortality seen in post-MI patients with ST elevation receiving throm- 
bolytic therapy, tPA indicates tissue-type lasminogen activator; US 
Hosp, patients reated in a US hospital; CVD, cardiovascular disease; 
CABG, coronary artery bypass graft; DM, diabetes mellitus; AMI, 
acute myocardial infarction; BP, blood pressure. From Lee KL. 
Predictors of 30-day mortality in the era of reperfusion for acute 
myocardial infarction: results from an international trial of 41 021 
patients. Circulation. 1995;91:1659-1668. Reproduced with permission. 
Also modified from Management of Acute Myocardial lnfarction (Julian 
D, Braunwald E, eds). Antman EM. Medical therapy for acute 
coronary syndromes: anoverview. In: Califf RM, ed. Acute Myocardial 
Infarction and Other Acute Ischemic Syndromes, p 54, 1994, by permis- 
sion of the publisher, WB Saunders Co Ltd, London. 
have a greater influence on a given patient's mortality risk than 
the exact hrombolytic agent prescribed. A recent analysis from 
the contemporary reperfusion era provides useful information 
by summarizing the independent influence of clinical charac- 
teristics on 30-day mortality in patients with ST elevation 
treated with thrombolysis 199 (Fig 9). 
Triage of Patients With Acute Myocardial Infarction 
and Other Coronary Syndromes 
The premium on cardiac intensive care beds makes it 
imperative that alternatives to the CCU be developed for 
patients for whom an M1 is excluded and MI patients with a 
low-risk profile. Persons who are considered at very low risk 
and who are expected to derive little benefit from thrombolytic 
theraw (eg, lack of ST-segment displacement on ECG, con- 
stellation of clinical features uggesting less impact of throm- 
bolysis on mortality) should nevertheless remain in the hospital 
to receive other medical interventions, including rest, anti- 
platelet herapy, antithrombin therapy, and /3-adrenoceptor 
blockers. 
Data compiled from multiple studies (largely before the 
reperfusion era) suggest that patients admitted to the CCU for 
observation and treatment ofsuspected MI can be triaged to a 
low-risk category. 1°2.2°°-2°3 Although extensive data have not 
been recompiled in this era of reperfusion therapy for MI, 
clinical experience suggests that patients can be transferred 
safely out of the CCU as early as 24 to 36 hours after admission 
if they do not have a history of previous infarction, persistent 
ischemic pain, CHF, hypotension, heart block, or hemodynam- 
ically compromising ventricular arrhythmias. It is unlikely that 
such patients will require transfer back to the CCU or will die 
in the hospital. 2°4 
One of the most important determinants of resource use for 
management of MI patients i  diagnostic testing--an expendi- 
ture that may not be necessary in low-risk MI patients and that 
may prolong hospital stay. zo5 Considerable variation exists 
among countries in management of MI, 2o6 across and within 
geographic regions in the United States, 207 across medical 
specialties, 205 among patients of differing race and gender, z°8 
and between young and old patients with MI. z°9 Even after 
adjusting for baseline determinants of risk, part of this varia- 
tion in practice patterns cannot be explained by medical issues, 
highlighting the need for contemporary guidelines for clinical 
practice and regular updating of local hospital protocols and 
critical pathway maps. 
Two trends in nursing care have been developed to reduce 
costs: (1) the use of personnel with less training or without 
licenses in place of registered nurses and (2) changes in 
staff-patient ratios. Although patients identified as low risk 
may be able to be safely managed following such changes, few 
data are available to document the safety and quality implica- 
tions of these trends. There is concern that reduction i  staffing 
ratios has not only curtailed time available for in-patient 
education but has increased the level of stress experienced by 
critical-care nurses today. Additionally there are data to sug- 
gest that alterations instaffing may negatively influence patient 
recovery rates and treatment success. When mortality rates of 
hospitals documented to attract high-quality nurses were com- 
pared with a matched sample of hospitals that failed to attract 
such staff, the magnet hospitals had a 4.6% lower mortality rate 
after adjusting for differences in predicted mortality 
(P=.026). 2I~ Superior outcomes could not be attributed to 
patient, organizational, or physician characteristics. Although 
flexibility in staffing patterns is desirable to respond to the 
frequent fluctuations in levels of acuity, more data are required 
before a general recommendation can be made about changes 
in nurse staffing patterns. 
Summary of Identification and Treatment of the 
Patient at Low Risk 
Clinicians should strive to identify patients with an acute 
coronary syndrome who have not sustained an MI ideally 
within 8 to 12 hours of onset of symptoms. This can be 
accomplished by serial sampling of serum cardiac markers and 
use of 12-lead ECGs and their interpretation in the context of 
the number of hours that have elapsed since onset of the 
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patient's ymptoms rather than adherence to a rigid protocol 
that requires a specified number of samples be drawn in the 
hospital. For example, to exclude an MI in a patient presenting 
to the ED within 4 hours of onset of ischemic-type chest 
discomfort, blood specimens might be drawn at admission 
and 8 hours later. A patient presenting 12 hours after onset 
of discomfort who has a normal ECG and normal serum 
cardiac marker levels in the ED need not be admitted to the 
CCU. 
The mortality risk of patients who do sustain an MI can be 
evaluated using an integrated assessment of demographic and 
clinical variables according to the scheme shown in Fig 9. 
Low-risk patients include those without a history of previous 
infarction and who do not experience persistent ischemic pain, 
CHF, hypotension, heart block, or hemodynamically compro- 
mising ventricular arrhythmias. Such patients can be safely 
transferred out of the CCU within 24 to 36 hours of admission 
and, provided they remain asymptomatic and without compli- 
cations, constitute a group of patients who can be considered 
for early discharge in another 24 to 48 hours. 
Identification and Treatment of the Patient at 
High Risk 
Recommendations for Management of Recurrent 
Chest Discomfort 
Class I
1. Aspirin for pericarditis. 
2. /3-Adrenoceptor blockers intravenously, then orally for 
ischemic-type chest discomfort. 
3. (Re)administration of thrombolytic therapy (alteplase) 
for patients with recurrent ST elevation. 
4. Coronary arteriography for ischemic-type chest discom- 
fort recurring after hours to days of initial therapy and 
associated with objective evidence of ischemia in patients who 
are candidates for revascularization. 
Class lla 
1. Nitroglycerin intravenously for 24 hours, then topically 
or orally for ischemie-type chest discomfort. 
Class lib 
1. Corticosteroids for periearditis. 
2. Indomethacin for pericarditis. 
Recurrent Chest Pain in the Post-MI Patient: 
Pericarditis and Ischemia 
Recurrent chest pain in the patient still hospitalized after 
MI requires an evaluation of the cause of the pain while 
initiating therapy to resolve it, if possible. 
The two most common cardiac causes of recurrent chest 
pain are acute pericarditis and ischemia, with the latter being 
the more common and potentially more serious. An ECG 
taken during the recurrent pain and compared with the initial 
one is clinically helpful, 38 Usually, recurrent pain within the 
first 12 hours after onset of infarction is considered to be 
related to the original infarction itself. Pericarditis is probably 
not responsible for significant chest discomfort in the first 24 
hours. 
Pericarditis in acute MI occurs with extension of myocardial 
necrosis throughout the wall to the epicardium. The Multi- 
center Investigation of the Limitation of Infarct Size (MILIS) 
study 211 found that pericarditis (defined as the presence of a 
pericardial friction rub) occurred in 20% of 703 patients 
following acute MI. Postinfarction pericarditis occurs in ap- 
proximately 25% of patients with acute transmural MI not 
treated with thrombolytic therapy when typical symptoms or a 
pericardial friction rub are accepted as indicative of pericardi- 
tis, whereas the average incidence is only 14% when the 
presence of a friction rub is required for the diagnosis. 212 
Patients with pericarditis have larger infarcts (defined by 
CK-MB), lower ejection fraction (measured with radionuclide 
ventriculography), and a higher incidence of CHF. 211,2t3 Peri- 
carditis may appear up to several weeks after acute MI. 
Anterior chest discomfort mimicking ischemia can occur with 
pericarditis. However, pericardial pain usually has distinguish- 
ing characteristics such as pleuritic or positional discomfort, 
radiation to the left shoulder, scapula or trapezius muscle and 
a pericardial rub, electrocardiographic J-point elevation with 
concave upward ST-segment elevation and PR depression. 
Pericardial effusion is evident echocardiographically in more 
than 40% of cases z14 but is rarely of hemodynamic conse- 
quence. A small effusion is not diagnostic of pericarditis as it 
can be demonstrated in the majority of patients with acute 
MI.:a 
Focal pericarditis can be diagnosed electrocardiographi- 
cally by either persistently positive T waves or reversal of 
initially inverted T waves during the first week after acute 
transmural MI. However, similar T-wave alterations have also 
been observed when postinfarction pericardial effusion exists 
in the absence of clinically recognized pericarditis. 215 Pericar- 
ditis is not associated with re-elevation of CK-MB, and there 
are data to suggest i s incidence has decreased in the reperfu- 
sion era. 216-21s Interestingly, Dressler syndrome (post-MI syn- 
drome), an autoimmune-type carditis, has essentially disap- 
peared 219 in the reperfusion era. 
Aspirin (160 to 325 mg daily) is the treatment of choice, but 
high doses (650 mg every 4 to 6 hours) may be required. 22°,221 
Indomethacin provides effective relief of symptoms; however, 
one study has presented ata that suggest it may cause 
increased coronary vascular esistance 222 and experimentally 
causes thinning of developing scar. 223 Ibuprofen and cortico- 
steroids, also efficacious for pain relief, exert a tendency for 
thinning of scar and myocardial rupture, e24,225 The risk-benefit 
ratio of continuing antithrombotic therapy such as heparin in 
the presence of acute pericarditis i always a clinical challenge. 
Usually such therapy can be continued safely but requires 
added vigilance for the detection of enlarging pericardial 
effusion or signs of hemodynamic instability. Any evidence of 
impending cardiac tamponade is an indication for prompt 
termination of antithrombotic therapy. 
It is important to differentiate between pain due to pericar- 
JACC Vol. 28, No. 5 RYAN ET AL. 1359 
November 1, 1996:1328-428 MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
ditis and that due to ischemia. The latter is more likely when 
the chest pain is similar to the initial ischemic-type chest 
discomfort, occurring at rest or with limited activity during 
hospitalization. This may or may not be associated with 
re-elevation of the CK-MB, ST-segment depression or eleva- 
tion, or pseudonormalization f inverted T waves (T-wave 
inversion on baseline ECG becoming upright during isch- 
emia). 214 Early recurrent angina, especially after successful 
reperfusion, may occur in up to 58% of patients. 226 
Reinfarction has been reported to occur in approximately 
10% of patients during the first 10 days but only in up to 3% to 
4% of patients who have undergone thrombolytic therapy and 
received aspirin. 97,~27-23o Reinfarction is associated with re- 
elevation of serum CK-MB after the initial peak of the index 
infarction. Diagnosis of reinfarction within 18 hours after 
initiation of thrombolytic therapy should be based on recur- 
rence of severe ischemic-type chest discomfort lasting at least 
30 minutes, usually, but not always, accompanied by recurrent 
ST-segment elevation of at least 0.1 mV in at least two 
contiguous ECG leads and re-elevation of CK-MB to more 
than the upper limit of normal or increased by at least 50% 
over the previous value97 Pathological findings of reinfarction 
show areas of healing myocardium along with the more recent 
necrosis usually in the same vascular isk region of myocardial 
tissue perfused by the original infarct-related artery. Death, 
severe CHF, and arrhythmias are early complications of rein- 
farction, and there is an increased incidence of cardiogenic 
shock or cardiac arrest. 227,231 
With recurrent suspected ischemic-type chest discomfort, 
coronary arteriography often clarifies the cause of chest dis- 
comfort with demonstration f a high-grade coronary obstruc- 
tion. Prompt reperfusion using PTCA (if available and the 
lesion is suitable) or additional thrombolysis appropriate, 
especially if a thrombus is present. If multiple high-grade 
lesions are present, more complete revascularization byCABG 
is appropriate. 
Cardiac rupture may account for recurrent pain and occurs 
in 1% to 4% of all patients admitted with acute MI. 230,232-234 
Left ventricular f ee wall rupture is typically heralded by chest 
pain and electrocardiographic ST-T wave changes with rapid 
progression to hemodynamic collapse and electromechanical 
dissociation. The frequency of cardiac rupture has two peaks: 
an early peak within 24 hours and a late one from 4 to 7 days 
after acute MI. Early rupture is related to the initial evolution 
of infarction before significant collagen deposition, and late 
rupture is related to expansion of the infarct-related ventricu- 
lar wan. 9°,232 Cardiac rupture is observed most frequently in 
patients with the first MI, those with anterior infarction, the 
elderly, and women. Other risk factors include hypertension 
during the acute phase of MI, lack of previous angina or MI, 
lack of collateral blood flow, Q waves on the ECG, use of 
corticosteroids or nonsteroidal anti-inflammatory drugs, and 
use of thrombolytic therapy more than 14 hours after on- 
set. 9°,234 However, thrombolytic therapy early after acute MI, 
ie, within 14 hours, decreases risk of cardiac rupture. 91,233 The 
most important determinants in preventing rupture are suc- 
cessful early reperfusion and the presence of collateral circu- 
lationY 2,233 Pseudoaneurysm is a serious complication repre- 
senting rupture of the free wall. Clot forms in the pericardial 
space, and an aneurysmal wall containing clot and pericardium 
prevents exsanguination. The echocardiogram characteristi- 
cally shows a small neck opening into the body of the 
aneurysmY ~Surgical correction is always indicated. 
Pericardiocentesis for relief of tamponade and emergency 
surgical repair may be lifesaving. 235,23~ Transesophageal echo- 
cardiography is valuable in the diagnosis of free wall rupture 
and pseudoaneurysm, but for relief of tamponade in this 
setting, rapid fluid replacement is essential. Ideally the patient 
should be in the operating room and fully prepared for or 
already on cardiopulmonary b pass to prevent hemodynamic 
collapse. 
Heart Failure and Low-Output Syndromes 
Left Ventricular Dysfunction 
Pump failure due to acute MI is manifested clinically by a 
weak pulse, poor peripheral perfusion with cool and cyanotic 
limbs, obtundation, and oliguria. Blood pressure (taken by 
cuff) is usually low, and there are variable degrees of pulmo- 
nary congestion. A third heart sound may be audible. 
The treatment of LV dysfunction is determined by the 
specific hemodynamic derangements hat are present, most 
importantly (1) pulmonary capillary wedge pressure, (2) car- 
diac output (measured with a balloon flotation catheter), and 
(3) systemic arterial pressure (preferably measured with an 
intra-arterial cannula). Often the patient has a cardiac index 
less than 2.5 L/min/m 2, a modestly elevated left-sided filling 
pressure (greater than 18 mm Hg), and a systolic arterial 
pressure 100 mm Hg or greater. Although this subject has 
evidence of LV dysfunction, systemic arterial pressure is 
adequate to allow for (l) modest diuresis (best accomplished 
with intravenous furosemide) in combination with (2) after- 
load and preload reduction, using nitroglycerin. Nitroglycerin 
offers a greater degree of venodilation than sodium nitroprus- 
side and relieves ischemia by dilating epicardial coronary 
arteries. In the early hours of acute infarction, when ischemia 
often contributes substantially toLV dysfunction, nitroglycerin 
is the more appropriate agent. Its intravenous infusion should 
be initiated at 5 /xg/min and increased gradually until mean 
systolic arterial pressure falls by 10% to 15% but not below 
90 mm Hg. The institution of ACE inhibitor therapy is also 
appropriate in this setting. 
The patient with more severe LV dysfunction has a de- 
pressed cardiac output, an abnormally high left-sided filling 
pressure, and systolic arterial pressure less than 90 mm Hg; this 
patient has, or is rapidly approaching, cardiogenic shock. If the 
patient is markedly hypotensive, intravenous norepinephrine 
should be administered until systolic arterial pressure rises to 
at least 80 mm Hg, at which time a change to dopamine may be 
attempted, beginning at 5 to 15 p~g/kg per minute. Once 
arterial pressure is brought o at least 90 mm Hg, intravenous 
dobutamine may be given simultaneously in an attempt o 
reduce the magnitude of the dopamine infusion. In addition, 
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consideration should be given to initiating intra-aortic balloon 
counterpulsation. 
Recent nonrandomized and retrospective studies have sug- 
gested that mechanical reperfusion by PTCA or CABG of 
occluded coronary arteries may improve survival in patients 
with MI and cardiogenic shock. In large clinical trials such 
patients have an in-hospital survival rate ranging from 
20% to 50% when treated with intravenous thrombolytic 
therapy. 237-24° In other case series mechanical reperfusion with 
PTCA has been reported to result in hospital survival rates as 
high as 70%, but selection bias may have influenced these 
findings. Multicenter, prospective, randomized studies are 
currently under way to verify these promising results. 241 
In the setting of cardiogenic shock complicating acute MI, 
emergency CABG has been used when other interventions 
have failed or not been indicated. A multicenter trial of 
surgically controlled repeffusion using total vented cardiopul- 
monary bypass and substrate-enhanced blood cardioplegia in 
patients with acute non-PTCA-related coronary occlusion 
noted 3.4% mortality overall with 9% mortality in patients with 
preoperative shock. 242,243 Data from the SHOCK (Should We 
Emergently Revascularize Occluded Coronaries for Cardio- 
genic Shock?) Registry suggest hat, in some patients, emer- 
gency CABG (without specific recommendations regarding 
intraoperative myocardial protection strategies) is associated 
with lower mortality (19%) than emergency PTCA (60%) for 
patients with cardiogenic shock complicating acute MI. 241 In 
other nonrandomized studies surgical mortality ranged from 
12% 244 to 42% 245 but is generally superior to other treatment 
modalities. The efficacy of emergency CABG in patients with 
cardiogenic shock may be better defined by an ongoing clinical 
trial. 241 
Based on these earlier studies, consideration for emergency 
CABG should be given for acute MI patients with multivessel 
disease or cardiogenic shock and who are not candidates for or 
who have undergone unsuccessful thrombolytic therapy and/or 
PTCA, and who are within 4 to 6 hours of onset of MI. 
Right Ventricular Infarction and Dysfunction 
Right ventricular infarction encompasses a spectrum of dis- 
ease states ranging from asymptomatic mild right ventricular 
(RV) dysfunction through cardiogenic shock. Most patients 
demonstrate a return of normal RV function over a period of 
weeks to months, suggesting RV stunning has occurred rather 
than irreversible necrosis. In this sense RV ischemia can be 
demonstrated in up to half of all inferior MIs, although only 
10% to 15% of patients how classical hemodynamic abnor- 
malities.24~,,247 
Right ventricular infarction accompanying inferior MIs is 
associated with a significantly higher mortality (25% to 30%) 
and thus identifies a high-risk subgroup of patients with 
inferior Mls (6%) who should be considered high-priority 
candidates for reperfusion. 246 One group of investigators e- 
cently reported a 31% in-hospital mortality rate in patients 
with inferior MIs complicated by RV infarction compared with 
6% in patients who had an inferior MI without RV involve- 
ment. 246 The treatment of patients with RV ischemia is 
different and occasionally diametrically opposed to manage- 
ment of LV dysfunction. 
Anatomic and Pathophysiological Considerations 
The right coronary artery usually supplies most of the RV 
myocardium; thus, occlusion of this artery proximal to the RV 
branches will lead to RV ischemia, z4s Hemodynamically sig- 
nificant RV infarctions occur almost exclusively in the setting 
of inferior acute MIs. 249 Because the right ventricle has a much 
smaller muscle mass than the left ventricle, due to the lower 
vascular resistance of the pulmonary circuit, myocardial oxygen 
demand is significantly less than that of the left ventricleY ° 
Coronary perfusion of the right ventricle occurs in both systole 
and diastole. 25° The right ventricle also has a more favorable 
oxygen supply-demand ratio than the left ventricle, because of 
the more extensive collateral flow from left to right351,25z 
These factors likely explain the absence of hemodynamically 
significant RV ischemia in most patients with proximal right 
coronary artery occlusions, as well as improvement in RV 
function observed in the majority of patients following RV 
ischemia. 253 
The severity of the hemodynamic derangements a sociated 
with RV ischemia is related to (1) the extent of ischemia nd 
subsequent RV dysfunction, (2) the restraining effect of the 
surrounding pericardium, and (3) interventricular dependence 
related to the shared interventricular septum. When the right 
ventricle becomes ischemic, it acutely dilates, resulting in an 
increased intrapericardial pressure caused by the restraining 
forces of the pericardium. As a consequence, there is a 
reduction in RV systolic pressure and output, decreased LV 
preload, a reduction in LV end-diastolic dimension and stroke 
volume, and a shifting of the interventricular septum toward 
the left ventricle. 254 Because of this RV systolic and diastolic 
dysfunction, the pressure gradient between the right and left 
atria becomes an important driving force for pulmonary per- 
fusion. Factors that reduce preload (volume depletion, diuret- 
ics, nitrates) or diminish augmented right atrial contraction 
(concomitant atrial infarction, loss of AV synchrony), as well 
as factors that increase RV afterload (concomitant LV dys- 
function), are likely to have profoundly adverse hemodynamic 
effects. 255-257 Goldstein and coworkers 256 have demonstrated 
the importance of a paradoxical interventricular septal motion 
that bulges in pistonlike fashion into the right ventricle, 
generating systolic force, which allows pulmonary perfusion. 
The loss of this compensatory mechanism with concomitant 
septal infarction may result in further deterioration i patients 
with RV ischemia. 
Clinical Diagnosis 
Evidence of RV ischemia should he sought in all patients 
with acute inferior MI. The clinical triad of hypotension, clear 
lung fields, and elevated jugular venous pressure in the setting 
of an inferior MI is characteristic of RV ischemia. Although 
specific, this triad has a sensitivity of less than 25%. z58 Dis- 
tended neck veins alone or the presence of Kussmaul's ign 
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Table 6. Treatment S rategy for Right Ventricular 
Ischemia/Infarction 
Maintain right ventricular preload 
Volume loading (IV normal saline) 
Avoid use of nitrates and diuretics 
Maintain AV synchrony 
AV sequential pacing for symptomatic high-degree heart block 
unresponsive to atropine 
Prompt cardioversion for hemodynamically significant SVT 
Inotropic support 
Dobutamine (if cardiac output fails to increase after volume loading) 
Reduce right ventricular afterload with left ventricular dysfunction 
Intra-aortic balloon pump 





CABG (in selected patients with multivessel disease) 
IV indicates intravenous; AV, atrioventricular; SVT, supraventricular t chy- 
cardia; ACE, angiotensin converting en~me; PTCA, percutaneous transluminal 
coronary angioplasty: CABG, coronary, arte~, bypass graft. 
(distention ofthe jugular vein on inspiration) are both sensitive 
and specific for RV ischemia in patients with an inferior MI. 2s9 
These findings may be masked in the setting of volume 
depletion and may only become vident after adequate volume 
loading. A right atrial pressure of 10 mm Hg or greater and 
greater than 80% of pulmonary wedge pressure is a relatively 
sensitive and specific finding in patients with RV ischemia. 26° 
Demonstration f 1 mm ST-segment elevation in the right 
precordial lead V4R is the single most predictive lectrocardio- 
graphic finding in patients with RV ischemia. 261 The finding 
may be transient; half of patients how resolution of ST 
elevation within 10 hours of onset of symptoms. 262 It is 
important for physicians to ensure that hospital personnel 
(house officer, nurse, technician) recording the ECG in this 
setting know how to properly record lead V4R, especially in 
view of the variety of multilead recording systems available. All 
patients with inferior infarctions hould be screened initially 
for this finding at the time of admission. Critical-care staff 
should be encouraged to choose routine monitoring leads 
based on infarct site. Echocardiography can be helpful in 
patients with suspicious but nondiagnostic findings, va It can 
show RV dilation and asynergy, abnormal interventricular and 
interatrial septal motion, and even right to left shunting 
through a patent foramen ovale. 2~+26~ This latter finding is 
unique to RV ischemia nd should be suspected when persis- 
tent hypoxia is not responsive to supplemental oxygen. 265 
Management of Right Ventricular Ischemia/Infarction 
Treatment of RV infarction includes early maintenance of 
RV preload, reduction of RV afterload, inotropic support of 
the dysfunctional right ventricle, and early reperfusion 73 (Ta- 
ble 6). Because of their influence on preload, drugs routinely 
used in management of LV infarctions, such as nitrates and 
diuretics, may reduce cardiac output and produce severe 
hypotension when the right ventricle is ischemic. Indeed, a 
common clinical presentation for RV infarction is profound 
hypotension following administration f sublingual nitroglyc- 
erin, with the degree of hypotension ften out of proportion to 
the electrocardiographic severity of the infarct. Volume load- 
ing with normal saline alone often resolves accompanying 
hypotension and improves cardiac output, z*6 In other cases, 
volume loading further elevates the right-sided filling pressure 
and RV dilatation, resulting in decreased LV output. 267 Al- 
though volume loading is a critical first step in the management 
of hypotension associated with RV ischemia, inotropic support 
(in particular, dobutamine hydrochloride) should be initiated if
cardiac output fails to improve after 1 to 2 L of fluid has been 
given. 
Another important factor for sustaining adequate RV pre- 
load is maintenance of AV synchrony. High-degree heart block 
is common, occurring in as many as half of these patients. 26~ 
Atrioventricular sequential pacing leads to a significant in- 
crease in cardiac output and reversal of shock, even when 
ventricular pacing alone has not been of benefit. 269 Atrial 
fibrillation may occur in up to one third of patients with RV 
ischemia 27° and has profound hemodynamic effects. Prompt 
cardioversion from atrial fibrillation should be considered at 
the earliest sign of hemodynamic compromise. When LV 
dysfunction accompanies RV ischemia, the right ventricle is 
further compromised because of increased RV afterload and 
reduction in stroke volume. 271 In such circumstances, the use 
of afterload-reducing agents uch as sodium nitroprusside or 
an intra-aortic ounterpulsation device is often necessary to 
"unload" the left and subsequently the right ventricle. 
Fibrinolytic therapy and primary PTCA with subsequent 
reperfusion have been shown to improve RV ejection frac- 
tion 272 and reduce the incidence of complete heart block. 272-274 
Prognosis 
The mere presence of RV ischemia evident by noninvasive 
criteria is associated with significantly increased short-term 
morbidity and mortality and may also influence long-term 
outcome. 246,275,276 Clinical and hemodynamic recovery even- 
tually occur even in patients with RV dysfunction 259,277-279 
that persists for weeks or months. This return to normal 
may be due to improvement of concomitant LV dysfunction, 
resulting in a reduction in RV afterload, or to a gradual 
stretching of the pericardium with amelioration of its restrain- 
ing effect. 277 
Hemodynamie Monitoring 
Recommendations for Balloon Flotation Right-Heart 
Catheter Monitoring 
Class I 
1. Severe or progressive CHF or pulmonary edema. 
2. Cardiogenic shock or progressive hypotension. 
3. Suspected mechanical complications of acute infarction, 
ie, VSD, papillary muscle rupture, or pericardial tamponade. 
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Class Ila 
1. Hypotension that does not respond promptly to fluid 
administration in a patient without pulmonary congestion. 
Class III 
1. Patients with acute infarction without evidence of car- 
diac or pulmonary complications. 
The balloon flotation catheter is often very helpful in 
management of acute MI and concomitant hemodynamic 
instability, including low cardiac output, hypotension, persis- 
tent tachycardia, pulmonary edema, and apparent cardiogenic 
shock. In the patient with hypotension and tachycardia, the 
balloon flotation catheter allows quick and easy differentiation 
of (1) inadequate intravascular volume, with a resultant low 
left-sided filling pressure, and (2) adequate intravascular vol- 
ume and a high left-sided filling pressure due to extensive LV 
dysfunction. Treatment of the former is prompt expansion of 
intravascular volume (with normal saline), whereas manage- 
ment of the latter often includes diuresis, inotropic support, 
afterload reduction, and/or other supportive measures. In 
those with extensive LV dysfunction, a balloon flotation cath- 
eter in the right side of the heart can be used to monitor 
therapeutic efforts to adjust he left-sided filling pressure so as 
to maximize cardiac output at the lowest possible filling 
pressure. These sophisticated manipulations of intracardiac 
pressures and cardiac output are usually made considerably 
easier with information provided by a flotation catheter. 
Although the balloon flotation catheter is quite safe when 
used by experienced operators, its use has a recognized 
association with adverse vents, including ventricular tachyar- 
rhythmias (during its manipulation) and pulmonary hemor- 
rhage or infarction. In addition, it causes ome patient discom- 
fort and requires that the patient be relatively immobile. 
Because the pressure waveform recorded from the catheter tip 
may be distorted, the clinician should routinely examine the 
actual waveform rather than rely on the digital display of 
pressure. Because of the risk of infection, balloon flotation 
catheters generally should not remain in the same site for more 
than 5 days. 
Recommendations for Intra-arteriai 
Pressure Monitoring 
Class I 
1. Patients with severe hypotension (systolic arterial pres- 
sure less than 80 mm Hg) and/or cardiogenic shock. 
2. Patients receiving vasopressor agents. 
Class lla 
1. Patients receiving intravenous odium nitroprusside or 
other potent vasodilators. 
Class lib 
1. Hemodynamically stable patients receiving intravenous 
nitroglycerin for myocardial ischemia. 
2. Patients receiving intravenous inotropic agents. 
Class III 
1. Patients with acute infarction who are hemodynamically 
stable. 
All CCUs should have the equipment and personnel to 
monitor intra-arterial pressure. Such monitoring isuseful in all 
hypotensive patients, particularly those with cardiogenic shock. 
Long-term onitoring isbest accomplished through the radial 
artery, although the brachial or femoral arteries may be used as 
alternatives. Perfusion of the limb or hand distal to the 
catheter site must be carefully and periodically examined for 
evidence of ischemia. Because of risk of arterial thrombosis 
and infection, intra-arterial catheters generally should not 
remain in the same arterial site for prolonged periods of time, 
certainly no longer than 72 hours. Intra-arterial nd central 
catheters can be left in place for this amount of time only if 
carefully inserted and properly cared for with a sterile occlu- 
sive dressing. Before insertion, the site should be adequately 
prepared under sterile conditions. Antibacterial ointments are 
no longer ecommended. 28° 
Recommendations for Intra-aortic 
Balloon Counterpulsation 
Class I 
1. Cardiogenic shock not quickly reversed with pharmaco- 
logical therapy as a stabilizing measure for angiography and 
prompt revascularization. 
2. Acute mitral regurgitation or VSD complicating MI as a 
stabilizing therapy for angiography and repair/revascularization. 
3. Recurrent intractable ventricular arrhythmias with he- 
modynamic instability. 
4. Refractory post-MI angina as a bridge to angiography 
and revascularization. 
Class lla 
1. Signs of hemodynamic instability, poor LV function, or 
persistent ischemia in patients with large areas of myocar- 
dium at risk. 
Class lib 
1. In patients with successful PTCA after failed thrombo- 
lysis or those with three-vessel coronary disease to prevent 
reocclusion. 
2. In patients known to have large areas of myocardium at 
risk with or without active ischemia. 
Since its introduction i the late 1960s, intra-aortic balloon 
counterpulsation has been recognized as an effective treatment 
for patients with unstable ischemic syndromes and cardiogenic 
shock. 2sl-286 Reduction of LV afterload by rapid deflation of 
the balloon in end diastole appears to be the predominant 
mechanism ofthe balloon's effect. 287,288 By inflating in diastole, 
the balloon also raises diastolic coronary and systemic perfu- 
sion. Studies on the effects of this increased perfusion pressure 
on coronary blood flow and myocardial oxygen consumption 
have yielded conflicting results. 2s9,29° Recently Kern et al, z91 
using Doppler flow velocity measurements, were able to show 
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a nearly twofold increase in proximal coronary flow velocity. 
This combination ofdecreased myocardial oxygen demand and 
maintained or improved coronary flow make intra-aortic bal- 
loon pumping a powerful tool for patients with cardiogenic 
shock or acute ischemic syndromes. 
Counterpulsation was first used as a stand-alone modality 
to treat patients with post-MI cardiogenic shock. 281 Counter- 
pulsation stabilized most patients, but in-hospital mortality 
remained a dismal 83%. 2sl In virtually all shock-management 
strategies in which counterpulsation s used today, it acts as a 
stabilizing device or bridge to facilitate diagnostic angiography 
and revascularization r repair. In selected patient populations 
survival rates for cardiogenic shock treated in the first 16 to 24 
hours with intra-aortic balloon pumping and surgical and 
angioplasty revascularization range between 60% and 
75%. 2~4,2~2 Similarly, intra-aortic balloon pumping and early 
repair for acute VSD and mitral regurgitation show survival 
rates of 60% or sometimes higher. 2s5 Patients with severe 
recurrent ischemia after MI can be stabilized with an intra- 
aortic balloon pump so that they can undergo angiography and 
emergency revascularization with PTCA or CABG. 24° 
Several early studies, before reperfusion therapy, showed 
that routine prophylactic use of intra-aortic balloon pumping 
in acute MI 2s2-293 did not affect infarct size. A retrospective 
review of the Thrombolysis and Angioplasty in Myocardial 
Infarction (TAMI) trials suggested that placement of an 
intra-aortic balloon pump after eperfusion with either throm- 
bolytic therapy or PTCA reduced the incidence of reocclu- 
sion. 294 In a subsequent randomized trial, patients with rescue 
PTCA at 90 minutes or those with three-vessel CAD 295 showed 
a reduction of reocclusion events from 21% to 8% after 
intra-aortic balloon pumping. In a second randomized trial of 
the use of prophylactic placement of these devices in high-risk 
patients (age greater than 70, ejection fraction less than 45%, 
three-vessel disease, suboptimal PTCA, saphenous graft occlu- 
sion, ventricular arrhythmias) undergoing primary PTCA, 437 
patients were studied to determine the effect of balloon 
pumping on resulting LV function and a composite clinical end 
point (death, reocclusion, reinfarction, CHF, and stroke). 
There was no significant difference in clinical outcome, includ- 
ing rate of reocclusion (6.2% versus 8.0%), nor did it influence 
global or regional LV function. 29~, However, there was a 
reduction in the incidence of recurrent ischemia, including the 
need for repeat angiography and PTCA of the infarct-related 
artery. In summary, for patients without LV dysfunction, the 
prophylactic and routine use of intra-aortic balloon pumping 





1. Electrical cardioversion for patients with severe hemo- 
dynamic compromise or intractable ischemia. 
2. Rapid digitalization to slow a rapid ventricular esponse 
and improve LV function. 
3. Intravenous /]-adrenoceptor blockers to slow a rapid 
ventricular response in patients without clinical LV dysfunc- 
tion, bronchospastic disease, or AV block. 
4. Heparin should be given. 
Class l la 
1. Either diltiazem or verapamil intravenously to slow a 
rapid ventricular response if/3-adrenoceptor blocking agents 
are contraindicated or ineffective. 
Atrial fibrillation (AF) associated with acute MI most often 
occurs within the first 24 hours and is usually transient but may 
recur. The incidence of AF in acute MI ranges from 10% to 
16%, 2~7,2'~8 whereas atrial flutter or supraventricular tachycar- 
dia is much less frequent. The consequences and acute treat- 
ment of all three conditions may be considered together, 
recognizing that in atrial flutter and supraventricular tachycar- 
dia, atrial pacing may be effective in terminating the 
tachycardia. 299-3°5 The incidence of AF increases with age, 
occurring in 4.2% of patients aged 59 years or less and in 16% 
of patients aged 70 or older. Atrial fibrillation occurs more 
often in patients with larger infarcts, those anterior in location, 
and in patients whose hospital course is complicated by CHF, 
complex ventricular arrhythmias, advanced AV block, atrial 
infarction, or pericarditis. Atrial fibrillation may also occur in 
patients with inferior MI secondary to proximal right coronary 
artery occlusion due to involvement of the sinoatrial nodal 
artery, which provides the major blood supply to the atria. 
The incidence of AF after acute MI is decreased in patients 
receiving thrombolytic therapy, 3"°-3°6 and in the GUSTO trial 
patients treated with accelerated alteplase and intravenous 
heparin had a significantly lower incidence of AF and atrial 
flutter compared with other fibrinolytic therapies. 22s The oc- 
currence of AF is also associated with excess catecholamine 
release, hypokalemia, hypomagnesemia, hypoxia, underlying 
chronic lung disease, and ischemia of the sinus node or left 
atrial circumflex arteries, z7~,297,3°°,307-31° 
Systemic embolization is more frequent in patients with 
paroxysmal AF (1.7%) compared with those without (0.6%), 
with one half of embolic events occurring on the first day of 
hospitalization and more than 90% occurring by the fourth 
day. 29s Because AF can be associated with pericarditis, the 
development of PR-segment displacement onserial ECGs may 
predict risk of developing AF during hospitalization? o6 
When hemodynamic compromise occurs due to rapid ven- 
tricular ate or loss of atrial contraction, immediate cardiover- 
sion is indicated, beginning with 100 J, then 200 to 300 J, then 
360 J if lower energies fail. In the conscious patient, support 
with brief anesthesia s essential. 
In the absence of CHF or severe pulmonary disease, one of 
the most effective means of slowing the ventricular rate in AF 
is the use of intravenous/3-adrenoceptor blocking agents uch 
as atenolol (2.5 to 5.0 mg over 2 minutes to a total of 10 mg in 
10 to 15 minutes) or metoprolol (2.5 to 5.0 mg every 2 to 5 
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minutes to a total of 15 mg over 10 to 15 minutes). Heart rate, 
blood pressure, and the ECG should be monitored, and 
treatment should be halted when therapeutic efficacy is 
achieved or if systolic blood pressure falls below 100 mm Hg or 
heart rate below 50 bpm during treatment. 
Rapid administration of digitalis to achieve rate slowing 
may be accomplished by giving intravenous digoxin (8 to 
15 Ixg/kg [0.6 to 1.0 mg in a person weighing 70 kg]) with half 
the dose administered initially and the additional increment in
4 hours. 221 This method provides a slower response than 
intravenous/3-adrenoceptor blockade; however, some effect on 
rate slowing may be detectable in one half to 2 hours. 
Rate slowing may also be achieved by intravenous vera- 
pamil (5 to 10 mg [0.075 to 0.15 mg/kg]) given over 2 minutes 
with a repeat dose 30 minutes later or similarly by intravenous 
bolus administration f diltiazem (20 mg [0.25 mg/kg]) over 2 
minutes followed by an infusion of 10 mg/h. If rate response is
inadequate, a second ose of diltiazem (25 mg [0.35 mg/kg]) 
may be given over 2 minutes after an interval of 15 minutes. A 
subsequent i fusion is given at a rate of 10 to 15 mg/h. Because 
of their negative inotropic effect and newer concerns regarding 
the use of calcium channel blockers in acute MI, these agents 
are not recommended as first-line drugs despite their effective- 
ness in slowing heart rate, especially if given to patients also 
receiving/3-blocking a ents. 311 Although AF after acute MI is 
usually transient, heparin therapy should be given to patients 
not already receiving it. 
Guidelines for use of Class I and Class III antiarrhythmic 
agents and electric shock for converting persistent AF have not 
been formulated. It is not clear whether antiarrhythmic agents 
should be used for prevention of AF if it recurs during 
hospitalization, although its recurrence portends a worse prog- 
nosis? °5 For this reason it has become common practice to use 
antiarrhythmic agents such as quinidine, procainamide, or, 
preferably, amiodarone or sotalol. 312 Transient AF does not 
obligate the patient o receive long-term anticoagulation r 
antiarrhythmic agents, but if such treatment is elected, it is 
appropriate to limit their use to 6 weeks if sinus rhythm has 
been restored. 
Ventricular Tachycardia/Ventricular Fibrillation 
Recommendations 
Class I 
1. Ventricular fibrillation should be treated with an unsyn. 
chronized electric shock with an initial energy of 200 J; if 
unsuccessful, a second shock of 200 to 300 J should be given, 
and, if necessary, a third shock of 360 J. 
2. Sustained (more than 30 seconds or causing hemody- 
namic collapse) polymorphic VT should be treated with an 
unsynchronized electric shock using an initial energy of 200 J; 
if unsuccessful, a second shock of 200 to 300 J should be given, 
and, if necessary, a third shock of 360 J. 
3. Episodes of sustained monomorphic VT associated with 
angina, pulmonary edema, or hypotension (blood pressure 
less than 90 mm Hg) should be treated with a synchronized 
electric shock of 100 J initial energy. Increasing energies may 
be used if not initially successful. 
4. Sustained monomorphic VT not associated with angina, 
pulmonary edema, or hypotension (blood pressure less than 
90 mm Hg) should be treated with one of the following 
regimens: 
a. Lidocaine: bolus 1.0 to 1.5 mg/kg. Supplemental bo- 
luses of 0.5 to 0.75 mg/kg every 5 to 10 minutes to a maximum 
of 3 mg/kg total loading dose may be given as needed. Loading 
is followed by infusion of 2 to 4 mg/min (30 to 50 pg/kg per 
minute). 
b. Procainamide: 20 to 30 mg/min loading infusion, up 
to 12 to 17 mg/kg. This may be followed by an infusion of 1 to 
4 mg/min. 
c. Amiodarone: 150 mg infused over 10 minutes followed 
by a constant infusion of 1.0 mg/min for 6 hours and then a 
maintenance infusion of 0.5 mg/min. 
d. Synchronized electrical cardioversion starting at 
50 J (brief anesthesia is necessary). 
Comment: Knowledge of the pharmacokinetics of these agents 
is important because dosing varies considerably, depending on 
age, weight, and hepatic and renal function. 
Class IIa 
1. Infusions of antiarrhythmic drugs may be used after an 
episode of VTNF but should be discontinued after 6 to 24 
hours and the need for further arrhythmia management 
assessed. 
2. Electrolyte and acid-base disturbances hould be cor- 
rected to prevent recurrent episodes of VF when an initial 
episode of VF has been treated. 
Class lib 
1. Drug-refractory polymorphic VT should be managed by 
aggressive attempts to reduce myocardial ischemia, including 
therapies such as fl-adrenoceptor blockade, intra-aortic bal- 
loon pumping, and emergency PTCA/CABG surgery. Amioda- 
rone, 150 mg infused over 10 minutes followed by a constant 
infusion of 1.0 mg/min for up to 6 hours and then a mainte. 
nance infusion at 0.5 mg/min, may also be helpful. 
Class III 
1. Treatment of isolated ventricular premature beats, cou- 
plets, runs of accelerated idioventricular hythm, and nonsus- 
tained VT. 
2. Prophylactic administration of antiarrhythmic therapy 
when using thrombolytic agents. 
Ventricular Fibrillation--Background 
Disturbances of cardiac rhythm are common during acute 
MI. Early-phase arrhythmias are probably largely a result of 
micro reentry. Although other electrophysiological mecha- 
nisms such as enhanced automaticity and triggered activity 
have been proposed in experimental models of MI, convincing 
evidence of their role in human MI is not yet established. 313 
Important contributory factors include heightened adrenergic 
nervous ystem tone, hypokalemia, hypomagnesemia, intracel- 
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lular hypercalcemia, cidosis, free fatty acid production from 
lipolysis, and free radical production from reperfusion of 
ischemic myocardium? 13-315 The relative importance ofeach of 
these factors in the pathogenesis of arrhythmias during acute 
MI has not been established, nor has it been clearly shown that 
aggressive measures pecifically targeted at one or more of 
these mechanisms can be relied on clinically to reduce arrhyth- 
mia frequency in acute MI. 
Primary VF should be distinguished from secondary VF, 
the latter occurring in the presence of severe CHF or cardio- 
genie shock. 3u' Late VF develops more than 48 hours after 
onset of infarction. The incidence of primary VF is highest 
(around 3% to 5%) in the first 4 hours after MI and declines 
markedly thereafter. 3~7 Epidemiological data suggest that the 
incidence of primary VF in acute MI may be decreasing in the 
current era, possibly due to aggressive attempts at infarct-size 
reduction, correction of electrolyte deficits, and a greater use 
of/3-adrenoceptor blocking agents? 'aContrary to prior belief, 
primary VF appears to be associated with a significantly higher 
in-hospital mortality, but those persons who survive to hospital 
discharge have the same long-term prognosis as patients who 
do not experience primary VF. 3> 
Management Strategies for Ventricular Fibrillation 
PROPHYLAXIS 
Primary VF remains an important contributor to risk of 
mortality during the first 24 hours after MI. Therefore, a 
reliable method for its prediction and prevention remains 
desirable but has not been established despite xtensive clinical 
investigation. Classification of ventricular arrhythmias in as- 
cending order of risk of primary VF ("warning arrhythmias") 
was proposed, but this approach lacks appropriate specificity 
and sensitivity? 2°-~-2 
Accelerated i ioventricular rhythm occurs frequently dur- 
ing the first 12 hours of infarction. Data from the prereperfu- 
sion era do not support development of accelerated i ioven- 
tricular hythm as a risk factor for development of VF. 32~,32~ In 
patients receiving thrombolysis or undergoing primary PTCA, 
accelerated i ioventricular rhythm may be a reperfusion ar- 
rhythmia nd does not indicate an increased risk of VF? 24 
Thus, it is best managed by observation and should not trigger 
initiation of antiarrhythmic prophylaxis against VF. 
Meta-analysis of randomized trials of prophylaxis with 
lidocaine has shown a reduction i  the incidence of primary VF 
by about 33%, but this was offset by a trend toward increased 
mortality, probably from fatal episodes of bradycardia nd 
asystole. 32s The prior practice of routine ("prophylactic") 
administration of lidocaine to all patients with known or 
suspected MI has been largely abandoned in most contempo- 
rary CCU protocols because of an unfavorable risk-benefit 
ratio and a decreased incidence of the target arrhythmia. Thus, 
its routine use is not recommended, with the possible excep- 
tion being situations in which a defibrillator is unavailable, 
provided there is a skilled professional always available who 
can initiate CPR if asystole occurs. Prophylactic regimens with 
other antiarrhythmic drugs have not been evaluated as exten- 
sively as lidocaine, and no other agents, even including the 
close structural nalogues mexiletine and tocainide, have been 
shown to decrease the incidence of primary VF when given on 
a prophylactic basis. 
Routine administration of intravenous /3-adrenoceptor 
blockers to patients without hemodynamic or electrical (AV 
block) contraindications is associated with a reduction in 
incidence of early VF. Intravenous followed by oral 
,6-adrenoceptor blockers should be given in the absence of 
contraindications. Suitable regimens include intravenous 
metoprolol (5 mg every 2 minutes for 3 doses, if tolerated, 
followed by 50 mg orally twice a day for at least 24 hours and 
then increased to 100 mg twice a day). An alternative r gimen 
is atenolol (5 to 10 mg intravenously followed by 100 mg orally 
on a daily basis). 
Clinical experience as well as observational data from CCU 
populations has identified hypokalemia as an arrhythmogenic 
risk factor for VF. 314-315 Low serum levels of magnesium have 
not been clearly shown to be associated with an increased risk 
of VF, -~15 although tissue depletion of magnesium remains a 
potential risk factor. Although randomized clinical trial data 
do not exist to confirm the benefits of repletion of potassium 
and magnesium deficits in preventing VF, it is sound clinical 
practice to maintain serum potassium levels at greater than 
4.0 mEq/L and magnesium levels at greater than 2.0 mEq/L in 
patients with acute MI. 
TREATMENT 
Ventrieular fibrillation should be treated with an unsyn- 
chronized electric shock using an initial energy of 200 J. If this 
is unsuccessful, a second shock using 200 to 300 J and, if 
necessary, a third shock using 360 J is indicated? 26Ventricular 
fibrillation that is not easily converted by defibrillation may be 
treated with additional adjunctive measures. No rigorous sci- 
entific support exists to favor one pharmacological treatment 
program over another or even to confirm that hey improve the 
likelihood of resuscitation over repeated shocks given alone. 
The ACLS protocol recommends adjunctive therapy in the 
following hierarchy, as needed, for resistant VF32~': (1) epi- 
nephrine (1 mg IV push); (2) lidocaine (1.5 mg/kg); (3) 
bretylium (5 to 10 mg/kg). Intravenous amiodarone (150 mg 
bolus), now available, also may be used. 
There are no firm data to help define an optimal manage- 
ment strategy for prevention of recurrent VF in patients who 
have sustained an initial episode of VF in the setting of MI. It 
seems prudent to correct any electrolyte and acid-base distur- 
bances and administer /3-adrenoceptor-blocking a ents to 
inhibit increased sympathetic nervous system tone and 
prevent ischemia. 313 If infusion of an antiarrhythmic drug is 
initiated (eg, lidocaine 2 mg/min), it should probably be 
maintained for only 6 to 24 hours and then discontinued sothat 
the patient's ongoing need for antiarrhythmic treatment can be 
reassessed. 
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Ventricular Tachycardia--Background 
Several definitions have been used for VT in the setting of 
acute MI. Nonsustained VT lasts less than 30 seconds, whereas 
sustained VT lasts more than 30 seconds and/or causes earlier 
hemodynamic compromise requiring immediate intervention. 
Based on electrocardiographic appearance, VT has also been 
categorized as monomorphic or polymorphic. While short 
bursts (fewer than 5 beats) of nonsustained VT of either 
monomorphic or polymorphic onfiguration may be seen fre- 
quently, contemporary epidemiological data do not suggest 
that they are associated with a sufficiently increased risk of 
sustained VT or VF to warrant a recommendation of prophy- 
lactic therapy. 
The vast majority of post-MI VT and VF occur within the 
first 48 hours of MI. 31v Sustained VT or VF occurring outside 
of this time frame deserves careful evaluation, including con- 
sideration of electrophysiology studies. In addition, monomor- 
phic VT at rates less than 170 bpm are unusual as a post-MI 
arrhythmia and suggests a more chronic (mature) arrhythmo- 
genic substrate. 32v-33° 
Management S rategies for Ventricular Tachycardia 
1. Only for episodes of sustained hemodynamically com- 
promising VT is treatment always indicated. 3j3 In the absence 
of clinical evidence of effective perfusion, urgent electrical 
conversion of VT is indicated. Rapid, polymorphic-appearing 
VT should be considered similar to VF and managed with an 
unsynchronized discharge of 200 J, while monomorphic VT 
with rates greater than 150 bpm can usually be treated with a 
100-J synchronized discharge. 32~ If the patient is hemodynam- 
ically stable, brief trials of medications (lidocaine or procain- 
amide) may be given first. Immediate cardioversion is generally 
not needed for rates under 150 bpm. 
2. Episodes of sustained VT that are somewhat better 
tolerated hemodynamically may initially be treated with one of 
the following drug regimens: 
a. Lidocaine: bolus 1.0 to 1.5 mg/kg. Supplemental 
boluses of 0.5 to 0.75 mg/kg every 5 to 10 minutes to a 
maximum of 3 mg/kg total loading dose may be given as 
needed. Loading is followed by infusion of 2 to 4 mg/min (30 
to 50/sg/kg per minute), in older patients and those with CHF 
or hepatic dysfunction, infusion rates should be reduced to 
avoid lidocaine toxicity. 
b. Procainamide: 20 to 30 rag/rain loading infusion, up 
to 12 to 17 mg/kg. This may be followed by an infusion of 1 to 
4 mg/min. Infusion rates should be lower in the presence of 
renal dysfunction. 
c. Amiodarone: 150 mg infused over 10 minutes fol- 
lowed by a constant infusion of 1.0 mg/min for 6 hours and 
then a maintenance infusion at 0.5 mg/min. 
3. Rare episodes of drug-refractov sustained polymor- 
phic VT ("electrical storm") have been reported in cases of 
acute MI. Anecdotal evidence suggests that these may be 
related to uncontrolled ischemia and increased sympathetic 
tone and are best treated by intravenous /3-adrenoceptor 
blockade, 331 intravenous amiodarone, 332 intra-aortic balloon 
pumping, or emergency revascularization. 
Bradyarrhythmias nd Heart Block 
Background, Epidemiology, and Importance 
Sinus bradycardia occurs frequently (in 30% to 40% of 
patients) with acute MI, especially within the first hour of 
inferior MI and with reperfusion of the right coronary artery 
(Bezold-Jarish reflex), a result of increased parasympathetic 
activity (vagal tone). 97 Heart block may develop in approxi- 
mately 6% to 14% of patients with acute MI and predicts an 
increased risk of in-hospital mortality but is a poor predictor of 
long-term mortality in those surviving to discharge. 333-335 In- 
traventricular conduction delay has been reported in about 
10% to 20% of patients with acute MI in past reviews. 336 Of 
acute MI patients entered in recent hrombolysis trials, BBB 
was present on admission in only 4% but predicted a substan- 
tially increased in-hospital mortality, z7 
The increased mortality associated with heart block and 
intraventricular conduction delay is related more to extensive 
myocardial damage than to heart block as such. Indeed, pacing 
has not been clearly shown to reduce mortality associated with 
AV block or intraventricular conduction delay. 334,337 The dif- 
ficulty in showing benefit may reflect he overriding impact on 
mortality of extensive infarction that may obscure benefit in a 
fraction of these patients. 337,338 Thus, pacing to protect against 
sudden hypotension, acute ischemia, and precipitation of 
ventricular arrhythmias sociated with sudden heart block is 
still recommended in selected high-risk patients. 
Prognosis 
Prognosis in AV block is related to the site of infarction 
(anterior versus inferior), the site of block (intranodal [proxi- 
mal]--above the His bundle--versus infranodal [distal]- 
below the His bundle), the nature of the escape rhythm, and 
the hemodynamic consequences. 221.337-339 
The risk of developing heart block with acute MI is 
increased when one or more of the following are present: 
first-degree AV block, Mobitz type I AV block, Mobitz type II 
AV block, left anterior hemiblock, left posterior hemiblock, 
right bundle branch block (RBBB), and LBBB. 
Treatment 
Recommendations for Atropine (also see "Initial 
Recognition and Management in the Emergency 
Department" for early use) 
Class I
1. Symptomatic sinus bradycardia (generally, heart rate 
less than 50 bpm associated with hypotension, ischemia, or 
escape ventricular arrhythmia). 
2. Ventricular asystole. 
3. Symptomatic AV block occurring at the AV nodal level 
(second-degree type I or third degree with a narrow-complex 
escape rhythm). 
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Class lla 
None. 
Class II I  
1. Atrioventricular block occurring at an infranodal level 
(usually associated with anterior MI with a wide-complex 
escape rhythm). 
2. Asymptomatic sinus bradycardia. 
Atropine reverses decreases in heart rate, systemic vascular 
resistance, and blood pressure mediated by parasympathetic 
(cholinergic) activity. Atropine is useful for treating symptom- 
atic sinus bradycardia, nd may be beneficial in the presence of 
AV block at the AV node level or for ventricular asystole. 32~, 
Atropine is most effective for sinus bradycardia occurring 
within 6 hours of onset of symptoms of acute MI. 33~' Sinus 
bradycardia t this time may be related to ischemia, reperfu- 
sion (Bezold-Jarish reflex), ischemic-type chest discomfort, or 
morphine or nitroglycerin therapy. Atropine is also effective 
for profound sinus bradycardia with hypotension associated 
with thrombolytic therapy (especially of the right coronary 
artery). 34° Atropine should be used with caution in the setting 
of acute MI because of the protective ffect of parasympathetic 
tone against VF and myocardial infarct extension.326, 34~ Doses 
in increments of 0.5 rag, titrated to achieve minimally effective 
heart rate (for example, about 60 bpm), up to a maximum of 
2.0 rag, may be given. 342 (Doses less than 0.5 nag occasionally 
may elicit a parasympathomimetic response with a paradoxic 
slowing of heart rate.) 
Temporary Pacing 
Pacing recommendations i  these revised guidelines place 
more emphasis on transcutaneous pacing. ~ The newly available 
transcutaneous pacemaker systems are suitable for providing 
standby pacing in acute MI, especially for those not requiring 
immediate pacing and at only moderate risk of progression to 
AV block, and do not entail the difficulty in application and 
risk of complications of intravenous systems. 3a3,344 Transcuta- 
neous technology is also well suited to patients receiving throm- 
bolytic therapy, reducing the need for vascular interventions. 
Recommendations for Placement of 
Transcutaneous Patches* and Active (Demand) 
Transcutaneous Pacingt 326 
Class I 
I. Sinus bradycardia (rate less than 50 bpm) with symp- 
toms of hypotension (systolic blood pressure less than 
80 mm Hg) unresponsive to drug therapy.t 
*Transcutaneous patches applied; system ay be attached and activated 
within a brief time if needed. Transcutaneous pacing may be very helpful as an 
urgent expedient. Because it is associated with significant pain, high-risk patients 
likely to require pacing should receive a temporary' pacemaker. 
tApply patches and attach system; system isin either active or standby mode 
to allow immediate use on demand as required. Infacilities inwhich transvenous 
pacing or expertise are not available toplace an IV system, consideration should 
be given to transporting the patient to one equipped and competent i  placing 
transvenous systems. 
2. Mobitz type II second.degree A¥ block.t 
3. Third-degree heart block.t 
4. Bilateral BBB (alternating BBB, or RBBB and alternat- 
ing left anterior fascicular block [LAFB], left posterior fascic- 
ular block [LPFB]) (irrespective of time of onset).* 
5. Newly acquired or age indeterminate LBBB, LBBB and 
LAFBa, RBBB and LPFBa.* 
6. RBBB or LBBB and first-degree AV block.* 
Class lla 
1. Stable bradycardia (systolic blood pressure greater than 
90 mm Hg, no hemodynamic compromise, or compromise 
responsive to initial drug therapy).* 
2. Newly acquired or age.indeterminate RBBB.* 
Class llb 
1. Newly acquired or age-indeterminate first-degree A¥ 
block.* 
Class II I  
1. Uncomplicated acute MI without evidence of conduction 
system disease. 
Transcutaneous systems are available that use a single pair 
of adequately sized, multifunctional electrodes that allow 
electrogram onitoring, transcutaneous pacing, and defibril- 
lation as needed. These systems may be used in a standby 
mode in potentially unstable patients. Because transcutaneous 
pacing may be uncomfortable, specially when prolonged, it is 
intended to be prophylactic and temporary. A transvenous 
pacing electrode should be placed in patients who require 
ongoing pacing and in those with a very high probability of 
requiring pacing (risk of AV block of 30% or more). Thus, 
transcutaneous pacing systems have allowed both the broad- 
ening of the application of standby pacing and the narrowing of 
the application of transvenous pacing. Technical aspects of 
transcutaneous pacing are reviewed elsewhere. 345 The revised 
recommendations reflect this change. 
Recommendations for Temporary Transvenous Pacing:~ 
Class I 
1. Asystole. 
2. Symptomatic bradycardia (includes sinus bradycardia 
with hypotensiou and type I second-degree AV block with 
hypotension not responsive to atropine). 
3. Bilateral BBB (alternating BBB or RBBB with alternat- 
ing LAFB/LPFB) (any age). 
4. New or indeterminate age bifascicular block (RBBB with 
LAFB or LPFB, or LBBB) with first.degree AV block. 
5. Mobitz type I1 second-degree AV block. 
~:It should be noted that in choosing an intravenous pacemaker system, 
patients with substantially depressed ventricular performance, including RV 
infarction, may respond better to atrial/AV sequential pacing than ventricular 
pacing.34~,..~47 
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Class lla (note also "Recommendations for 
Transcutaneous Standby Pacing" above) 
1. RBBB and LAFB or LPFB (new or indeterminate). 
2. RBBB with first-degree AV block. 
3. LBBB, new or indeterminate. 
4. Incessant VT, for atrial or ventricular overdrive pacing. 
5. Recurrent sinus pauses (greater than 3 seconds) not 
responsive to atropine. 
Class lib 
1. Bifascicular block of indeterminate age. 
2. New or age-indeterminate isolated RBBB. 
Class III 
1. First-degree heart block. 
2. Type I second-degree AV block with normal hemody- 
namics. 
3. Accelerated idioventricular hythm. 
4. Bundle branch block or fascieular block known to exist 
before acute MI. 
Transvenous access to the right heart (ie, RV apex) with a 
catheter for temporary pacing can be achieved percutaneously 
through the internal (or external) jugular, subclavian, or 
femoral veins and through the brachial veins, percutaneously 
or by cutdown. 34s Details of pacemaker placement are pro- 
vided elsewhere. 345 Review of the clinical course of 1022 
consecutive patients who received a temporary transvenous 
pacemaker in the CCU during a 5-year period at Mayo 
Clinic 34~ suggests that the preferred routes of insertion, espe- 
cially if fluoroscopy is not immediately available, are the right 
internal jugular vein (generally first choice) or left subclavian 
vein (second choice), provided that he operator iswell-trained 
in venous access at these sites. In overall experience, loss of 
ventricular capture was observed in 18% of patients and 
complications in 14% (without associated mortality,). The 
highest rates of loss of capture and pacemaker-related compli- 
cations occurred with brachial venous pacing. 
Choosing between ventricular (single-chamber) and se- 
quential, AV (dual-chamber) pacing forms part of the 
decision-making process when proceeding with transvenous 
pacing. Because of its greater ease and reliability, ventricular 
pacing with a single lead is usually chosen. However, selected 
patients may require AV synchrony to maintain adequate 
hemodynamic compensation, especially those who are pace- 
maker dependent. In these cases, an atrial J-lead is also placed 
and guided to the right atrial appendage fluoroscopically. 
Alternatively, coronary sinus pacing may be used. Patients with 
RV infarction and other acute MIs with substantially impaired 
systolic and/or diastolic function are frequently best treated 
with AV sequential pacing. 
Once placed, temporary transvenous pacing may be per- 
formed in bipolar or unipolar configurations using a variety of 
commercially available leads. 345 Temporary pacing requires 
meticulous oversight to ensure safety and efficacy. Temporary 
pacemaker care is best provided in an intensive care unit 
setting (generally the CCU). Care includes ensuring sterility of 
the venous access ite and securely attaching the transvenous 
lead to the skin; attending to appropriate function and settings of 
the rate, mode, and threshold functions of the external generator 
box; continuous monitoring to ensure appropriate pacing and 
sensing functions and absence of dislodgment; and frequent (eg, 
at least once per shift) testing of pacing thresholds (pacing energy 
is usually set at more than three times the threshold). 
Permanent Pacing After Acute Myocardial Infarction 
Use of permanent pacemakers after acute MI is addressed 
in the ACC/AHA guidelines for implantation ofcardiac pace- 
makers and antiarrhythmia devices. 34'~ The requirement for 
temporary, pacing in acute MI does not by itself constitute an 
indication for permanent pacing. The unfavorable long-term 
prognosis of patients with acute MI that has caused conduction 
disturbances i related primarily to the extent of associated 
myocardial injury. Consequently these patients are at greater 
risk for death from heart failure and ventricular tachyarrhyth- 
mia than from progressive heart block. Indications for perma- 
nent pacing after acute MI in patients experiencing conduction 
disturbances are related primarily to the degree and type of 




1. Persistent second-degree AV block in the His-Purkinje 
system with bilateral BBB or complete heart block after acute 
MI. 
2. Transient advanced (second- or third-degree) AV block 
and associated BBB.* 
3. Symptomatic AV block at any level. 
Class lib 
1. Persistent advanced (second- or third-degree) block at 
the AV node level. 
Class III 
1. Transient A¥ conduction disturbances in the absence of 
intraventricular conduction defects. 
2. Transient AV block in the presence of isolated LAFB. 
3. Acquired LAFB in the absence of AV block. 
4. Persistent first-degree AV block in the presence of BBB 
that is old or age indeterminate. 
Other Surgical Interventions 
Recommendations for Emergency or Urgent Cardiac 
Repair of Mechanical Defects 
Class I 
1. Papillary muscle rupture with severe acute mitral insuf- 
ficiency. 
*An clectrophysiology study should be considered to assess the site and 
extent of heart block in uncertain cases. 
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2. Postinfarction VSD or free wall rupture and pulmonary 
edema or cardiogenic shock (emergency or urgent). 
3. Postinfarction ventricular aneurysm associated with in- 
tractable ventricular tachyarrhythmias and/or pump failure 
(urgent). 
Class III 
1. Acute infarctectomy in hemodynamically stable patients. 
Clinical Situations Leading to Coronary Artery Bypass 
Graft Surgery 
Evolving Myocardial Infarction 
The role of emergency CABG for evolving MI has been 
discussed in "Initial Recognition and Management in the 
Emergency Department." The prevailing opinion at this time 
is that CABG should be limited to patients who have suitable 
surgical anatomy and who are not candidates for or who have 
failed thrombolytic therapy/PTCA and who are within 4 to 6 
hours of the onset of MI. 
In the setting of cardiogenic shock complicating acute MI, 
emergency CABG has been used when other interventions 
have failed or have not been indicated. This topic has been 
discussed in "Initial Recognition and Management in the 
Emergency Department." 
Failed Pereutaneous Transluminal Coronary Angioplasty 
Emergency CABG is indicated for most patients with acute 
MI who have persistent angina pectoris or hemodynamic 
instability following failed PTCA. Coronary artery bypass graft 
surgery, optimally performed within 2 to 3 hours, can limit 
myocardial necrosis. However, mortality (3.7% to 12.0%) and 
morbidity rates exceed those for elective CABG, in particular 
postoperative hemorrhage, the need for blood products, and 
perioperative MI (21% to 43% in unstable patients). Operative 
mortality is increased in patients with unstable hemodynamic 
status, myocardial ischemia, multivessel disease, and prior 
CABG?5".~51 
Postthrombolytic Therapy 
For the 3339 patients enrolled in the TIMI-II trial, CABG 
was used emergently (1.6%) or electively (10% during initial 
hospitalization), primarily for left main coronary stenosis or 
coronary anatomy not amenable to PTCA and continuing, 
recurrent, or exercise-induced ischemia. 352 For the 41021 
patients enrolled in the GUSTO trial, CABG was used in 8.6% 
at a mean of 8.5 days following thrombolytic therapy? 53
Unstable patients undergoing CABG shortly after thrombo- 
lytic therapy, primarily for continuing myocardial ischemia, 
have a higher operative mortality (13% to 17%) and increased 
use of blood products 35a35"*-355 than hemodynamically stable 
patients operated on within 8 hours of thrombolytic therapy, 
who have a relatively low (2.8%) mortality. 35(' The only inde- 
pendent predictor of perioperative mortality in TIMI-II was 
performance ofCABG within 24 hours of entry or PTCA. The 
low 1-year mortality rate (2.2%) noted for operative survivors 
in this group may support he use of emergency operation for 
selected patients, howeverY 2The intraoperative use of apro- 
tinin may reduce hemorrhage r lated to use of thrombolytic 
agents? 57 
Recurrent Ischemia 
Urgent CABG should be considered when recurrent isch- 
emia occurs in patients who have sustained an acute MI and 
whose coronary artery anatomy is not suitable for PTCA. 
Operative mortality in such patients is correlated closely with 
ejection fraction, and for patients with normal ejection fraction 
is nearly the same as that of elective CABG. 35s-36° The survival 
benefit for patients with reduced LV function supports the use 
of CABG in this situation. 
Elective Coronary Artery Bypass Graft Surgery After 
Acute Myocardial Infarction 
Elective CABG would be expected to improve long-term 
survival in patients with MI who have left main coronary artery 
stenosis (greater than 50%), three-vessel disease, two-vessel 
disease with proximal left anterior descending coronary artery 
stenosis, or two-vessel disease not amenable to PTCA and 
reduced ejection fraction. ~2s The optimal timing of surgery has 
not been established ina randomized controlled trial, although 
recent retrospective reports have suggested that elective 
CABG may be carried out 3 to 7 days after MI with operative 
mortality approaching that for other elective CABG. Risk of 
operation is increased for patients with emergency or urgent 
surgery, older age, and poor ventricular functionY '°-3~'s 
Ventricular Taehyarrhythmias 
Ventricular tachyarrhythmia is not an indication for emer- 
gency CABG except in rare circumstances when refractory 
ventricular tachyarrhythmia is thought to be due to ischemia. 
Intra-aortic balloon pump support has been successful in 
temporarily reducing the incidence of refractory ventricular 
tachyarrhythmia in some casesY '(' 
Patients With Prior Coronary Artery Bypass 
Graft Surgery 
Progression of atherosclerosis, particularly in saphenous 
vein bypass grafts, can result in recurrent myocardial ischemia 
and the need for reintervention? ~'7 These patients typically 
have an increased prevalence of unfavorable risk factors, such 
as previous MI, lower ejection fraction, CHF, and other 
comorbid conditions as well as risk of atheroembolism from 
severely diseased bypass grafts, which increase the risk of 
reoperation i general to approximately 2.0 to 3.5 times the 
risk of the first operation. 244.363-3~7,~6~ Emergency reoperative 
CABG has been reported to have a 17% operative mortality 
with a high rate of recurrent angina in operative survivors 
(74% at 24.9 months). 24~ 
Patients Undergoing Cardiopulmonary Resuscitation 
Mortality rates in patients who have sustained cardiac arrest 
in the cardiac catheterization laboratory and who are not 
responsive to resuscitative measures are reported to be be- 
tween 43% and 100%.  3~¢~'37° Rapid institution of extracorpo- 
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Table 7. Clinical Profile of Mechanical Complications of Myocardial Infarction 
Free Wall Papillary Muscle 
Variable VSD Rupture Rupture 
Age (mean, y) 63 
Days post MI 3-5 
Anterior Ml 66% 
New murmur 90% 
Palpable thrill Yes 
Previous MI 25% 










Visualize defect May have pericardial effusion Flail or prolapsing leaflet 
Detect shunt Regurgitating jet in LA 
Ox'ygen step-up in Equalization of diastolic Prominent V wave in PCW 
Hi RV pressure tracing 
Mortality 
Medical 9(1% 90% 90% 
Surgical 50% Case reports 40-90% 
VSD indicates ventricular septal defect; MI, myocardial infarction; PA, pulmonary arte~,; LA, left atrium; RV, right 
vcntricle; PCW, pulmonary capillary wedge. Modified with permission from Labovitz A J, et al. Mechanical complications 
of acute myocardial infarction. Cardiovasc Rev Rep. 1984;5:948. 
real cardiopulmonary bypass with adequate decompression f
the heart can limit myocardial injury and provide other organ 
perfusion during the interval between cardiac arrest and 
myocardial reperfusion. 371 The decision to proceed with sur- 
gery in such cases requires careful consideration of whether 
the patient's condition is reversible. 
Intraoperative Myocardial Protection in the Acutely 
Injured Heart 
Acute ischemia following coronary occlusion results in 
structural, functional, and metabolic derangements ot only in 
the ischemic myocardium but also in adjacent and remote 
myocardium. The use of intraoperative myocardial preserva- 
tion strategies may limit and perhaps reverse ischemic injury in 
all areas. 372 Emergency CABG using substrate-enhanced 
reperfusate for cardiogenic shock has resulted in reversal of 
refractory LV dysfunction i 94% (75 of 80 patients) 242 and 
hospital survival in 91%. Other myocardial protection strate- 
gies that have been proposed to provide enhanced myocardial 
protection include normothermic blood cardioplegia without 
substrate nhancement 373,374 and hypothermic fibrillatory ar- 
rest without aortic cross-clamping and liberal use of preoper- 
ative intra-aortic balloon pumping. 375,-~7~' The choice of intra- 
operative myocardial protection strategy should rest with the 
individual surgeon. 
Previous reports of operation in the setting of acute MI 
have stressed the use of saphenous vein bypass grafts that 
permit antegrade delivery of cardioplegia solutions into the 
ischemic zone? v7 The use of retrograde (coronary sinus) 
cardioplegia that can perfuse the ischemic zone may permit 
greater use of internal mammary artery bypass grafts, 37~ with 
the potential advantage of better long-term patency. 
Management ofMechanical Defects After Acute 
Myocardial Infarction 
Diagnosis 
Mechanical defects can occur after acute MI and include 
acute mitral valve regurgitation, postinfarction VSD, LV free 
wall rupture, and LV aneurysm. Sudden and/or progressive 
hemodynamic deterioration with low cardiac output and/or 
pulmonary edema should lead to prompt consideration of 
these defects and rapid institution of diagnostic and therapeu- 
tic measures. The clinical and hemodynamic profiles of the 
common mechanical defects that occur after acute MI are 
summarized in Table 7. 
These defects, when they occur, usually present within the 
first week after acute MI. On physical examination, the pres- 
ence of a new cardiac murmur indicates the possibility of either 
VSD, mitral regurgitation, or, occasionally, ventricular up- 
ture. A precise diagnosis can usually be established with 
transthoracic or transesophageal chocardiography. 
Use of a balloon flotation catheter is helpful for both 
diagnosis and monitoring of therapy. With a VSD and left-to- 
right shunting, oxygen saturation will be higher in the pulmo- 
nary artery compared with the right atrium; in this instance, 
thermodilution cardiac output and pulmonary artery samples 
for mixed venous o~gen saturation will be falsely elevated. 
With acute mitral regurgitation, a large V wave will often be 
evident on the pulmonary artery wedge pressure tracing. With 
ventricular rupture and pericardial tamponade, qualization of 
diastolic pressure may be seen. 
Coronary angiography can delineate the presence of surgi- 
cally correctable coronary artery disease and should be done 
unless the patient is hemodynamically severely unstable from 
the mechanical defect alone. Cardiac catheterization may 
JACC Vol. 28, No. 5 RYAN ET AL. 1371 
November 1. 1996:1328-428 MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
better delineate the presence of a mechanical defect if other 
studies are not clear. Insertion of an intra-aortic balloon pump 
can help stabilize the patient as noted in "Hospital Manage- 
ment." Surgical consultation should be obtained when a me- 
chanical defect is suspected so that preparations for surgical 
repair can be optimized. In general, prompt surgical repair is 
indicated, because medical treatment alone is associated with 
extremely high mortality. 
Acute Mitral Valve Regurgitation 
With total rupture of a papillary muscle, medical treatment 
alone is associated with 75% mortality within the first 24 
hours. 379 While emergency surgery is being arranged, the 
patient should receive nitroprusside to help lower pulmonary 
capillary pressures and improve peripheral perfusion. Al- 
though emergency mitral valve replacement is associated with 
relatively high mortality (27% to 55%), both overall mortality 
and subsequent ventricular function are improved, compared 
with medical therapy alone. 38°,381 Delay in operation appears 
to increase the risk of further myocardial injury, other organ 
injury due to hypoperfusion, and subsequent death. 38° Repair 
of the mitral valve has also been reported in selected circum- 
stances of both acute and chronic ischemic mitral insufficiency 
with good results. 382 When technically possible, the supporting 
structure of the mitral valve should be retained to more 
effectively preserve ventricular function. 
Postinfarction Ventricular Septal Defect 
Increased frequency of acute rupture of the interventricular 
septum (VSD) as well as earlier presentation may be noted in 
patients who have undergone thrombolytic therapy. 3s3 Emer- 
gency surgical repair is indicated when pulmonary edema or 
cardiogenic shock is present; repair may be deferred in the 
hemodynamically stable patient. For patients with concomitant 
cardiogenic shock, only patients who underwent surgery within 
48 hours survived. 3~4 Operative mortality is related to early 
operation (34% in the first week after infarction compared 
with 11% after the first week), but this is related to differences 
in the case mix; the presence of cardiogenic shock (39% 
compared with 8% without shock), site of infarction (32% 
inferior, 12% anterior), and age (25% older than 65 years, 17% 
for 65 years and younger). 3s5 Simultaneous CABG, if feasible, 
is indicated for associated significant coronary disease because 
long-term survival is improved. 38s.3~6 
Left Ventricular Free Wall Rupture 
Surgery includes repair of the ventricle using a direct suture 
technique or patch to cover the ventricular perforation 23s in 
addition to CABG as needed. Alternatively, the use of cyano- 
acrylate glue has been described to hold the patch in place over 
necrotic myocardium. 3~7 
Left Ventricular Aneurysm 
Left ventricular aneurysm ay be associated with refractory 
CHF, VT, or systemic embolization despite therapeutic anti- 
coagulation. Surgical techniques designed to retain ventricular 
geometry using endoventricular patches may maintain better 
physiological function with lower (3.3% to 6.5%) mortality 
than earlier linear repair techniques (11.6% to 12.5% mortal- 
ity),388'389 
Mechanical Support of the Failing Heart 
Intra-aortic balloon pump (IABP) support improves diastolic 
coronary blood flow and reduces myocardial work. Its use is 
covered in detail in "Hospital Management." 
Circulatory support devices include the use of prosthetic 
ventricles, 39°-392 the LV turbine (Hemopump), 393-395 and per- 
cutaneous cardiopulmonary b pass circuits. 396 Each has been 
used in patients with cardiogenic shock after acute MI with 
improvement in other organ perfusion, in many cases as a 
bridge to definitive revascularization r cardiac transplanta- 
tion. Total artificial heart implantation has also been used as a 
bridge to transplantation. 397 Success rates have varied and are 
generally correlated with the presence of correctable cardiac 
disease. Survival has been considered fair (from 20% to 33% at 
best) for this group of patients generally categorized as at very 
high risk for death if not otherwise treated. None of these 
devices has been used in a randomized fashion to assess their 
comparative efficacy in patients. 
Transplantation After Acute Myocardial Infarction 
Cardiac transplantation has been reported for patients who 
sustained irreversible acute myocardial injury with no correct- 
able lesion and who were otherwise acceptable candidates. 398 
Of 15 patients reported, 9 had onset of shock within 3 days of 
onset of chest pain, and 6 had onset of shock within the first 
day. Cardiac assist devices were used in 6 patients as a bridge 
to transplantation. Early post-transplant mortality was 3 of 15 
(20%). 
Relation Between Volume of Surgery and Outcome 
Increasing attention isbeing directed at the better quality of 
surgical outcomes as a direct relation to a greater volume of 
surgical procedures per hospitaP 9~ and per surgeon. 4°° A 
retrospective r view of 18 986 CABG procedures in 77 Cali- 
fornia hospitals uggested that higher volume hospitals had 
lower in-hospital mortality, particularly for "nonscheduled" 
surgery? mThis suggests that patients with acute MI who might 
require emergency CABG should be directed to hospitals with 
higher surgical volume and acceptable surgical results. 
Minimum Operative Caseload 
The ACC/AHA guidelines on coronary artery bypass graft 
surgery 1~8 suggest a minimum caseload of 200 to 300 open- 
heart operations per institution and 100 to 150 operations per 
surgeon, with the majority of operations done for coronary 
artery disease. 
Case Selection Concerns 
As cardiac surgical programs and individual surgeons come 
under scrutiny with regard to operative mortality rates, con- 
1372 RYAN ET AL. JACC Vol. 28, No. 5 
MANAGEMENT OF ACUI'E MYOCARDIAL INFARCTION November l, 1996:1328 428 
cern has been raised about he possibility that salvageable but 
high-risk patients may not be offered surgery. The committee 
believes trongly that patients hould be offered surgical treat- 
ment if the treating team believes that the benefits outweigh 
the risks and that meaningful survival of the patient could 
result. Furthermore, appropriately validated risk-adjusted out- 
come measures should be used when evaluating the perfor- 
mance of an individual surgeon or surgical program. 
V. Rationale and Approach 
to Pharmacotherapy 
Nit~vglycerin 
Mechanism of Action 
The primary action of nitrates is vasodilation, which is 
attributable primarily to nitrate-induced relaxation of vascular 
smooth muscle in veins, arteries, and arterioles. The metabolic 
conversion of organic nitrates to nitric oxide at or near the 
plasma membrane of the vascular smooth muscle cell repre- 
sents the cellular basis for the vasodilatory action of these 
compounds. 4"-~ Believed to be an endothelium-derived relaxing 
factor (EDRF), nitric oxide is an important endogenous 
modulator of vascular tone. Nitrate administration has been 
viewed as a means of providing an exogenous source of nitric 
oxide that may help replenish or restore the actions of EDRF, 
which are usually impaired in patients with coronary artery 
atherosclerosis. 403
The reduction in right and left ventricular preload resulting 
from peripheral vasodilation, particularly in the splanchnic and 
mesenteric irculations, combined with afterload reduction 
resulting from arterial vasodilation, decreases cardiac work 
and lowers myocardial oxy.gen requirements. 4°aAs a conse- 
quence, the ratio of myocardial o~gen demand to myocardial 
o~gen supply improves, and myocardial ischemia is alleviated. 
Because of their hemodynamic profile, nitrates are particularly 
useful in patients with impaired LV systolic function or CHF. 
Additionally, both direct vasodilator effects of nitrates on the 
coronary bed and drug-induced prevention of episodic coro- 
nary artery vasoconstriction can increase global and regional 
myocardial blood flow, improving the subendocardial- 
epicardial blood flow ratio. 4°5.4°~ Enlargement of obstructive 
atherosclerotic lesions containing intact vascular smooth mus- 
cle can increase the caliber of some stenoses, improving 
coronary flow? ~v Nitrates also have been shown to dilate 
coronary collateral vessels, reverse vasoconstriction of small 
coronary arteries distal to a coronary obstruction, and reduce 
platelet aggregation. 4"s 
Pharmacokinetics and Dosage 
As summarized by Abrams, 4~ three nitrate compounds-- 
nitroglycerin, isosorbide dinitrate (ISDN), and isosorbide-5- 
mononitrate (ISMN)--are available for clinical use in the 
United States. Nitroglycerin ischaracterized bya short half-life 
of only several minutes. Isosorbide dinitrate is an organic 
nitrate that is extensively metabolized in the liver to two active 
metabolites, isosorbide-2- and ISMN. The half-life of ISDN 
ranges from 40 to 90 minutes. Isosorbide-5-mononitrate, the
principal active metabolite of ISDN, is a synthetic nitrate 
approved by the Food and Drug Administration (FDA) in 
1991. ISMN does not undergo hepatic metabolism and as a 
result is 100% bioavailable after oral dosing. Its half-life is 4 to 
5 hours. Both ISDN and ISMN are available in sustained- 
release formulas. Nitroglycerin is the only nitrate available for 
intravenous use in the United States and the preparation of 
choice in the management of acute MI or unstable angina. 
Intravenous nitroglycerin can be successfully titrated by fre- 
quent measurement of blood pressure and heart rate. Al- 
though invasive hemodynamic monitoring isnot mandatory, it 
may be preferable if high doses of vasodilating agents are 
required, blood pressure instability or hypotension ensues, or 
there is clinical doubt about the adequacy of LV filling 
pressure .4~,, 
When titrating intravenous nitroglycerin, begin with a bolus 
injection of 12.5 to 25.0/xg and a pump-controlled infusion of 
10 to 20/xg/min, and increase the dosage by 5 to 10/xg every 
5 to 10 minutes while carefully monitoring hemodynamic and 
clinical responses. Titration end points are control of clinical 
symptoms or decrease in mean arterial pressure of 10% in 
normotensive patients or 30% in hypertensive patients (but 
never a systolic pressure less than 90 mm Hg), an increase in 
heart rate greater than 10 bpm (but not exceeding 110 bpm), or 
a decrease in pulmonary artery end-diastolic pressure of 10% 
to 30%. Infusions are slowed or temporarily discontinued 
when mean blood pressure drops below 80 mm Hg or systolic 
blood pressure drops below 90 mm Hg. Although there is no 
absolute upper dosage limit, doses greater than 200/xg/min are 
associated with increased risk of hypotension, and alternative 
therapy should be considered. 
The combination of intravenous nitroglycerin with a 
/3-adrenergic blocking agent in appropriate patients is well 
tolerated and theoretically attractive because the risk of un- 
desired tachycardia may be reduced. As nitrate tolerance 
develops, the infusion rate can be increased, but if it becomes 
necessary to administer more than 200/xg/min, another vaso- 
dilator such as nitroprusside or an ACE inhibitor should be 
substituted with the knowledge that effectiveness of nitroglyc- 
erin usually returns 12 hours after discontinuance. 
Limitations and Adverse Effects 
In addition to frequently causing headaches, nitroglycerin 
may also aggravate hypoxemia by increasing ventilation- 
perfusion mismatch. The most serious ide effect is inadvertent 
systemic hypotension, which may result in reflex tachycardia 
and worsening myocardial ischemia. Nitroglycerin should be 
carefully titrated in patients with inferior wall MI because of its 
frequent association with RV infarction. Such patients are 
especially dependent on adequate RV preload to maintain 
cardiac output and can experience profound hypotension 
during nitrate administration. 73 When nitroglycerin adminis- 
tration results in bradycardia and hypotension, discontinuation 
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of the drug, leg elevation, rapid fluid administration, and 
atropine are appropriate. 
Continuation ofthe anti-ischemic effects of organic nitrates 
with repeated osing is the major limitation in use of these 
drugs. Nitroglycerin tolerance is a complex multifactorial 
phenomenon that may partially be explained by a relative 
depletion of sulfhydryl groups required for conversion of 
organic nitrates to nitric oxide. 41~ More recently it has been 
suggested that enhanced vascular superoxide production plays 
an important role in this phenomenon. 4~2 It is now clear that 
intermittent dosing regimens that allow for a drug-free interval 
represent the only practical and effective strategy for avoiding 
nitrate tolerance. When ISDN is used, anti-ischemic activity is 
more likely to be maintained with a dosing schedule of 2 or 3 
times daily. FDA labeling now indicates adose-free interval of 
14 hours is required to avoid tolerance. An asymmetric ISMN 
dosing regimen, with administration at 8 AM and 3 PM, has been 
shown to sustain the anti-ischemic effects of the short-acting 
preparation ofth is agent.4 ~3 When using intravenous nitroglyc- 
erin for 24 to 48 hours continuously in the early stages of acute 
MI, it is well to note that drug tolerance is not usually 
recognized at the bedside. If the desired nitrate ffects are lost 
during this period, it is appropriate oincrease the intravenous 
infusion dose. 
Physicians need to be aware of a potential drug interaction 
between heparin and intravenous nitroglycerin, although as yet 
unresolved, because these agents are frequently administered 
at the same time. Several reports have suggested that intrave- 
nous nitroglycerin may interfere with the actions of heparin on 
the activated partial thromboplastin a d prothrombin time, 
thereby decreasing sensitivity to heparin. 4H-4jS~, Thus, in addi- 
tion to requiring increased heparin dosage to achieve adesired 
anticoagulation e d point, patients may be at greater isk for 
bleeding when nitroglycerin is discontinued and infusion of 
heparin continues. 
Clinical Trials 
There is experimental nd clinical evidence that intrave- 
nous nitroglycerin may reduce infarct size and improve re- 
gional myocardial function. 4",,4w It has also been suggested 
that nitroglycerin may prevent LV remodeling that frequently 
occurs after a large transmural MI. 4t7 In the prereperfusion 
era a number of small studies demonstrated animprovement 
in mortality and major cardiovascular morbidity following early 
administration f intravenous nitroglycerin. A meta-analysis of
these earlier trials involving 2042 patients suggested that 
nitrates reduced the odds of death after acute MI by 35% (95% 
CI, 28 to 49%; P<.001).4~s Similar analyses involving the use of 
oral nitrates in fewer patients estimated a treatment effect of 
about 20%, but this was not statistically significant, and the 
greatest reduction in mortality occurred uring the first week 
or so of follow-up. 4~s,4~'J 
The use of nitrate therapy was investigated inthe context of 
routine use of thrombolytic therapy and aspirin with short- 
term mortality as the primary, end point in two recently 
completed large trials. The GISSI-3 trial 4~'' randomly assigned 
19 394 patients to a 24-hour infusion of nitroglycerin (begin- 
ning within 24 hours of onset of pain), followed by topical 
nitroglycerin (10 mg daily) for 6 weeks (with patch removed at 
bedtime, allowing a 10-hour nitrate-free interval to avoid 
tolerance), or control. Approximately 50% of patients in the 
control group received nitrates on the first day or two at the 
discretion of their physician. There was an insignificant reduc- 
tion in mortality at 6 weeks in the group randomly assigned to 
nitrate therapy alone, compared with the control group (6.52% 
versus 6.92%, respectively). GISSI-3 evaluated lisinopril in a 
similar fashion; 6-week mortality was reduced slightly. At both 
6-week and at 6-month follow-up, the combined use of lisino- 
pril and nitrates led to a greater eduction in mortality when 
compared with the group that received no nitrate therapy or 
lisinopril alone. The other large trial, ISIS-4, 42L compared 
28-day treatment of controlled-release oral isosorbide mono- 
nitrate with placebo control (as well as intravenous magnesium 
sulfate versus control and the ACE inhibitor captopril versus 
placebo control) in a 2×2×2 factorial design in 58 050 patients 
with suspected MI. Nitrate therapy in ISIS-4 was associated 
with a small, nonsignificant reduction in 35-day mortality 
compared with the control group (7.34% versus 7.54%) in the 
overall comparison. All subgroups examined, including those 
not receiving short-term nonstudy intravenous or oral nitrates 
at entry, failed to demonstrate a significant mortality benefit 
with nitrate use. In both GISSI-3 and ISIS-4, the power to 
detect potential beneficial effects of routine nitrate therapy was 
reduced by the extensive arly use (greater than 50%) of 
nontrial nitrate in the control subjects. When data from all 
randomized control trials of nitrate use in the management of 
acute MI are combined, there is a small relative reduction in 
mortality that is statistically significant (5.5%_+2.6%; 
2P=.03)? 2~ which represents approximately 4 lives saved per 
1000 treated. 
The totality of evidence from all pertinent randomized 
clinical trials does not support routine use of long-term nitrate 
therapy in patients with uncomplicated acute MI. However, it 
is prudent to use intravenous nitroglycerin for the first 24 to 48 
hours in patients with acute MI and recurrent ischemia, CHF, 
or management of hypertension. It should be continued orally 
or topically in patients with CHF and large transmural MIs as 
well. Intravenous administration is recommended in the early 
stage of acute MI because of its onset of action, ease of 
titration, and the opportunity for prompt ermination i the 
event of side effects. 
Aspirin and Other Platelet-Active Drags 
Platelets and thrombosis play important roles in the patho- 
genesis of acute coronary, artery, syndromes, and the role of 
antiplatelet agents has been recently reviewed in two publica- 
tions, the AHA statement "Aspirin as a Therapeutic Agent in 
Cardiovascular Disease ''4-'~ and the fourth American College 
of Chest Physicians (ACCP) Consensus Conference on Anti- 
thrombotic Therapy. 423 
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Mechanism of Action of Aspirin 
In platelets, aspirin prevents formation of thromboxane A 2, 
a substance that induces platelet aggregation? 24-426 Because 
platelets are unable to generate new cyclo-oxygenase, enzyme 
inhibition lasts for the life of the cell, or about 10 days. In 
vascular endothelial cells aspirin prevents the synthesis of 
prostacyclin, which inhibits platelet aggregation. 427 Endothe- 
lial cells can recover cyclo-oxygenase ynthesis o that the 
inhibitory effects of aspirin may be of shorter duration than 
with platelets) 28,429 
Aspirin in Prevention of Thrombotic Complications 
of Atherosclerosis 
As summarized in the fourth ACCP Consensus Conference 
on Antithrombotic Therapy423: 
In the recently reported overview of the Antiplatelet Trial- 
ists' Collaboration that involved 145 trials, the antiplatelet 
therapy (mainly aspirin) of 70 000 high-risk patients and 30 000 
low-risk patients was found to be protective against vascular 
events among the following patients: (1) patients with acute MI, 
10% versus 14% (at 1 month); (2) a history of MI, 13% versus 
17% (2-year follow-up); (3) a history of stroke or transient 
cerebral ischemia, 18% versus 22% (3-year follow-up); (4) 
unstable angina, 9% versus 14% (6-month follow-up); and (5) 
other miscellaneous vascular diseases, 6% versus 8% (1-year 
follow-up). 
When all high-risk patients are considered together, there is 
about a 30% reduction in nonfatal MI, a 30% reduction in 
nonfatal stroke, and a 17% reduction in vascular death. For 
patients with prior infarction or stroke, aspirin is estimated to 
prevent between 35 and 40 events per 1000 patients treated. In 
contrast, when used in asymptomatic men, aspirin prevents 
only 4 events per 1000 subjects treated. 
Aspirin: Risk of Hemorrhagic Stroke 
A small increase in incidence of stroke in healthy men 
treated with aspirin was reported in both the American 
Physician and the British Doctors primary prevention stud- 
ies. 43° However, there has been no evidence of an increased 
incidence of stroke in studies in which aspirin was used for 
secondary prevention of coronary artery disease. These sec- 
ondary prevention trials clearly indicate that in patients with 
clinical manifestations of atherosclerotic disease, aspirin re- 
duces risk of stroke. It is likely that as a consequence of its 
antihemostatic effect, aspirin produces a small increase in risk 
of cerebral hemorrhage, which is masked by the beneficial 
effects of aspirin in patients with an increased risk for throm- 
boembolic stroke but becomes manifest in healthy individuals 
at very low risk for this event. 
Aspirin: Side Effects and Dosage 
The side effects of aspirin are mainly gastrointestinal nd 
dose related. 431 Gastric side effects may also be reduced by 
administration f diluted solutions of aspirin, 432 treatment with 
cimetidine, 433 antacids, 432,434 or use of enteric-coated or buf- 
fered aspirin. 435,436 
Aspirin should be avoided in those with a known hypersen- 
sitivity and used cautiously in those with blood dyscrasias or 
severe hepatic disease. If the patient has a history of bleeding 
peptic ulcers, rectal aspirin suppositories can be used safely. 
Another potentially deleterious effect of aspirin is risk of 
bleeding from surgical sites. Patients who received aspirin in 
the Veterans Administration Cooperative Study 437 were noted 
to have significantly increased postoperative chest drainage 
and reoperation for bleeding (6.5% for aspirin groups com- 
pared with 1.7% for nonaspirin groups, P<.01). Others have 
noted that preoperative aspirin use has been associated with 
increased postoperative chest drainage but not an increased 
rate of reoperation for bleeding. 438.439 In another Veterans 
Administration Cooperative Study, 44° starting aspirin 6 hours 
after surgery conferred the benefits of improved saphenous 
vein brass graft patency without he increased postoperative 
bleeding seen with preoperative administration f aspirin. 
Aspirin is an effective antithrombotic agent in doses be- 
tween 75 mg and 1.2 g/d. It is also possible that 30 mg/d is 
effective. There is no evidence that low doses are either more 
or less effective than high doses when used over the long term, 
although doses less than 160 mg/d may not be effective acutely. 
Ticiopifline 
Ticlopidine is an antiplatelet drug with a different mecha- 
nism of action than aspirin. It inhibits platelet aggregation 
induced by a variety of agonists, including adenosine diphos- 
phate, possibly by altering the platelet membrane and blocking 
the interaction between fibrinogen and its membrane glyco- 
protein receptor, GPIIb/IIIa. 441 The inhibitory effect of ticlo- 
pidine is delayed for 24 to 48 hours after its administration; 
thus, ticlopidine may not be useful when a rapid antiplatelet 
effect is required. 
Ticlopidine has been shown to be more effective than a 
control therapy in reducing vascular death and MI in patients 
with unstable angina. 44~ The most serious ide effect of its use 
is reversible neutropenia, which has only been observed when 
treatment is continued for more than 2 weeks. It has been 
approved for clinical use in patients with cerebral ischemia 
when aspirin has failed, cannot be tolerated, or is contraindi- 
cated. 
Rationale for Thrombolytic Therapy 
Background 
Herrick 442 in the United States and Obrastzow and Stras- 
chesko 443 in the Soviet Union first described the clinical 
features of sudden obstruction of the coronary arteries more 
than 80 years ago. However, the pathophysiology of acute MI 
and specifically the role of coronary thrombosis were contro- 
versial until the early 1980s. The landmark study of DeWood 
and colleagues, ~° published in 1980, demonstrated complete, 
presumably thrombotic occlusion of the infarct-related artery 
in 87% of patients with MI and ST elevation studied anglo- 
graphically within 4 hours of onset of symptoms and in 65% 
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Table 8. Comparison of US FDA-Approved Thrombolytic Agents 
SK APSAC TPA 
Dose 1.5 million U in 30-60 rain 30 mg in 5 min 100 mg in 90 min* 
Circulating half-life (rain) 20 100 6 
Antigenic Yes Yes No 
Allergic reactions Yes Yes No 
Systemic fibrinogen depletion Severe Severe Moderate 
Intracerebral hemorrhage ~0.3% ~0.6% ~l).6% 
Recanalization rate, 90 mini" ~40% ~63% ~79% 
Lives saved per 100 treated ~2.5 ~2.5 ~3.5~ 
Cost per dose (approx US dollars) 290 1700 2200 
US FDA indicates United States Food and Drug Administration; SK, streptokinase; APSAC, anisoylated plasmin- 
ogen streptokinase activator complex; TPA, tissue plasminogen activator; approx, approximately. *Accelerated TPA 
given as follows: 15 mg bolus, then 0.75 mg/kg over 30 min (maximum, 50rag), then 0.50 mg/kg over 60 rain (maximum, 
35 rag). iBased on published data nd assuming that 20% of arteries are open before therapy. :~Based on the finding from 
the GUSTO (Global Utilization of Streptokinase and TPA for Occluded Arteries) trial that accelerated TPA saves 1 
more additional life per 100 treated than does SK. Adapted from Table 3.1 and reprinted from Management of Acute 
Myocardial Infamtion (Julian D, Braunwald E,eds). Martin GV, Kennedy JW. Choice of tbrombolytic agent, p73, 1994. 
By permission fthe publisher, WB Saunders Co Ltd, London. 
studied between 12 and 24 hours. The subsequent demonstra- 
tion of intraluminal thrombus at the time of emergency coronary 
surgery ~° and the demonstration f infarct-related artery recana- 
lization by intracoronary thrombolytic therapy 443-445 led to the 
unequivocal role of intracoronary thrombus in acute coronary 
occlusion. Subsequent pathological nd angioscopic observations 
led to the concept that fissuring or rupture of a vulnerable 
atherosclerotic plaque was the initiating mechanism of coronary 
occlusion as a result of coronary spasm, intraplaque hemorrhage, 
and luminal thrombosis. 446-448 A second premise supporting large 
trials of thrombolytic therapy in acute MI was the observation i
animal models and early clinical studies that reperfusion could 
lead to myocardial salvage and improved outcome, but that 
benefit was time dependent. Reimer, Jennings, and coworkers 449 
showed that coronary artery occlusion in an animal model ed to 
MI that proceeded in a "wavefront" from subendocardium to 
subepicardium, beginning within 20 minutes and evolving to more 
than 70% transmural necrosis in 6 hours, with a small amount of 
additional necrosis between 6 and 24 hours. Of note, reestablish- 
ment of coronary flow within 2 hours resulted in substantial 
myocardial salvage and functional recovery of the ischemic myo- 
cardium, whereas reperfusion as late as 6 hours resulted in 
limited, subepicardial salvage. Subsequent early controlled clini- 
cal trials demonstrated the potential for functional and mortality 
benefit, but only if therapy was given early and reperfusion 
resulted.45o-453 
Clinical use of intravenous preparations containing strep- 
tokinase for acute MI dates back four decades. 454,455 However, 
contemporary interest in intravenous thrombolytic therapy was 
reawakened with reports in the mid 1980s of its feasibility and 
comparability o intracoronary therapy. 456-45s Subsequent clin- 
ical studies and practical application of thrombolytic therapy 
has focused on the more broadly and rapidly applicable 
intravenous application of thrombolytic agents. 
Thrombolytic Agents: General Mechanisms of Action 
and Pharmacological Properties 
Recognition that acute coronary thrombosis is primary to 
the pathogenesis of acute MI led to the consideration of 
plasminogen activators as a preferred therapeutic approach to 
achieving rapid thrombolysis. All of the thrombolytic (fibrino- 
lytic) agents currently available and under investigation are 
plasminogen activators. 45'~ They all work enzymatically, directly 
or indirectly, to convert he single-chain plasminogen molecule 
to the double-chain plasmin (which has potent intrinsic fibrino- 
lyric activity) by splitting a single bond at the arginine 560- 
valine 561 site, exposing the active enzymatic enter of plas- 
rain. 
Aside from this similarity, however, there are many differ- 
ences among these agents in dose, circulating half-life, "fibrin- 
specificity" (relative activity against clot-bound fibrin versus 
circulating fibrinogen), rates of coronary recanalization, risks 
of ICH, and cost. Some comparative features of the FDA- 
approved thrombolytic agents for intravenous therapy (strep- 
tokinase, anistreplase), and the tissue plasminogen activator 
alteplase are presented in Table 8. Streptokinase and uroki- 
nase are approved for intracoronary use, but this route of 
administration for acute MI is now virtually obsolete. In 
addition, newer agents are being developed leg, prourokinase, 
staphylokinase, and various mutant plasminogen activators). 
Recent trials with alteplase have used an accelerated or 
frontloaded osing regimen (dose given over 90 minutes rather 
than 3 hours). Because the accelerated regimen leads to 
greater early patency rates without an increase in hemorrhagic 
risk, it has become the preferred method of administration. 
Efficacy of Intravenous Thrombolytic Therapy in 
Acute Myocardial Infarction 
It has now been well established that thrombolytic therapy 
provides a survival benefit for patients with acute MI, based on 
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large, well-controlled clinical trials. Benefit has been shown 
individually for therapy with streptokinase, anistreplase, and 
alteplase. 2s,2~,46~',461 In an overview of the nine controlled 
randomized trials involving more than 1000 patients, a highly 
significant (P<.00001) 18% proportional reduction in mortal- 
ity was observed, corresponding tothe avoidance of 18 deaths 
per 1000 patients treated. 27 Furthermore, the largest of these 
studies (ISIS-2, more than 17 000 patients), showed that when 
aspirin was combined with streptokinase and treatment was 
given within 4 hours of onset of symptoms, an odds reduction 
in mortality of 53% was achieved (control, 13.1%; streptoki- 
nase plus aspirin, 6.4%) (P<.0001). 2'~ Information from both 
animal studies as well as clinical trials has provided strong 
support for the concept hat achievement of early, complete, 
and sustained coronary, patency is primarily responsible for 
benefit of treatment? ° Mechanisms of benefit include favor- 
able effects on myocardial salvage as well as postinfarction 
remodeling. 
Benefits of Thrombolytic Therapy in Specific 
Patient Subgroups 
The overview of thrombolysis trials shows that thrombolytic 
therapy is clearly beneficial in the vast majority of patients. 
Differences in outcome in subgroups inclinical trials should be 
interpreted more cautiously than overall differences in out- 
come with therapy, given the problems of multiple compari- 
sons and chance deviations from the mean. Sometimes differ- 
ences in degree (and rarely, direction) of benefit appear among 
some subgroups, and when these are replicated in independent 
trials and supported by a clear pathophysiological r tionale 
may reflect valid differences. Implications of overall and sub- 
group results from the overview of the major randomized, 
controlled clinical trials 27 for use of thrombolytic therapy in 
acute M1 are presented in "Initial Recognition and Manage- 
ment in the Emergency Department." 
Comparative Thrombolytic Efficacy 
Since publication of the first guidelines for the early man- 
agement of patients with acute myocardial infarction, ~ results 
of important rials comparing thrombolytic regimens directly 
have been published, evaluating relative rates of corona~ 
patency, functional benefit, and survival. In two large mortality 
trials (GISSI-2/Internationa146: and ISIS-3463), mortality rates 
at 4 to 5 weeks were similar (GISSI-2/International: TPA 
[duteplase]=8.9%, streptokinase=8.5%; ISIS-3: alte- 
plase = 10.3%, streptokinase = 10.6%, anistreplase = 10.5%). In 
these studies conjunctive antithrombotic therapy included as- 
pirin in all patients (160 to 325 mg on admission and daily) and 
subcutaneous heparin in half (12 500 U twice a day, beginning 
4 to 12 hours after thrombolytic therapy). At the time, 
intravenous heparin was not used in either of these studies 
because of concerns about increasing the incidence of ICH. 
The specific failure to use intravenous heparin with TPA in 
these trials has been the source of some criticism. The GUSTO 
trial subsequently tested four thrombolytic regimens among 
41 021 patients. -~2~ Alteplase was given in an accelerated dose 
regimen to further improve early patency rates and concomi- 
tant heparin administered intravenously to maintain patency. 
Other regimens included streptokinase with subcutaneous or
intravenous heparin and a combination of alteplase and strep- 
tokinase. Thirty-day mortality was lower with alteplase (6.3%) 
than streptokinase and subcutaneous heparin (7.2%), strep- 
tokinase and intravenous heparin (7.4%), and combined strep- 
tokinase and alteplase plus intravenous heparin therapies 
(7.0%). Differences were highly significant, although propor- 
tionately modest, when accelerated alteplase was compared 
with combined streptokinase groups (14% mortality reduction, 
P=.001). There was a significant excess of hemorrhagic stroke 
for accelerated alteplase (P=.03) and the combination strategy 
(P<.001), compared with streptokinase only. However, net 
benefit was still achieved with alteplase compared with strep- 
tokinase, with 9 fewer deaths or disabling strokes per 1000 
patients treated. Other complications of acute MI were gen- 
erally less frequent with alteplase, including allergic reactions, 
heart failure, cardiogenic shock, and atrial and ventricular 
arrhythmias. 
Other conclusions drawn from GUSTO are (1) intravenous 
heparin provides no added benefit over aspirin and subcuta- 
neous heparin when given with streptokinase and in addition 
increases bleeding risk (the power of this comparison, how- 
ever, was markedly reduced by the fact that 36% of patients 
randomly assigned to receive subcutaneous heparin also re- 
ceived intravenous heparin); (2) combination therapy in- 
creases bleeding risk (relative to alteplase with intravenous 
heparin) and provides less benefit; and (3) although the 
rationale for use of intravenous heparin with alteplase appears 
sound, other factors, specifically, earlier time to therapy, 
frontloading alteplase, and requiring ST elevation on entry 
ECG, likely explain much of the difference in results between 
GUSTO and ISIS-3. 464 The mechanism of improved benefit 
with alteplase was assessed in the GUSTO angiographic sub- 
study, which found differences in early (90-minute) patency 
among regimens (81%, 56%, 61%, 73%) for alteplase, strep- 
tokinase-subcutaneous heparin, streptokinase-intravenous 
heparin, and combination regimens, respectively. 465 These 
differences in patency in the angiographic substudy closely 
predicted survival outcomes among the four strategies when 
applied to the main trial results 4~'~' and furnish a biological 
explanation for mortality differences among regimens. The 
data, coupled with that of additional, independent compari- 
sons showing superior outcomes with accelerated alteplase 
compared with anistreplases, 4~'7.46s provide a strong impetus 
for early and complete restoration of infarct artery perfusion as 
an essential goal of thrombolytic therapy. 
Considerations in Selecting Thrombolytic Regimens 
GUSTO 22s and other recent studies 4~'7,4~s suggest that 
accelerated alteplase with intravenous heparin is currently the 
most effective therapy for achieving early coronary reperfusion 
and its associated survival benefits but is also substantially 
more expensive and carries a greater isk of ICH. Thus, the 
cost-benefit ratio is greatest in patients presenting early after 
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symptom onset with a large area of injury (eg, anterior acute 
MI) and at low risk of ICH. In groups with a smaller potential 
for survival benefit and a greater isk for ICH, streptokinase 
appears to be the agent of choice, particularly in view of the 
cost. Other promising thrombolytic agents are under investi- 
gation (eg, prourokinase, reteplase, staphylokinase, TNK- 
plasminogen activator). 
A number of proposals for selection of thrombolytic regi- 
mens after GUSTO have been suggested. 9°,469-471 Additional 
considerations include avoiding reuse of streptokinase or 
anistreplase for at least 2 years (preferably indefinitely) be- 
cause of a high prevalence of potentially neutralizing antibody 
titers. Alternatively, Simoons 47o has proposed considering pri- 
mary PTCA for those at highest risk (about 10% of patients), 
alteplase for those at moderate to high risk (40%), streptoki- 
nase for those at low to moderate risk (40%), and no lytic 
therapy for those at lowest risk (10%). All of these recommen- 
dations await prospective testing. 
Current Use Rates for Thrombolytic Therapy 
The industry-sponsored National Registry of Myocardial 
Infarction tracks the use of thrombolytic therapy in the United 
States and has enrolled 220 171 patients treated at 1370 US 
hospitals during its second phase (NRMI 2) from June 1994 
through December 1995. Overall, 37.2% received reperfusion 
therapy (83% thrombolysis, 15.4% primary angioplasty, 1.4% 
immediate CABG) (written communication, W. J. Rogers, 
June 1996). Among a subset of patients presenting with ST 
elevation or LBBB within 12 hours of symptom onset 
(n=64211), the use of reperfusion therapy was 70%, with 
8.2% of the cohort receiving primary PTCA. 472 
Because many patients have contraindications or other 
exclusions for fibrinolytic agents, it has been ditficult o ascer- 
tain the proportion of patients with ST elevation who fail to 
receive fibrinolytic therapy that actually should have received 
such therapy. 472~' Critical to any such assessment of appropri- 
ateness of care, however, is whether the diagnosis of acute MI 
was suspected on entry into the healthcare system or was an 
"outcomes" diagnosis made after 12 to 24 hours in the hospital 
or at some later point in time before hospital discharge. 
Experience to date suggests that in patients younger than 65 
years, overall usage of thrombolytic thera W ranges between 
40% and 50% (as high as 70% to 75% for patients with 
ST-elevation MI). In those older than 65, the overall use rate 
is below 20% and should be higher. Some increase in use rates 
probably can be achieved, but contraindications prohibit a vast 
increase in use rates. 
Antithrombotics/Anticoagulants 
Once fissuring of an atherosclerotic plaque has occurred, 
whether an epicardial coronary, vessel becomes totally oc- 
cluded, develops amore severe, flow-limiting stenosis, or heals 
without incident depends to a large extent on the degree to 
which thrombus propagates in the vessel lumen. As previously 
discussed, platelet activation and aggregation are crucial ete- 
Table 9. Heparin Adjustment Nomogram for Standard Laboratory 
Reagents With a Mean Control aPTY of 26-36 s 
aPTY Bolus Dose Stop Infusion Rate Change Repeat 
(s) (U) (rain) (mL/h) aPTI' 
<40 3000 0 +2 6 h 
40-49 0 0 + 1 6 h 
5(1-75 0 0 0 (no change) Next AM 
76-85 0 l) - 1 Next AM 
86-100 0 30 2 6 h 
101-150 0 60 3 6 h 
>1511 0 60 -6  6 h 
aPTT indicates activated partial thrornboplastin time. Heparin infusion 
concentration = 50 U/mL. Target aPT]" = 50-75 s. For aPTI's obtained before 
12 h after initiation of thrombolytic therapy: 1, Do not discontinue or decrease 
infusion unless ignificant bleeding or aVIT >150 s. 2. Adjust infusion upward if 
aPTT <50 s. For aPTl's obtained > 12 h after initiation of thrombolytic therapy, 
use entire nomogram: Deliver bolus, stop infusion, and/or change rate of infusion 
based on aPTI', as noted on appropriate line of nomogram. Adapted with 
permission from Hirsh J, Raschke R. Warkentin TE, Dalen JE, Deykin D, Piller 
L Heparin: mechanism of action, pharmacokinetics, dosing considerations, 
monitoring, efficacy, and safety. Chest. 1995;108:258S-275S. 
ments of the process, but the balance between activation of the 
coagulation cascade and its inhibition is also critical. The 
process by which a thrombus is formed is complex, and our 
understanding of it continues to evolve, 473 but much of the 
therapeutic effort has focused on inhibiting thrombin and 
thereby preventing conversion of fibrinogen to fibrin. In addi- 
tion to having a primary role in this initial process of coronary 
thrombosis, thrombin also is an important platelet activator; 
activation of platelets by thrombin is not inhibited by aspirin. 
Another reason that thrombin is considered critical is that 
active thrombin becomes bound to a developing clot, and as 
the clot lyses, either pharmacologically or through endogenous 
means, the "clot-bound" thrombin can convert fibrinogen to 




1. Patients undergoing percutaneous or surgical revascu- 
larization. 
Comment: For PTCA, monitoring of activated clotting time 
(ACT) is recommended, with a goal of 300 to 350 seconds during 
the procedure. 
Class lla 
1. Intravenously in patients undergoing reperfusion ther- 
apy with alteplase. 
Comment: The recommended regimen is 70 U/kg as a bolus at 
initiation of alteplase infusion, then an initial maintenance dose 
of approximately 15 ~g/kg per hour, adjusted to maintain aPTT at 
1.5 to 2.0 times control (50 to 75 seconds) for 48 hours (Table 9). 
Continuation of heparin infusion beyond 48 hours should be 
restricted to patients at high risk for systemic or venous thrombo- 
embolism. 
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2. Subcutaneously (7500 U twice daily) (intravenous hepa- 
rin is an acceptable alternative) in all patients not treated with 
thrombolytic therapy who do not have a contraindication to 
heparin. In patients who are at high risk for systemic emboli 
(large or anterior MI, AF, previous embolus, or known LV 
thrombus), intravenous heparin is preferred. 
3. Intravenously in patients treated with nonselective 
thrombolytic agents (streptokinase, anistreplase, urokinase) 
who are at high risk for systemic emboli (large or anterior MI, 
AF, previous embolus, or known LV thrombus). 
Comment: It is recommended that heparin be withheld for 4 
hours and that aPTT testing begin at that time. Heparin should be 
started when aPTT returns to less than two times control (about 
70 seconds), then infused to keep aPTT 1.5 to 2.0 times control 
(initial infusion rate about I000 U/h). After 48 hours, a change to 
subcutaneous heparin, warfarin, or aspirin alone should be 
considered. 
Class lib 
1. Patients treated with nonselective thrombolytic agents, 
not at high risk, subcutaneous heparin, 7500 U to 12 500 U 
twice a day until completely ambulatory. 
Class III 
1. Routine intravenous heparin within 6 hours to patients 
receiving a nonselective fibrinolytic agent (streptokinase, anis- 
treplase, urokinase) who are not at high risk for systemic 
embolism. 
Heparin has been available as an anticoagulant for many 
years; it was initially described in 1916. The pharmacological 
entity consists of a mixture of molecules with molecular 
weights varying between 5000 and 20 000, with different-size 
molecules having different effects on the coagulation system. 
After forming a complex with antithrombin III (AT-III), the 
heparin-AT-III complex has the ability to inactivate both 
thrombin and activated factor X. When a dose of heparin is 
given, the actual measured effect on coagulation ismodulated 
by a number of factors, including the particular admixture of 
heparin molecules in the dose, circulating levels of AT-III, 
availability of platelet factor IV and other plasma proteins that 
inactivate heparin, and the ability of heparin to reach thrombin 
bound to clot. The heparin-AT-III complex is quite large and 
generally does not appear to be effective against clot-bound 
thrombin. 
In patients who will not be given thrombolytic therapy, 
there is little evidence about the benefit of heparin in the 
modern era, in which aspirin, /3-adrenoceptor blockers, ni- 
trates, and ACE inhibitors are routinely available. Neverthe- 
less, the best available data emanate from a series of random- 
ized clinical trials performed before the reperfusion era. A 
systematic overview of these studies demonstrated a 17% 
reduction in mortality and a 22% reduction in risk of reinfarc- 
tion with heparin? 74 The control groups in these trials were not 
treated with other therapies, particularly aspirin, that are now 
considered routine. Not withstanding, it is primarily these 
randomized ata from an earlier era that support he recom- 
mendation to use heparin in patients not treated with throm- 
bolytic therapy. 
In patients who are treated with thrombolytic therapy, 
recommendations for heparin therapy depend on the throm- 
bolytic agent chosen. Streptokinase, anistreplase, and uroki- 
nase are nonspecific fibrinolytic agents that produce systemic 
breakdown of the coagulation system, including depletion of 
factors V and VIII and massive production of fibrin(ogen) 
degradation products, themselves anticoagulants. From this 
perspective, the need for conjunctive systemic anticoagulation 
with these agents is conceptually ess. In comparison, relatively 
fibrin-specific agents, including alteplase and newer agents 
such as reteplase, produce a variable effect on the systemic 
coagulation system, and in many patients very little breakdown 
of fibrinogen or depletion of coagulation factors is evi- 
dent.475A76 
More than 60 000 patients were enrolled in the randomized 
ISIS-3463 and GISSI-2/InternationaW 7 trials comparing subcu- 
taneous heparin with no routine heparin in conjunction with 
streptokinase, anistreplase, and alteplase. During the period in 
which heparin was given, a small reduction in mortality (4 to 5 
lives per 1000 treated) was observed in ISIS-3; however, by 30 
days the 2 to 3 lives saved per 1000 treated was no longer 
statistically significant. A small excess rate of hemorrhagic 
stroke (1 to 2 per 1000 treated patients) was observed together 
with a larger excess in systemic bleeding (3 to 5 per 1000 
patients), although total stroke rate was not significantly 
increased. In the GUSTO-I trial, 228 more than 20 000 patients 
treated with streptokinase were randomly assigned to routine 
intravenous heparin versus routine subcutaneous heparin. No 
significant differences were observed in death, reinfarction, or 
nonhemorrhagic stroke rates, while excess rates of systemic 
bleeding and hemorrhagic strokes (trend) were observed in the 
intravenous heparin group. 
Several angiographic studies have evaluated coronary per- 
fusion as a function of heparin therapy. 228,478,479 Two trials 
have shown more rapid resolution of ST-segment elevation in 
patients treated with intravenous heparin immediately at the 
time of streptokinase infusion compared with intravenous 
heparin started at a later time. 478,479 The OSIRIS study, 
however, showed no difference in perfusion at 24 hours or in 
clinical outcomes in the two groups. In the GUSTO-I angio- 
graphic substudy, patients treated with intravenous heparin 
had an 88% patency rate at 5 to 7 days compared with 72% in 
patients treated with subcutaneous heparin (P<.05), although 
less reinfarction occurred in the subcutaneous heparin group 
(3.4% versus 4.0%, P<.05). A small group of patients were 
randomly assigned to anistreplase with or without intravenous 
heparin in the DUCCS-1 study, 48° and no differences inclinical 
end points were observed, other than a higher rate of bleeding 
in heparin-treated patients. Viewing these studies as a whole, 
intravenous heparin appears to have no advantage over sub- 
cutaneous heparin when used with a nonspecific thrombolytic 
agent, and the evidence for use of subcutaneous heparin is 
equivocal. 4al 
The occurrence of a large, anterior infarction, documenta- 
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tion of thrombus in the left ventricle by echocardiography, 
history of a previous embolic event, and AF have been 
associated with a high risk of embolic stroke. Although no 
randomized trial evidence exists to demonstrate a definite 
benefit specific to this group, some empirical evidence xists 
that he risk of systemic emboli n the general population of MI 
patients can be reduced by early initiation of heparin? 82 In the 
SCATI trial patients were randomly assigned to a 2000 IU 
bolus of heparin followed by 12 500 IU subcutaneously twice a 
day or to placebo. In the subgroup also treated with streptoki- 
nase, aspirin was withheld. In-hospital mortality was 4.6% in 
the heparin group and 8.8% in the control group, and a 
reduction in stroke was observed. Therefore, heparin is rec- 
ommended for these patients at high risk of systemic arterial 
emboli, regardless of the thrombolytic agent given. 
When alteplase is chosen as the thrombolytic agent, the 
empirical information to confirm the pathophysiological rea- 
soning discussed above is primarily inferential. In a series of 
angiographic trials? 83-4~5 intravenous heparin has been shown 
to lead to higher rates of infarct-related artery perfusion in 
conjunction with alteplase. When aPTI" has been evaluated, a 
direct relation between duration of aP'IT and the likelihood of 
infarct-related artery perfusion has been observed. 4s4,4s5 A 
recent overview 4s6 points out, however, that the effects of 
intravenous heparin on clinical outcomes from these studies 
are not as convincing; a significant increase in the rate of 
bleeding and nonsignificant increases in rates of reinfarction 
and hemorrhagic and nonhemorrhagic stroke are evident. 486 
These negative findings are tempered by a point estimate of an 
18% reduction i  mortality with broad confidence limits. Until 
the uncertainty is resolved, it seems judicious to use heparin 
for at least 48 hours with alteplase and to target he aPTI" to a 
50- to 75-second range. 
When primary angioplasty is chosen as the route of reper- 
fusion, high-dose heparin therapy is recommended. This rec- 
ommendation does not come specifically from empirical data 
in the acute MI setting but from general observations in the 
setting of angioplasty that an ACT of at least 300 to 350 
seconds is associated with a lower rate of complications than 
lower ACT values. 4s7,488 
Very recently abciximab, a Fab fragment of humanized 
monoclonal ntibody to the glycoprotein IIb/IIIa receptor on 
the platelet surface, has been demonstrated to reduce the risk 
of adverse outcomes significantly, both at 30 days 489 and at 6 
months 49° after high-risk percutaneous intervention. 489.491 
Benefit, however, was accomplished atthe price of an increase 
in major bleeding from 13% to 24%. Abciximab, like experi- 
mental IIb/IIIa antagonists, increases the ACT measurement 
with a given dose of heparin by an average of 35 seconds. 491 A 
recent rial with abciximab compared this agent with placebo in 
the context of standard heparin dosing in the placebo group 
and two heparin regimens with abciximab: a weight-adjusted 
standard ose and a lower dose aimed at achieving an ACT of 
150 to 300 seconds during routine as well as high-risk percu- 
taneous procedures. 492 The trial was terminated early when an 
interim analysis howed a combined rate of death and nonfatal 
MI of 8.1% in the placebo group, 3.6% in the weight-adjusted 
heparin arm, and 2.6% in the low-dose heparin arm. A trend 
toward less bleeding in the low-dose heparin arm compared 
with the placebo arm was also reported. A third trial evaluating 
abciximab in the treatment of refractory unstable angina also 
was stopped early because of a 40% reduction i  the composite 
end point of death, MI, or need for repeat revasculariza- 
tion.492.4'~3 
The dose of heparin in the thrombolytic-treated patient 
remains omewhat controversial. Based on the infarct-related 
artery perfusion results described above, it would be reason- 
able to recommend an aPTI" value more than threefold higher 
than the median control value. However, recent information 
strongly supports a lower aPTT because death, stroke, rein- 
farction, and bleeding were found to be lowest in the aPTT 
range of 50 to 75 seconds or approximately 1.5 to 2.0 times the 
control value. 494 Because of the clear evidence that the mea- 
sured effect of heparin on the aPTr is important for patient 
outcome and that the predominant variable mediating the 
effect of a given dose of heparin is weight, 4'j4 it is important to 
administer the initial doses of heparin as a weight-adjusted 
bolus. 481 A 70 U/kg bolus followed by 15 U/kg per hour has 
been useful, although other mitigating factors including age 
and gender, require careful aPTI" measurement and dose 
adjustment. More recent information for both heparin and the 
novel antithrombin agent hirudin indicate that when used with 
thrombolytic therapy, an aPTT goal of 60 to 90 seconds is 
associated with an unacceptably high rate of ICH. 495,496 
An algorithm for heparin dosing in the setting of thrombo- 
lytic therapy or treatment of non-ST-segment elevation is 
provided in Table 9. It is important to check the aPTI" 4 to 6 
hours after initiating therapy or changing dose, given the 
information about increased risk with a high aPTI'. Consider- 
ing the substantial delay in reporting aPT? values in many 
hospitals, the use of bedside coagulation monitoring, 497 if 
reliably performed, may be helpful. 
The previous ACC/AHA guidelines on acute MI recom- 
mended low-dose subcutaneous heparin (5000 U every 12 
hours for 24 to 48 hours) in all MI patients without contrain- 
dication who were not otherwise being treated with heparin for 
another eason. Current recommendations call for 7500 U 
twice a day (ACCP guidelines)? 23 The empirical basis for this 
recommendation was the demonstration that deep venous 
thrombosis was reduced from 12% to 4% in an overview of 
three randomized controlled trials. 498 Continued adherence to
this standard is reasonable, although routine earlier mobiliza- 
tion and use of aspirin may make this treatment unnecessary. 
Once heparin has been started, the appropriate duration of 
therapy is uncertain. Based on the evidence for disruption of 
the atherosclerotic plaque and the concept hat a healed 
endothelial surface would be salutary, aduration of 3 to 5 days 
has been standard. The only randomized trial to address this 
issue found, however, that discontinuation f heparin after 24 
hours following thrombolytic therapy with alteplase resulted in 
no measurable increase in ischemic events, 499 although this 
study did not have adequate power to detect modest differ- 
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ences. A reasonable approach isto use intravenous heparin for 
48 hours and then to use heparin according to the clinical 
characteristics ofthe patients. Heparin may be discontinued in 
low-risk patients, given subcutaneously in patients at high risk 
of systemic embolization, and intravenously inpatients at high 
risk for coronary reocclusion. 
Concern is mounting that when heparin is discontinued 
abruptly, the patient undergoes a high-risk period for recurrent 
thrombosis. 5°".5°~ Despite this concern, no specific policy has 
been tested to attempt to reduce this clinical "rebound" effect. 
Several ongoing studies, however, are reducing heparin infu- 
sions in a gradual fashion (eg, by one half within 6 hours then 
discontinuing over the subsequent 12 hours). 
Platelet counts should be monitored aily in patients on 
heparin. Recent evidence suggests the incidence of heparin- 
induced thrombocytopenia is 3% and is associated with a 
substantial risk of prothrombotic events. 5°2 If the platelet 
count drops below 100 000, a test for heparin-induced throm- 
bocytopenia should be obtained, and the clinician should be 
vigilant for thrombotic omplications as the prognosis in 
patients with thrombocytopenia is substantially worse. 5°3 
The deficiencies of heparin as an antithrombotic agent have 
been discussed in detail. 5°4 Fractionated heparins have been 
developed with variable effects on inhibition of thrombin and 
factor Xa. Although unfractionated heparin and low molecular 
weight heparin both catalyze the inhibition of thrombin by 
AT-Ill at clinically administered doses, the higher ratio of 
anti-Xa:anti IIa activity of low molecular weight heparins offers 
the potential advantage of inhibiting the coagulation cascade 
at a more proximal step, leading to reduction i  the generation 
of thrombin. 5"5 The addition of a low molecular weight heparin 
preparation to a regimen of aspirin,/3-adrenoceptor bl ckers, 
and nitrates in patients with unstable angina/non-Q wave MI is 
superior to placebo for reducing the risk of death and nonfatal 
MI in hospital, 5°~' although this effect was lessened in longer- 
term follow-up. Some evidence xists that subcutaneous ad- 
ministration of a low molecular weight heparin appears to be 
superior to infusion of unfractionated heparin for reducing 
episodes of recurrent ischemia in patients with unstable 
angina. 5''7 These agents are superior in many forms of venous 
thrombosis, 5°s but their relative value in coronary arterial 
thrombosis has not been established. 
Newer direct antithrombin agents are also in an advanced 
stage of development. The prototypical direct antithrombin 
agent hirudin was initially isolated from the saliva of the 
medicinal leech. Now, synthesized by recombinant technology, 
this compound has several conceptual dvantages: it does not 
require AT-Ill for its activity, it is not neutralized by plasma 
proteins, and it is able to inhibit clot-bound thrombin. Its 
characteristics also yield a stable aPTT value for a given dose, 
although its predominant renal excretion leads to unpredict- 
able buildup in patients with significant renal dysfunction. 
After very promising early phase trials in acute MI s"9,51~' 
and unstable angina, 51~ large-scale trials were initiated but 
had to be reconfigured ue to an excess rate of ICH in pa- 
tients treated with thrombolytic agents. 4'~5,4'~, The GUSTO-lib 
study comparing hirudin with heparin in conjunction with 
standard medical therapy in the management of 12 142 pa- 
tients with acute coronary syndromes recently reported a 
30-day death or MI rate (primary end point) of 8.9% for 
patients randomly assigned to hirudin treatment versus 9.8% 
for those randomly assigned to heparin (P=.058). 512 The TIMI 
9B trial of 3002 patients receiving either TPA or streptokinase 
for ST-segment elevation MI reported a 30-day rate of death, 
MI, or severe CHF of 11.9% in patients randomly assigned to 
heparin compared with 12.9% in patients assigned to 
hirudin.Sla~ 
Antiarrhythmics 
Antiarrhythmic therapy plays an important but more lim- 
ited role in acute MI care than in the past, as summarized in
"Hospital Management." The use of anticholinergic therapy 
with atropine for bradyarrhythmias is summarized in "Hospital 
Management." This section briefly summarizes antiarrhythmic 
agents in Vaughan-Williams Classes I through III that are 
appropriate in the acute setting and can be intravenously 
administered. Use of agents from Classes II 03-adrenoceptor 
blockers) and IV (calcium-channel entry blockers) have several 
other mechanisms of action (anti-ischemic, antihypertensive, 
etc), and their use is primarily summarized in subsequent 
sections. In general, both acute and long-term antiarrhythmic 
therapy except with /3-adrenoceptor blocking agents is indi- 
cated only for life-threatening or severely symptomatic ar- 
rhythmias and not for risk reduction in patients with non-life- 
threatening arrhythmias. 
Lidoeaine 
Lidocaine is a local anesthetic with antiarrhythmic proper- 
ties, grouped in Class Ib based on its relatively rapid onset and 
offset kinetics of membrane sodium channel blockade. Lidoo 
caine is metabolized in the liver; its volume of distribution and 
rate of clearance are reduced in heart failure. 513 Previous 
randomized studies have shown that it reduces risk for primary 
VF in both prehospital and early hospital settings/~4,5~5 De- 
spite this fact, mortality is not reduced; indeed, VF deaths are 
offset by deaths associated with asystole and electromechanical 
dissociation.325.5~ 
Lidocaine is the drug of choice in the setting of acute MI 
when treatment is indicated for premature ventricular com- 
plexes, VT, or VF. It is generally well tolerated, except in 
patients with shock, in the most recent adult ACLS proto- 
col, 517 lidocaine is recommended as the first antiarrhythmic 
agent to be used in cardiac arrest patients with persistent 
VT/VF despite defibrillation and epinephrine, to prevent 
recurrence, to control unsustained ventricular ectopy requiring 
therapy, and to treat wide complex tachycardia of uncertain 
type.5 ~,5 ~ 
Lidocaine is given in an initial bolus of 1.0 to 1.5 mg/kg (75 
to 100 rag); additional boluses of 0.5 to 0.75 mg/kg (25 to 
50 rag) can be given every 5 to 10 minutes if needed up to a 
total of 3 mg/kg. This is followed by a maintenance infusion of 
JACC Vol. 2S, No. 5 RYAN ET AL. 1381 
November 1, 1996:1328 428 MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
1 to 4 mg/min, reduced after 24 hours (to 1 to 2 mg/min) or in 
the setting of altered metabolism (heart failure, hepatic con- 
gestion, etc) and as guided by blood level monitoring. 
Bretylium 
Bretylium is a quaternary ammonium compound with both 
direct (Class III) and indirect (sympathetic neuronal) actions. 
Its hemodynamic and electrophysiological profile are biphasic, 
with initial norepinephrine release from adrenergic nerve 
endings causing hypertension, tachycardia, shortening of AV 
nodal refractory periods, and subsequent euronal blockade 
leading to hypotension521'; clinical Class III effect (refractory 
period lengthening) also emerges with some (variable) delay. 
Experimentally and clinically, bretylium has potent antifibril- 
latory but weak antiarrhythmic effects. 
Clinically bretylium is used in treatment of resistant VF and 
hemodynamically unstable VT. It is not a first-line agent but is 
recommended in the current ACLS protocol after defibrilla- 
tion, epinephrine, and lidocaine have failed to convert VF (or 
pulseless VT) or after VF has recurred despite epinephrine 
and lidocaine. It may be used for VT in patients with a pulse, 
but only after lidocaine and procainamide have failed. 
For VF, bretylium is given as a 5 mg/kg bolus; if VF-related 
cardiac arrest persists, supplemental doses of 10 mg/kg can be 
given at 5-minute intervals to a maximum dose of 30 to 
35 mg/kg. In stable VT the loading dose is diluted to 50 mL 
with 5% dextrose and given over 8 to 10 minutes. Bretylium 
therapy is maintained with an infusion rate of 1 to 2 mg/min. 
Procainamide 
Procainamide is an antiarrhythmic drug grouped in Class Ia 
because of its intermediate onset and offset kinetics of 
membrane sodium channel blockade. Procainamide has local 
anesthetic properties and mild to moderate hypotensive and 
negative inotropic potential. Its rate of metabolism to N-acetyl- 
procainamide (NAPA), which has Class III antiarrhythmic 
activity, is bimodally distributed in the population (fast, slow 
acetylators). 
Procainamide is indicated for life-threatening ventricular 
arrhythmias but usually not as the drug of first choice. Pro- 
cainamide suppresses premature ventricular complexes and 
recurrent VT and may be used when therapy is required when 
lidocaine has failed or is contraindicated. It may also be used 
for wide complex tachycardias of uncertain mechanism, al- 
though it also is usually not the drug of first choice in this 
setting. ACES guidelines list procainamide as potential therapy 
for VF and pulseless VT refractory to defibrillation and 
epinephrine after lidocaine, bretylium, and magnesium have 
been considered. 517 
Intravenous procainamide is initiated with a loading infu- 
sion of 10 to 15 mg/kg (500 to 1250 rag), given at a rate of 
20 mg/min (ie, over 30 to 60 minutes), followed by a mainte- 
nance infusion of 1 to 4 mg/min. In responding patients, 
therapy may be continued orally as needed. 
Procainamide may cause proarrhythmia, including torsades 
de pointes. Patients with renal insufficiency may develop high 
levels of NAPA and are at increased risk for development of
torsades. 
~-Adrenoceptor Blockers 
/3-Adrenoceptor blockers uch as propranolol, metoprolol, 
and atenolol have been shown to reduce incidence of VF in 
patients with acute MI in studies preceding the reperfusion 
era. 521 13-Adrenoceptor blockers also may be of particular 
value early in the management of "electrical storm" (recurrent, 
polymorphic VT/VF) in the setting of recent MI, which is often 
unresponsive to standard antiarrhythmic therapy. 331 Addi- 
tional rationale for/3-adrenoceptor blocker use in acute MI is 
provided in the following section. 
Amiodarone 
Amiodarone is a complex antiarrhythmic with action in 
each of the four Vaughn-Williams classes. Its mechanisms of 
action when given over the short term are still poorly defined 
but may include (1) noncompetitive ¢3-adrenoceptor blockade, 
(2) calcium channel blockade, (3) blockade of sympathetic 
efferents, and (4) possible Class la effects. 522 Short-term 
(intravenous) amiodarone, unlike long-term (oral) administra- 
tion may have little Class III effect. Intravenous amiodarone is
now approved for treatment and prophylaxis of frequently 
recurring VF and hemodynamically destabilizing VT. If suc- 
cessful, therapy can be continued orally over the long term. In 
randomized studies in VF or destabilizing VT refractory to 
lidocaine, a dose response was observed between larger (500 to 
1000 mg/d) and small (125 mg/d) doses of amiodarone in time 
to first VT/VF recurrence, although not in mortality. 332 Ami- 
odarone also was equally as effective as bretylium in preventing 
VT/VF recurrence but was better tolerated (less hypoten- 
s ion) .  52-~ 
Because of individual variability, dosing of intravenous 
amiodarone should be titrated according to patient response. 
The recommended starting dose is 500 mg per 24 hours, given 
in three stages: (1) rapid infusion of 150 mg over 10 minutes, 
(2) an early maintenance infusion of 1 mg/min for 6 hours, 
and (3) later maintenance infusion of 0.50 mg/min. Intrave- 
nous amiodarone is reasonably well tolerated, but adverse 
effects such as hypotension, bradycardia, nd AV block may 
occur. With greater experience, amiodarone may become a 
preferred antiarrhythmic agent for intravenous therapy of 
life-threatening ventricular tachyarrhythmias n lidocaine fail- 
ures. 
[3-Adrenoceptor Blocking Agents 
Recommendations for Early Therapy (see also 
"Predischarge Preparation") 
Class I
1. Patients without a contraindication to /3-adrenoceptor 
blocker therapy who can be treated within 12 hours of onset of 
infarction, irrespective of administration of concomitant 
thrombolytic therapy. 
2. Patients with continuing or recurrent ischemic pain. 
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3. Patients with tachyarrhythmias, uch as AF with a rapid 
ventricular response. 
Class lib 
1. Non-Q wave MI. 
Class III 
1. Patients with moderate or severe L¥ failure or other 
contraindications to ~-adrenoceptor blocker therapy. 
/3-Adrenoceptor blocking agents may be given to patients 
with acute MI to reduce morbidity and/or mortality during (1) 
the initial hours of evolving infarction and (2) the weeks, 
months, and years after completed infarction (secondary pre- 
vention). 
During the first few hours of infarction, /3-adrenoceptor 
blocking agents may diminish myocardial oxygen demand by 
reducing heart rate, systemic arterial pressure, and myocardial 
contractility. In addition, prolongation of diastole caused by a 
reduction in heart rate may augment perfusion to injured 
myocardium, particularly the subendocardiurn. As a result, 
immediate/3-adrenoceptor blocker therapy appears to reduce 
(1) the magnitude of infarction and incidence of associated 
complications in subjects not receiving concomitant thrombo- 
lyric therapy and (2) the rate of reinfarction in patients 
receiving thrombolytic therapy. 
In subjects not receiving thrombolytic therapy, intrave- 
nously administered /3-adrenoceptor blocking agents exert a 
modestly favorable influence on infarct size524). More impor- 
tant, they diminish short-term mortality. In the First Interna- 
tional Study of Infarct Survival, -~:5 in which more than 16 000 
patients with suspected acute MI were enrolled within 12 hours 
of onset of symptoms, immediate intravenous atenolol, 5 to 
10 rag, followed by oral atenolol, 100 mg daily, reduced 7-day 
mortality from 4.3% to 3.7% (P<.02; 6 lives saved per 1000 
treated). The mortality difference between those receiving and 
not receiving atenolol was evident by the end of day 1 and was 
sustained subsequently. In the Metoprolol in Acute Myocar- 
dial Infarction (MIAMI) trial 526 more than 5700 subjects with 
evolving MI were randomly assigned to receive placebo or 
metoprolol, up to 15 mg intravenously in 3 divided doses 
followed by 50 mg orally every, 6 hours for 48 hours and then 
100 mg twice a day thereafter. Fifteen-day mortality was 
reduced with metoprolol from 4.9% to 4.3%. As in ISIS-l, the 
mortality difference between those given placebo and those 
receiving metoprolol was evident by the end of day 1, after 
which it was sustained. 
In subjects receiving concomitant thrombolytic therapy, 
intravenously administered/3-adrenoceptor blocking drugs di- 
minish the incidence of subsequent onfatal reinfarction and 
recurrent ischemia: in addition, they may reduce mortality if 
given particularly early (ie, within 2 hours) after onset of 
symptoms. In the TIMI-II trial, r~7 in which all patients received 
intravenous alteplase, those randomly assigned to receive 
intravenous metoprolol, 15 rag, followed by oral metoprolol, 
50 mg twice a day for 1 day and then 100 mg twice a day 
thereafter, had a diminished incidence of subsequent onfatal 
reinfarction and recurrent ischemia when compared with those 
begun on oral metoprolol 6days after the acute event. Among 
those treated especially early, ie, within 2 hours of symptom 
onset, the composite nd point, death or reinfarction, occurred 
less often in those given immediate intravenous metoprolol 
than in those who did not receive it. 
If intravenous /3-adrenoceptor blockade induces an un- 
toward effect, such as AV block, excessive bradycardia, or 
hypotension, the condition is quickly reversed by infusion of a 
/3-adrenergic agonist (ie, isoproterenol, 1 to 5 gg/min). 
Contraindications 
The following are relative contraindications to/3-adrenoceptor 
blocker therapy: 
• Heart rate less than 60 bpm 
• Systolic arterial pressure less than 100 mm Hg 
• Moderate or severe LV failure 
• Signs of peripheral hypoperfusion 
• PR interval greater than 0.24 second 
• Second- or third-degree AV block 
• Severe chronic obstructive pulmonary disease 
• History of asthma 
• Severe peripheral vascular disease 
• Insulin-dependent diabetes mellitus 
Angiotensin Converting Enzyme Inhibitors 
Recommendations 
Class I 
1. Patients within the first 24 hours of a suspected acute 
MI with ST-segment elevation in two or more anterior precor- 
dial leads or with clinical heart failure in the absence of 
significant hypotension or known coutraindications to use of 
ACE inhibitors. 
2. Patients with MI and LV ejection fraction less than 40% 
or patients with clinical heart failure on the basis of systolic 
pump dysfunction during and after convalescence from acute 
MI. 
Class lla 
1. All other patients within the first 24 hours of a suspected 
or established acute MI, provided significant hypotension or 
other clear-cut contraindications are absent. 
2. Asymptomatic patients with mildly impaired LV func- 
tion (ejection fraction 40% to 50%) and a history of old MI, 
Class lib 
1. Patients who have recently recovered from MI but have 
normal or mildly abnormal global LV function. 
A number of large, randomized clinical trials have assessed 
the role of ACE inhibitors early in the course of acute MI. All 
trials in which only oral ACE inhibitors were used demon- 
strated abenefit in mortality. The only trial not showing benefit 
using ACE inhibitors was the Cooperative New Scandinavian 
Enalapril Survival Study (CONSENSUS) II, in which patients 
were randomly assigned within the first day to receive either 
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intravenous enalaprilat or placebo followed by increasing oral 
dosages of either enalapril or placebo. This trial was termi- 
nated early by the Safety Committee because of the high 
probability that a significant beneficial effect of enalapril over 
placebo was unlikely to be demonstrated with continuation of
the trial, as well as a concern over an adverse ffect among 
elderly patients experiencing an early hypotensive reactionY 7
The 95% confidence limits ranged from showing a 7% benefit 
to 29% harm. 
Clarification of the role of ACE inhibitors early in the 
course of MI has more recently resulted from large-scale 
clinical trials in which oral ACE inhibitors were used. In the 
ISIS-4 trial 58 000 patients with suspected acute MI were 
randomly assigned within the first 24 hours (median 8hours) to 
receive either oral captopril or placebo; a significant 7% 
proportional reduction was observed in 5-week mortality 
among those randomly assigned to captopril? 21The largest 
benefit was among those with an anterior infarction. 528 Among 
the 143 fewer deaths in the group allocated captopril, 44 
occurred in days 0 through 1 and 37 in days 2 through 7, 529 
demonstrating that early therapy is important. The GISSI-3 
trial used oral lisinopril in over 19 000 patients with either 
ST-segment elevation or depression who were randomly as- 
signed to it or open control. 42o There was a significant reduc- 
tion in 6-week mortality (odds ratio 0.88; 95% CI, 0.79 to 
0.99); 60% of the lives were saved during the first 5 days of 
treatment. The SMILE (Survival of Myocardial Infarction: 
Long-Term Evaluation) study involved 1556 patients ran- 
domly assigned within 24 hours to receive either placebo or 
zofenopril. 53° The patient population was restricted to those 
with anterior MI who had not received thrombolytic therapy. 
Use of an early ACE inhibitor in this trial suggested a
strong trend of more lives saved in the first 6 weeks (RR 25%, 
P=.19). A Chinese captopril pilot study involving more 
than 13 600 patients with suspected acute MI also revealed 
an approximate 0.5% absolute mortality benefit among those 
who were randomly assigned to the ACE inhibitor compared 
with the control population. 53~ A meta-analysis of these major 
trials along with 11 smaller trials that involve more than 
100 000 patients reveals a 6.5% overall odds reduction 
(2P=.006) with an absolute benefit of 4.6 fewer deaths per 
1000 patients treated among those who received the ACE 
inhibitor. 529 These data suggest hat ACE inhibitors have a 
role in early management as well as in the convalescent phase 
of acute MI. 
Although detailed subgroup analysis of the ISIS-4 and 
GISSI-3 trials awaits further publication, it would appear that 
the benefits of ACE inhibitors are greater among those with 
an anterior infarct or who have evidence of previous in- 
farction, heart failure, and tachycardia, ie, those at highest risk. 
Nevertheless, all trials with oral ACE inhibitors have shown 
benefit from its early use, including those in which entry 
criteria included all suspected acute infarctions. Data from 
these trials indicate that ACE inhibitors should generally be 
started within the first 24 hours, ideally, after thrombolytic 
therapy has been completed and blood pressure has sta- 
bilized. When there are no patient complications and no 
evidence of symptomatic or asymptomatic LV dysfunction 
by 4 to 6 weeks, ACE inhibitors can be stopped. ACE 
inhibitors should not be used if systolic blood pressure is 
less than 100 mm Hg, if clinically relevant renal failure is 
present, if there is a history of bilateral stenosis of the 
renal arteries, or if there is known allergy to ACE inhibitors. 
ACE inhibitor therapy should start with low-dose oral admin- 
istration and increase steadily to achieve a full dose within 
24 to 48 hours. For example, in ISIS-4 an initial 6.25 mg dose 
of captopril was given, followed by 12.5 mg 2 hours later, 
25 mg 10 to 12 hours later, and then 50 mg twice a day. GISSI 
patients received 5 mg oral lisinopril at the time of random- 
ization, 5 mg after 24 hours, 10 mg after 48 hours, then 10 mg 
daily for 6 weeks or open control. Similar graded-dose ched- 
ules should be used with other ACE inhibitors, such as 
ramipril, zofenopril, enalapril, or quinapril. Intravenous ena- 
laprilat should be avoided. 




Class l la 
1. Verapamil or diltiazem may be given to patients in 
whom/3-adrenoceptor blockers are ineffective or contraindi- 
cated (ie, bronchospastic disease) for relief of ongoing isch- 
emia or control of a rapid ventricular esponse with AF after 
acute MI in the absence of CHF, LV dysfunction, or AV block. 
Class l ib 
1. In non-ST-elevation infarction, diltiazem may be given 
to patients without LV dysfunction, pulmonary congestion, or 
CHF. It may be added to standard therapy after the first 24 
hours and continued for 1 year. 
Class I I I  
1. Nifedipine (short acting) is generally contraindicated in 
routine treatment of acute MI because of its negative inotropic 
effects and the reflex sympathetic activation, tachycardia, and 
hypotension associated with its use. 
2. Diltiazem and verapamil are contraindicated in patients 
with acute MI and associated LV dysfunction or CHF. 
Comment: Calcium channel blocking agents have not been 
shown to reduce mortali O, after acute MI, and in certain patients 
with cardiovascular disease there are data to suggest hey are 
harmfuU -~2 It is the consensus of this committee that these agents 
are still used too frequently 84 in patients with acute MI and that 
[3-adrenoceptor blocking agents are a more appropriate choice 
across a broad spectrum of patients with acute MI (with excep- 
tions as noted). 
Nifedipine 
In patients with acute MI, immediate-release nifedipine 
does not reduce incidence of reinfarction or mortality when 
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given early (less than 24 hours) or late after acute MI. This lack 
of benefit is found in all patients, irrespective of gender, overall 
risk, type of infarction (Q wave versus non-Q wave), and 
presence or absence of concomitant/3-adrenoceptor blocking 
agents or thrombolytic therapy. Immediate-release nif dipine 
may be particularly detrimental in patients with hypotension 
and/or tachycardia; inthese patients it may induce a reduction 
in coronary perfusion pressure, disproportionate dilatation of 
the coronary arteries adjacent to the ischemic area (so-called 
"steal"), and/or reflex activation of the sympathetic nervous 
system, with an increase in myocardial oxygen demands. These 
findings are based on numerous clinical trials, including the 
Nifedipine Angina Myocardial Infarction Study (NAMIS), 533 
the Norwegian Nifedipine Multicenter Trial, 534 the Trial of 
Early Nifedipine Treatment in Acute Myocardial Infarction 
(TRENT), 5-~5 and the Secondary Prevention Reinfarction Is- 
raeli Nifedipine Trial (SPRINT). 536,537 These studies were 
performed using first-generation nonsustained-release nif di- 
pine. Whether the conclusions are valid for the entire class of 
agents is unknown. 311-532,53s 
Verapamil 
Although the overall results of trials with verapamil showed 
no mortality benefits, subgroup analysis showed that 
immediate-release verapamil nitiated several days after acute 
MI in patients who were not candidates for a {3-adrenoceptor 
blocking agent may be useful in reducing the incidence of the 
composite nd point of reinfarction and death, provided LV 
function is well preserved with no clinical evidence of heart 
failure. Verapamil is detrimental topatients with heart failure 
or bradyarrhythmias during the first 24 to 48 hours after acute 
MI. 539-542 One randomized study of 1700 patients, less than 75 
years of age, using verapamil within 2 weeks of acute MI 
showed a 16.7% reduction in major events (death or MI) over 
18 months. 543 
Diltiazem 
Data from the Multicenter Diltiazem Postinfarction Trial 
(MDPIT) (Q wave and non-Q wave infarction) 544 and the 
Diltiazem Reinfarction Study (DRS) (non-Q wave infarc- 
tion) 54a,541.545-546 suggest that patients with non-O wave MI or 
those with Q wave infarction, preserved LV function, and no 
evidence of heart failure may benefit from immediate-release 
diltiazem. Diltiazem was begun in MDPIT 3 to 15 days after 
acute MI and in DRS 24 to 72 hours afterward. The results of 
MDPIT may be confounded by the fact that 53% and 55% of 
placebo- and diltiazem-treated patients, respectively, received 
concomitant/3-adrenoceptor blocker therapy. 544 Also, both the 
MDPIT and DRS projects were conducted in an era when the 
use of aspirin was not as prevalent as it is today, raising further 
uncertainty about the relevance of their findings for contem- 
porary management of acute MI. Of particular clinical impor- 
tance is the detrimental mortality effect of diltiazem in patients 
with LV dysfunction. 
The INTERCEPT trial (Incomplete Infarction Trial of Euro- 
pean Research Collaborators Evaluating Prognosis Post Throm- 
bolysis) (diltiazem) will test the hypothesis that use of sustained- 
release diltiazem in patients receiving thrombolytic therapy for a 
first MI will decrease mortality, reinfarction, and angina. 547 
Summary of Calcium Channel Blockers 
Calcium channel blockers have not proven beneficial in 
early treatment or secondary prevention of acute MI, and the 
possibility of harm has been raised. In patients with first non-Q 
wave infarction or first inferior infarction without LV dysfunc- 
tion or pulmonary congestion, verapamil and diltiazem may 
reduce the incidence of reinfarction, but their benefit beyond 
that of/3-adrenoceptor blockers and aspirin is unclear. Simi- 
larly, there are no data to support the use of second-generation 
dihydropyridines (eg, amlodipine, felodipine) for improving 






1. Correction of documented magnesium (and/or potas- 
sium) deficits, especially in patients receiving diuretics before 
onset of infarction. 
2. Episodes of torsades de pointes-type VT associated with 
a prolonged QT interval should be treated with 1 to 2 g 
magnesium administered as a bolus over 5 minutes. 
Class lib 
1. Magnesium bolus and infusion in high-risk patients 
such as the elderly and/or those for whom reperfusion therapy 
is not suitable. 
Comment: The available data suggest that mortality reduction 
may be seen in high-risk patients, provided magnesium therapy is
administered soon after onset of o,mptoms (preferably less than 6 
hours). The optimum dose has not been established, but a bolus 
of 2 g over 5 to I5 minutes followed by an infusion of 18 g over 
24 hours has been used with success. 
Background 
Supplemental dministration of magnesium for reducing 
morbidity and mortality in patients with acute MI is a reason- 
able avenue to pursue because of abundant data relating 
magnesium tocardiovascular disease. 54~ It is the second most 
abundant intracellular cation and is involved in more than 300 
enzymatic processes. Evidence xists that magnesium produces 
systemic and coronary, vasodilatation, possesses antiplatelet 
activity, suppresses automaticity in partially depolarized cells, 
and protects myocytes against calcium overload under condi- 
tions of ischemia by inhibiting calcium influx especially at the 
time of reperfusion. 54~-552 
Meta-analyses of the seven randomized trials published 
between 1984 and 1991 suggest a significant mortality benefit 
of magnesium (odds ratio 0.44, CI 0.27 to 0.71). 553,554 The 
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Table 10. A Classification f Inotropic Agents 
Agent Mechanism Inotropic Vascular Effect Major Use 
Isoproterenol /3-1 receptor + + Dilatation 
Dobutamine + + Mild dilatation 







+ + Intense constriction 
+ + Dilatation 
+ + Dilatation 
+ Variable 
/3-1 receptor 
Low dose: dopaminergic receptor 
Medium dose: 13-1 rcceptor 




Inhibits NA+-K+ATPase pump 
Hypotension due to bradycardia; no 
pacing available 
Low output with SBP >90 mm Hg 
Hypoperfusion with SBP <90 mm Hg 
or >30 mm Hg below usual value 
Extreme hypotension despite use of 
dopamine 
Second-tier agcnt after failure of 
dopamine/dobutamine 
Established systolic LV dysfunction 
and symptoms of heart failure for 
chronic therapy 
SBP indicates ystolic blood pressure; LV, left ventricular. 
Second Leicester Intravenous Magnesium Intervention Trial 
(LIMIT-2) trial 555 subsequently reported a 24% reduction in 
mortality with magnesium treatment (P<.04). The 
magnesium-treated patients in LIMIT-2 had a 25% lower 
incidence of CHF in the CCU and a 21% lower rate of 
ischemic heart disease-related mortality over 4 years, con- 
sistent with the hypothesis that magnesium exerts its ben- 
eficial effects, at least in part, via a myocardial protective 
action .555,556 
The results of one large trial were negative. The ISIS-4 
investigators enrolled 58050 patients, 29011 allocated to 
magnesium, and 29 039 to control. There were 2216 deaths 
(7.64%) by 35 days in the magnesium group and 2103 
deaths (7.24%) in the control group (odds ratio 1.06; CI 
0.99 to 1.13), suggesting no mortality benefit of magnesium 
administration a d even the possibility of slight harm. 421 When 
ISIS-4 is added to the preceding randomized trials, meta- 
analysis indicates no beneficial effect of magnesium. Possible 
sources of heterogeneity that could explain these differences 
include: 
1. The relatively late administration of magnesium in 
ISIS-4.55v 
2. The control group mortality in ISIS-4 was only 7.2%. 
Regression analyses of the available data predict a null effect of 
magnesium when the control mortality is about 7% and 
increasing benefit of magnesium for higher control mortality 
rates.55s 
Shechter and colleagues 55'3 recently reported arandomized 
trial of 194 patients with acute MI unsuitable for thrombolysis. 
There was a significant reduction in mortality in the magne- 
sium group (4.2% versus 17.3%, P<.01), largely due to a lower 
incidence of cardiogenic shock and CHF. 
An NHLBI-sponsored trial (Magnesium in Coronary Dis- 
ease [MAGIC]) is planned to further evaluate the role of 
magnesium in acute MI, especially with early administration 
before thrombolysis n higher-risk patients. 557 
Inotropic Agents 
It is useful clinically to consider inotropic agents in terms of 
three classes (Table 10): inotropic agents with predominant 
vasoconstrictive properties; catecholamines with predominant 
inotropic properties with little or no vasoconstriction; and 
phosphodiesterase inhibitors, inotropic agents with predomi- 
nant vasodilating properties. 
Vasoconstrictor inotropic agents are represented by dopa- 
mine and norepinephrine. Contractility and heart rate are 
increased by dopamine through its direct stimulation of a and 
/3-adrenergic receptors and through release of norepinephrine 
from nerve endings. When given in low doses (1 to 3 ~g/kg per 
minute), its major effects are on dopaminergic receptors 
leading to renovascular dilatation and on /3 adrenoceptors 
modestly stimulating contractility. At a dose of 5 to 10/xg/kg 
per minute, the/3-1 receptor effects are dominant, leading to 
an increase in contractility and heart rate. At higher doses the 
c~-receptor effects predominate, leading to vasoconstriction. 
Norepinephrine is almost purely a vasoconstrictive agent with 
a positive effect on contractility. 
The catecholamine inotropic agents that do not cause 
vasoconstriction are represented by dobutamine. Through its 
effects on /3-1 receptors, it stimulates contractility; the hope 
that it would produce less tachycardia and fewer arrhythmias 
than dopamine has not been realized, lsoproterenol produces 
increased heart rate and contractility while causing vasodila- 
tion; therefore, it is not recommended xcept as an emergency 
measure when low output is caused by a profound bradycardia 
and temporary pacing is not available. 
Amrinone and milrinone (phosphodiesterase inhibitors) 
were developed with the hope that their different mechanism 
of action would lead to improved cardiac output without he 
risk of arrhythmia engendered by catecholamines. These 
agents are characterized by both inotropic and vasodilating 
effects and with a more substantial effect on preload than 
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catecholamines. Excessive mortality when oral milrinone was 
given long term and unacceptable toxicity of long-term use of 
amrinone 56° have dampened enthusiasm for long-term use of 
these drugs. Renal elimination of phosphodiesterase inhibitors 
is a problem in critically ill patients. 
In a patient with perceived low output, the clinician must 
simultaneously assess the patient for the possible cause and 
institute life-saving therapy. If volume depletion is a possible 
cause, an intravascular volume-expanding i fusion should be 
initiated. When blood pressure is low (systolic less than 
90 mm Hg or 30 points below usual), dopamine is the agent of 
first choice. If blood pressure remains low with institution of 
more than 20 /~g/kg, norepinephrine may be substituted in 
doses of 2 to 20 ~g/kg per minute. In all other situations 
dobutamine is the agent of first choice. All intravenous cat- 
echolamines have the advantage of a very short half-life, 
enabling titration of the dose in a matter of minutes while 
observing the clinical effect. 
Phosphodiesterase inhibitors are reserved for patients who 
have not responded to catecholamines or who have significant 
arrhythmias or ischemia-producing tachycardia on catechol- 
amine therapy. Milrinone is given in a dose of 0.25 to 
0.75 /~g/kg per minute. Special caution must be advised in 
patients with renal dysfunction because the drug will accumu- 
late. 
In general the current concept is that patients requiring 
intravenous inotropic support should be maintained on these 
agents for as short a time as possible. These agents are 
arrhythmogenic and increase myocardial oxygen demand. The 
only available empirical information on mortality, effects with 
long-term use are dismal. Whenever possible, afterload reduc- 
ing agents and intra-aortic balloon pumping should be substi- 
tuted for inotropic agents. 
Digitalis 
Despite the initial description of the inotropic properties of 
digitalis in 1785, its role in the post-MI patient remains 
controversial. Concern about increased mortality associated 
with long-term use of milrinone has fueled a reexamination f 
the empirical information about digitalis from previous obser- 
vational studies. These studies had mixed results, with some 
suggesting an increase in mortality and others a neutral effect 
on mortality. ~6~ Recent studies have demonstrated that in 
patients with definite systolic LV dysfunction, digitalis im- 
proves symptomatic status and has a favorable ffect on the 
neurohormonal system. 562,563 The Digitalis Investigator Group 
(DIG) recently reported a study of 7788 patients in CHF (due 
to ischemic heart disease in 70% of cases) who were in sinus 
rhythm. Digoxin was compared with placebo for prevention of 
all-cause mortality¢ 64More than 90% of patients were also on 
ACE inhibitors and/or diuretics. Important secondary objec- 
tives included hospitalization for CHF, cardiovascular mortal- 
ity, and death due to CHF. The overall findings of the trial 
showed no reduction in total mortality with digoxin. However, 
there were reductions in deaths due to CHF and combined 
heart failure-related deaths and hospitalizations in digoxin- 
treated patients. A trend toward increased eaths due to 
presumed arrhythmia or MI was observed inthe digoxin group. 
Of note, a recent MI was an exclusion criterion for enrollment 
in the DIG trial. Thus, the current recommendation, based on 
previous clinical experience, supports the use of digoxin in 
selected patients recovering from an MI if they have supraven- 
tricular arrhythmias or CHF refractory to ACE inhibitors or 
diuretics. Generally the loading dose is 8 to 15 p.g/kg lean body 
weight, with half the dose given immediately and the remain- 
der given in 25% increments 6 hours apart. A maintenance 
dose of 0.125 to 0.375 mg/d is given, based on renal function 
and lean body weight. 
VI. P reparat ion  for  D ischarge  F rom 
the  Hosp i ta l  
Noninvasive Evaluation of Low-Risk Patients 
Recommendations 
Class I 
1. Stress ECG 
a. Before discharge for prognostic assessment or func- 
tional capacity (submaximal at 4 to 6 days or symptom limited 
at 10 to 14 days). 
b. Early after discharge for prognostic assessment and 
functional capacity (14 to 21 days). 
c. Late after discharge (3 to 6 weeks) for functional 
capacity and prognosis if early stress was submaximal. 
2. Exercise, vasodilator stress nuclear scintigraphy, or 
exercise stress echocardiography when baseline abnormalities 
of the ECG compromise interpretation.* 
Class lla 
1. Dipyridamole or adenosine stress perfusion nuclear 
scintigraphy or dobutamine echocardiography before dis- 
charge for prognostic assessment in patients judged to be 
unable to exercise. 
2. Exercise two-dimensional echocardiography or nuclear 
scintigraphy (before or early after discharge for prognostic 
assessment). 
Class III 
1. Stress testing within 2 to 3 days of acute MI. 
2. Either exercise or pharmacological stress testing at any 
time to evaluate patients with unstable postinfarction angina 
pectoris. 
3. At any time to evaluate patients with acute MI who have 
uncompensated CHF, cardiac arrhythmia, or noncardiac on- 
ditions that severely limit their ability to exercise. 
*Marked abnormalities in the resting ECG such as LBBB, LV hypertrophy 
with strain, ventricular p e-excitation, r a ventricular paced rhythm render a
displacement of he ST segments virtually uninterpretable. For patients aking 
digoxin or who have less than 1 mm ST depression their esting tracing who 
undergo standard stress electrocardiographic testing, itmust be realized that 
further ST depression with exercise may have minimal diagnostic significance. 
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4. Before discharge to evaluate patients who have already 
been selected for cardiac catheterization. In this situation an 
exercise test may be useful after catheterization to evaluate 
function or identify ischemia in distribution of a coronary 
lesion of borderline severity. 
Role of Exercise Testing 
The role of exercise testing in evaluating patients after MI 
has been well established 565 and extensively covered in the 
earlier ACC/AHA guidelines. 1,566,567 The basic aims of early 
exercise testing after MI are to (1) assess functional capacity 
and the patient's ability to perform tasks at home and at work; 
(2) evaluate the efficacy of the patient's current medical 
regimen; and (3) risk-stratify the post-MI patient according to 
the likelihood of a subsequent cardiac event. Numerous tudies 
reported throughout the 1980s provided particularly important 
information about risk stratification and the development of
practical algorithms for further management of the post-MI 
patient. 56~472 The decade of the 1980s also witnessed a dra- 
matic change in treatment of patients with acute MI, charac- 
terized most notably by the broad use of thrombolytic therapy 
beginning in 1988. Equally important has been the widespread 
use of aspirin, /3-adrenoceptor blocking agents, vasodilator 
therapy, common use of ACE inhibitors, and a far more 
aggressive use of revascularization therapy in patients who 
have clinical markers of a poor prognosis. It is this constella- 
tion of new therapy and not solely the administration of 
thrombolytic therapy that marks what is generally referred to 
as the "reperfusion era." 
This period has witnessed an impressive reduction in early 
and 1-year mortality rates for acute MI patients, which is 
particularly striking in patients who have received thrombolytic 
therapy and revascularization during hospitalization. 573 
The improvement in 1-year mortality in patients who have 
received thrombolytic therapy is multifactorial. Such patients 
are less likely to have severe three-vessel coronary artery 
diseases 4 Patients who receive thrombol~ic therapy have a 
smaller infarct size. 575 Coronary angiography is frequently 
performed uring hospitalization due to recurrent chest pain, 
which identifies many patients with severe disease who subse- 
quently undergo revascularization. 576 The patient population 
eligible for predischarge xercise testing in clinical trials of 
thrombolytic therapy is therefore far different from less se- 
lected, historical populations. Their low cardiac event rate 
following discharge is therefore not surprising and substan- 
tially reduces the predictive accuracy of early exercise testing. 
The highest-risk subset of patients are those who are unable 
to exercises 7,57s Although patients with exercise-induced ST
depression have a higher 1-year mortality than patients without 
exercise-induced depression, their absolute mortality remains 
low (1.7%) by historical standards. 57s The duration of exercise 
is also known to be an important predictor of outcomes and the 
ability to perform at least 5 metabolic equivalents (METs) 
without early exercise ST depression and show a normal rise in 
systolic blood pressure is important in constituting a negative 
predictive value. 57'~,5s~ 
There is limited evidence on the ability of exercise testing to 
risk-stratify patients who have not received reperfusion in the 
current era. Although their subsequent mortality rates are 
lower because of the constellation of new therapy mentioned 
earlier, their absolute vent rates are higher than in patients 
who have received thrombolytic therapy, particularly if they 
have also not undergone revascularization. 573 Although the 
available vidence is limited, exercise testing presumably can 
still assist in the risk stratification of such patients. 
Low-level exercise testing appears to be safe if patients have 
undergone in-hospital cardiac rehabilitation, including low- 
level exercise, have had no symptoms of angina or heart 
failure, and have a stable baseline ECG 48 to 72 hours before 
the exercise test. Two different protocols have been used to 
determine the end points of these very early exercise 
tests.S~l-5~3 
The traditional submaximal exercise test (done at 3 to 5 
days in patients without complications) incorporates a series of 
end points, including a peak heart rate of 120 to 130 bpm or 
70% of maximal predicted heart rate for age, a peak work level 
of 5 METs, or clinical or ECG end points of mild angina or 
dyspnea, ST-segment depression greater than 2 mm, exertional 
hypotension, or three or more consecutive premature ventric- 
ular contractions, whichever end point is reached first. The 
second protocol is performance of a symptom-limited xercise 
test (done at 5 days or later) without stopping for target heart 
rates or MET levels. Although this level appears to be safe and 
will result in a higher frequency of abnormal exercise tests, the 
prognostic value of ST depression occurring at higher work 
levels in deconditioned patients is uncertain and may lead to 
unnecessary cardiac catheterization. 
The optimum time for performing the exercise test after MI 
remains unresolved. It is argued that a predischarge exercise 
test provides psychological benefits to the patient and will 
permit detection of profound ischemia that could be associated 
with postdischarge cardiac events that might occur before a 
scheduled 3- to 6-week postdischarge symptom-limited stress 
test. On the other hand, deferring exercise testing until approx- 
imately 3 weeks after MI in clinically low-risk patients appears 
safe and reasonable and enables more optimal assessment of
functional capacity. For patients without complications who 
have not undergone coronary arteriography before discharge, 
it is the consensus of this committee that patients who might be 
potential candidates for revascularization procedures hould 
undergo exercise electrocardiography before or just after 
discharge. 
Supplemental Imaging 
Exercise Myocardial Perfusion Imaging 
In a number of reports from a decade ago, before the use of 
thrombolytic therapy, the prognostic value of exercise myocar- 
dial perfusion imaging was found to be superior to that of 
exercise electrocardiographic testing. 5se-Ss7 Pharmacological 
stress perfusion imaging 5~-59o was also shown to have value for 
the prediction of postinfarction cardiac events. The key issues 
are whether these results apply to current patient populations 
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Figure 10. Strategies for exercise test evaluations soon after myocar- 
dial infarction (MI). If patients are at high risk for ischemic events, 
based on clinical criteria, they should undergo invasive valuation to 
determine if they are candidates for coronary revascularization proce- 
dures (Strategy l). For patients initially deemed to be at low risk at 
time of discharge after MI, two strategies for performing exercise 
testing can be used. One is a symptom-limited test at 14 to 21 days 
(Strategy II). If the patient is on digoxin or if baseline lectrocardio- 
gram precludes accurate interpretation of ST-segment changes (eg, 
baseline left bundle branch block or left ventricular hypertrophy), then 
an initial exercise imaging study can be performed. Results of exercise 
testing should be stratified to determine need for additional invasive or 
exercise perfusion studies. A third strategy isto perform a submaximal 
exercise test at 5 to 7 days after MI or just before hospital discharge. 
The exercise test results could be stratified using the guidelines in 
Strategy I. If exercise test studies are negative, a second symptom- 
limited exercise test could be repeated at 3 to 6 weeks for patients 
undergoing vigorous activity during leisure or at work. 
in the reperfusion era and whether myocardial perfusion 
imaging is worth the additional cost for risk stratification. 59~ 
The same issues outlined previously with respect o exercise 
electrocardiographic testing also apply to this methodology. 
In patients with ST elevation who have received thrombo- 
lyric therapy, several studies using myocardial perfusion imag- 
ing have found that it is less valuable than previously for risk 
stratification, -~'~2-594 primarily because of the low late cardiac 
event rate. 
In patients in the current era who have not received 
reperfusion therapy, particularly those who have not under- 
gone revascularization, the same considerations regarding 
subsequent patient outcome that were outlined above for 
exercise lectrocardiographic testing apply. There is evidence 
that myocardial perfusion imaging is useful for risk stratifica- 
tion in such patients, despite their better overall prognosis. 5')5 
It seems likely that the previously demonstrated superiority of 
stress myocardial peffusion imaging probably continues to apply 
to this population, although there is limited evidence on this 
point. It must be recognized that prospective studies are ditficult 
to conduct because clinicians frequently intervene in patients with 
abnormal predischarge stress perfusion imaging studies. 
Myocardial perfusion imaging with either thallium 20P 9f' or 
technetium 99m sestamibi 5'~v can assess infarct size. The mea- 
surement of infarct size by either one of these techniques i
significantly associated with subsequent patient mortality after 
thrombolytic therapy. 590,5'~7 Data are also emerging to suggest 
that vasodilator stress nuclear scintigraphy is safe and can be 
used for early (48 to 72 hours) risk stratification. 
Recommended strategies for exercise test evaluations soon 
after MI are presented in Fig 10. 
Role of Echocardiography 
The widespread availability, portability, and relative cost of 
echocardiography as resulted in its increased use as a practi- 
cal and reliable means of assessing both global ventricular func- 
tion and regional wall motion abnormalities. The uses of echo- 
cardiography in acute MI are discussed in detail in the ACC/ 
AHA guidelines for clinical application of echocardiography, s7~
Risk Stratification After Myocardial Infarction 
The incremental value of exercise chocardiography over 
regular exercise testing after MI has also not been established. 
The usefulness of exercise echocardiography as a means of 
assessing myocardial ischemia in patients with coronary artery 
disease has been well established, with overall sensitivity of 
81% and specificity of 89%. 59~-~"3 However, its value in pre- 
dicting cardiac events after MI has not been fully determined. 
A negative test is, in general, associated with a low risk of 
cardiac events and death, but it may be higher than that 
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associated with a negative perfusion scan? '°44'°s The usefulness 
of pharmacological stress testing with echocardiography or 
single-photon emission computed tomography (SPECT) imag- 
ing using agents such as dipyridamole or dobutamine in 
predicting cardiac events after acute MI is also a subject 
undergoing intense investigation. A positive dipyridamole 
echocardiogram after MI is associated with a higher late 
mortality rate, but a negative test does not preclude cardiac 
events in the 2-year follow-up period. ~,°u There are few data 
regarding the prognostic value of a positive or negative dobut- 
amine stress echocardiogram, but its safety in general and in 
the 3 to 5 days after MI ~,l~ is acceptably low. This agent, 
although widely used for pharmacological stress testing, has 
not been approved for this purpose by the FDA. Like scintig- 
raphy, there is great variation among institutions in expertise 
and study quality, and it is this local expertise that should 
determine the choice of test procedures. Exercise echocardi- 
ography generally, however, is a less costly procedure than 
radionuclide perfusion scintigraphy. 
Myocardial Viability 
A significant development since the previous et of recom- 
mendations i related to understanding and identifying myo- 
cardial viability. Up to one third of patients who have signifi- 
cant LV dysfunction may improve with revascularization? ,~ 
This usually refers to myocardial hibernation, ('~ in which 
chronic low flow state is associated with depressed myocardial 
function. Myocardial stunning ',~2 is more germane to the situation 
after MI, when depressed ventricular function is present despite 
adequate restoration of blood flow. Function will subsequently 
improve. The therapeutic mportance of myocardial stunning is 
perhaps less than hibernation because identification of the former 
does not in general initiate a change in management of revascu- 
larization. However, identification of extensive reversible LV 
dysfunction isof prognostic importance and may help to optimize 
medical management after MI. '~ 
Several noninvasive imaging modalities have been estab- 
lished as accurate predictors of myocardial viability. These 
include thallium imaging, positron emission tomography 
(PET), and dobutamine chocardiography. The choice of 
which technique to use should be dependent on center and 
regional expertise. Positron emission tomography scanning 
is most sensitive in detecting viable myocardium, but because 
of the limitations described above and the expense involved, 
it has little widespread applicability. Thallium imaging has 
been well established over time, while dobutamine echocardi- 
ography seems to have an acceptably high positive predictive 
accuracy. More important han technique, however, is the ques- 
tion of whether myocardial viability tests should be used in 
practice until large-scale outcome data can validate the useful- 
ness. 
Left Ventricular Function 
Assessment of LV function after acute MI has been dem- 
onstrated to be one of the most accurate predictors of future 
cardiac events in the risk stratification of patients with acute 
MI in both the prereperfusion 613 and the reperfusion 
eras. 614.~'15 Multiple techniques for assessing LV function of 
patients after infarction have been shown to have important 
prognostic value and include such basic principles as clinical 
estimates based on patients' symptoms (eg, exertional dyspnea, 
functional status), physical findings (eg, rales, elevated jugular 
venous pressure, cardiomegaly, S 3 gallop), exercise duration 
(treadmill time) and measurement of ejection fraction by 
contrast ventriculography, radionuclide ventriculography, and 
two-dimensional echocardiography. Zaret and colleagues 614 
found that an LV ejection fraction less than 0.30 as assessed 
by radionuclide ventriculography was still predictive of mor- 
tality in patients urviving infarction treated with thrombo- 
lytic therapy, despite the significantly reduced mortality of 
these patients compared with those in the prereperfusion 
era. White and colleagues ~6 performed contrast left ven- 
triculography in 605 patients 1 to 2 months after MI. They 
found postinfarction LV dilation, demonstrated by in- 
creased end-systolic volume greater than 130 mL, was an 
even better predictor of mortality after MI than an LV 
ejection fraction less than 40% or increased end-diastolic 
volume. In patients with normal ejection fractions, however, 
end-systolic volume did not provide any further stratifica- 
tion according to risk. 
Radionuclide Testing for the Diagnosis of Acute 
Myocardial Infarction 
Guidelines for cardiac radionuclide imaging have been 
published recently 5~'7 that indicate the clinical use of radionu- 
elide imaging for diagnosis of acute MI should be restricted to 
special imited situations in which the triad of history, electro- 
cardiographic hanges, and laboratory measurements is un- 
available or less reliable. 
In patients who present late (more than 24 hours and less 
than 7 days) without diagnostic electrocardiographic changes 
and in patients early after coronary artery bypass surgery, 
myocardial infarct-avid scintigraphy using 99mTc pyrophos- 
phate has moderate sensitivity and specificity for the diagnosis 
of acute MI. ~'~7,6~s More recently infarct-avid scintigraphy with 
antimyosin antibody has been described as an alternative to 
pyrophosphate scintigraphy ~j~,62' and has just received FDA 
approval for use in the United States. 
In selected patients with RV infarction, radionuclide imag- 
ing may also have a role in diagnosis by demonstrating a 
reduced RV ejection fraction and RV asynergy. 62~ 
Localized perfusion defects occur in a high percentage of 
patients with acute LV infarction associated with coronary 
occlusion. ~':2 However, such perfusion defects do not distin- 
guish between acute ischemia, acute infarction, or previous 
infarction. Serial changes on follow-up perfusion images with 
either 2°1T1 or 99mTc sestamibi suggest an acute process but 
still do not distinguish between ischemia or infarction. 
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Table 11. Uses of Radionuclide T sting in Acute Myocardial Infarction 
Diagnosis Risk Assessment 
Indication Test Class Indication Test Class 
1. RV infarction 
2. Infarction not diagnosed by standard 
means--early presentation with 
successful reperfusion 
3. Infarction not diagnosed by standard 
means--late presentation 
4. Routine diagnosis 
Rest RNA lla 1. Residual ischemia Stress (exercise/pharmacological) I 
thallium with redistribution 
'~'~'Tc pyrophosphate IIa Stress (exercise/pharmacological) 
sestamibi with redistribution 
Rest myocardial lib 2. Myocardial infarct size Tomographic thallium IIa 
perfusion imaging Tomographic sestamibi IIa 
9~)'Tc pyrophosphate lib 
'~mTc pyrophosphate lla 3. Hibernating myocardium Early, late thallium IIa 
Any technique III 4. Ventricular function RNA I 
RV indicates right ventricular; RNA, radionuclide angiography; 99mTc, technetium 99m. From the ACC/AHA task force. Guidelines for clinical use of cardiac 
radionuclide imaging: report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic 
Cardiovascular P ocedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society, of Nuclear Cardiology. J Am Coil Cardiol 
1995;25:521-547. 
Measurement of Infarct Size 
Technetium 99m sestamibi is uniquely suited to accurate 
measurement of myocardium at risk in clinical infarction. 
Because there is minimal redistribution of the radiopharma- 
ceutical over time, imaging can be delayed for several hours 
after injection and still provide accurate information about 
myocardial perfusion at the time of injection. The validity and 
feasibility of this approach as been well established in animal 
and clinical studies. ~23-626 
As mentioned previously, myocardium at risk is a major 
determinant of final infarct size. However, final infarct size 
may be considerably smaller than the initial myocardium at 
risk, reflecting the effects of reperfusion therapy, spontaneous 
reperfusion, and collateral blood flow. ~'27 Clinical data have 
demonstrated the importance of final infarct size as a major 
determinant of subsequent patient survival and quality of life. 
Radionuclide t chniques are clearly useful for this purpose. In 
patients who have not received reperfusion therapy, measure- 
ment of rest ejection fraction and end-systolic volume index 
before hospital discharge by equilibrium-gated radionuclide 
angiography is highly associated with subsequent patient out- 
come. ~'t3.~2s In patients who have received reperfusion therapy, 
the postdischarge r st ejection fraction by equilibrium radio- 
nuclide angiography after resolution of myocardial stunning 
and compensatory h perkinesia is highly associated with sub- 
sequent patient outcome. 59~-~29,~3° 
Myocardial perfusion imaging with 2°JTI and 99mTc sesta- 
mibi can also be used to assess infarct size. 5%,631,632 Most 
recently 9~)mTc sestamibi has been used with tomographic 
imaging for this purpose? '33,634 Measurement of infarct size 
with 99mTc sestamibi has been closely correlated with other 
measurements of infarct size, including ejection fraction, 635 
regional wall motion score, ~35 creatine kinase release) 2~ and 
2°ITI defect size. 632 Two studies have now shown an association 
between infarct size and patient outcome. 596.597 Table 11 
summarizes the uses for radionuclide t sting in acute MI. 
Summary of Stress Testing After Acute 
Myocardial Infarction 
It is the consensus of the task force that the current 
approach to risk stratification of patients after MI requires 
little change from the recommendations utlined in the origi- 
nal ACC/AHA task force report "Early Management of Pa- 
tients With Acute Myocardial Infarction." Patients who have 
clinically declared themselves to be at high risk should have 
coronary arteriography to identify those who are candidates 
for revascularizationS Patients without clinical complications 
after infarction should have a submaximal exercise stress test 
before discharge or, alternatively, a symptom-limited stress test 
3 weeks after discharge. Patients who can achieve at least 5 
METs are treated medically. If there are signs of severe 
ischemia t a low level of exercise, such as marked ST-segment 
change or inability to complete stage I, failure to achieve 3 to 
4 METs, or if blood pressure falls during exercise, the patient 
should undergo coronary arteriography. 
It must be acknowledged, however, that the positive pre- 
dictive value of virtually all noninvasive tests has declined as 
late prognosis improves, particularly those relatively highly 
selected patients who have received reperfusion therapy. The 
paradigm for the future will be a new database that examines 
the benefits, cost-effectiveness, and incremental value of non- 
invasive tests among lower-risk patients who have received 
reperfusion therapy. 
In patients for whom the resting ECG is uninterpretable 
because of BBB, major ST-T wave abnormalities, or digitalis 
therapy, radionuclide myocardial perfusion imaging with exer- 
cise or stress echocardiography s ould be performed, epend- 
ing on local experience and expertise. In the patient who 
cannot exercise, pharmacological stress agents can be used 
with either myocardial perfusion imaging or echocardiography. 
It is the view of the committee that exercise lectrocardiogra- 
phy is a valuable test in assessing prognosis in patients with 
coronary artery disease. It is generally available, with experi- 
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enced personnel capable of performing it safely, and it is 
relatively inexpensive. After uncomplicated MI, patients can 
be divided into relatively high- and low-risk groups for subse- 
quent cardiac events if all the information available on the 
treadmill test is used (Fig 10). 
Ambulatory Electrocardiographic Monitoring 
for Ischemia 
The value of ambulatory electrocardiographic monitoring 
in assessing reversible myocardial ischemia and the risk of a 
subsequent coronary event early after myocardial infarction 
have been evaluated in a number of studies. 63°-643 Up to one 
quarter of patients will show residual ischemia as detected by 
ambulatory electrocardiographic monitoring. Most episodes of 
transient myocardial ischemia are silent and occur at rest or 
during times of low-level physical activity or mental stressJ '44 
During long-term follow-up studies, a number of investigators 
have reported that the presence of ischemia detected by 
ambulatory electrocardiographic monitoring in the postinfarc- 
tion period is predictive of a subsequent poor outcome and 
increases the risk of cardiac events. 636-~43 One recent study 
found that the odds ratio for the patients with, as compared to 
those without, ambulatory ischemia was 2.3 for death or 
nonfatal MI at 1 year) 43 
Despite the promising initial results with ambulatory elec- 
trocardiographic monitoring, the totality of evidence does not 
support a general statement about its role in all postinfarction 
patients. Some studies have shown that the results of ambula- 
tory electrocardiographic monitoring could be predicted from 
exercise test data, °38,64° while others have found that additional 
prognostic information could be obtained by ambulatory elec- 
trocardiographic monitoring in postinfarction patients. 639 At 
present a cost-effective strategy has not been developed to 
identify patients who are at increased risk for ambulatory 
ischemia nd in whom ambulatory electrocardiographic mon- 
itoring might be more helpful for stratification into high- and 
low-risk subgroups for future coronary events. 
Assessment of Ventricular Arrhythmia (Signal- 
Averaged Electrocardiography, Ambulatory [Holter] 
Monitoring, Heart Rate Variability) 






1. Ambulatory (Holter) monitoring, signal-averaged ECG, 
heart rate variability, baroreflex sensitivity monitoring, alone 
or in combination with these or other tests, including func- 
tional tests (ejection fraction, treadmill testing) for risk 
assessment after MI, especially in patients at higher perceived 
risk, when findings might influence management issues, or for 
clinical research purposes. 
The risk of malignant ventricular arrhythmias after hospital 
discharge is greatest in the first year after acute MI. 645-649 
Recent data suggest that thrombolytic therapy reduces this risk 
and also confirm that LV dysfunction remains an important, 
although diminished, predictor of mortality, including sudden 
death. 6~4,~50-~53 An open infarct-related artery has emerged as 
an important predictor of late outcome in other studies. 65~ A 
number of strategies have been used to try to identify patients 
at high risk for arrhythmic events. Sustained monomorphic VT 
induced by electrophysiological study is associated with a high 
arrhythmic event rate 654 but is invasive and has a low specific- 
ity. Frequent ventricular premature complexes and higher- 
grade ventricular ectopy (unsustained VT) on a predischarge 
Holter monitor also have been associated with a higher 
mortality among MI survivors, in both the prereperfusion a d 
(less consistently) in the reperfusion eras. 645-653 
Recently, newer techniques, including signal-averaged or
high-resolution electrocardiography, eart rate variability, and 
baroreflex sensitivity, have been used to assess patient risk for 
sudden cardiac death after MI. Signal-averaged electrocardi- 
ography identifies delayed, fragmented conduction in the 
infarct zone in the form of late potentials at the terminus of the 
QRS complex and represents an anatomic substrate that 
predisposes the patient to reentrant VT. Kuchar et a1655 
reported late potentials to predict an increased incidence of 
sudden death in the post-MI patient population. Gomes et 
a165f' found late potentials to be the best single predictor among 
Holter monitoring and ejection fraction and contributed inde- 
pendently to a combined index, although the positive predic- 
tive value of each was poor. The filtered QRS duration was the 
most predictive feature of signal-averaged lectrocardiography 
in a CAST substudy. ~'57 More recent studies have shown 
reperfusion therapy to reduce the incidence of late potentials 
after acute MI. (,58 In the setting of frequent use of thrombol- 
ysis, the predictive value of signal-averaged electrocardiogra- 
phy has been variable. 65°-65z 
Heart rate variability, an analysis of the beat-to-beat varia- 
tion in cycle length, largely reflects the sympathovagal interac- 
tion regulating heart rate. Heart rate variability can be quan- 
tified in a number of ways, using either time or frequency 
domain parameters. 659 Low heart rate variability, indicative of 
decreased vagal tone, is a predictor of increased mortality, 
including sudden death, in patients after MI ~59,6~° and may add 
significant prognostic information to other parameters. 660 In 
one study decreased heart rate variability was more predictive 
of arrhythmic events than the presence of late potentials, 
Holter-derived data, treadmill test results, or ejection fraction; 
reduced heart rate variability and a late potential by signal- 
averaged electrocardiography was the strongest combined pre- 
dictor. 652 Standards of measurement, physiological interpreta- 
tion, and clinical use of heart rate variability have been recently 
published by a task force of the European Society of Cardiol- 
ogy and the North American Society of Pacing and Electro- 
physiology. 661 The predictive value of heart rate variability 
after MI, although significant, is modest when used alone. In 
combination with other techniques its positive predictive accu- 
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racy improves. However, the most practical, feasible, and 
cost-efficient combination of noninvasive predictive tests with 
heart rate variability remains to be determined. 
Baroreceptor sensitivity also quantifies the influence of 
parasympathetic tone on the heart. Baroreceptor sensitivity is
measured as the slope of a regression line relating beat-to-beat 
heart rate change in response to a change in blood pressure, 
often accomplished by giving a small bolus of phenylephrine. 662
Acute MI-associated reductions in baroreflex sensitivity 
have been associated with an increased susceptibility to 
arrhythmic events and sudden death in experimental models 
and initial clinical reports 6~'3-~5 and are being further charac- 
terized in a multicenter prospective post-MI study (Auto- 
nomic Tone and Reflexes After Myocardial Infarction 
[ATRAMI]). 
Summary/Conclusions 
Although several investigators have reported an increased 
likelihood of arrhythmic events in patients when one or more 
noninvasive test is abnormal, two important caveats prevent 
these techniques from being recommended forroutine clinical 
practice at present. First, although the negative predictive 
value of most of these tests taken in isolation is high (generally 
greater than 90%), the positive predictive value is unaccept- 
ably low (less than 30%). Second, although the positive 
predictive value of noninvasive testing for future arrhythmic 
events can be modestly increased by combining several test 
results, the therapeutic mplications of positive findings are 
unclear. Insufficient data are available to indicate whether 
general therapies, such as /3-adrenoceptor blockade, ACE 
inhibition, and revascularization procedures, or specific inter- 
ventions, such as treatment with amiodarone oran implantable 
cardioverter-defibrillator, argeted for high-risk patients iden- 
tified by a combination ofnoninvasive t sts after MI can more 
favorably impact mortality. ~'6' Moreover, it is difficult o justify 
the costs of the routine use of these procedures inthe absence 
of therapeutic guidelines or demonstrated clinical benefits 
associated with a positive test. Until these issues are resolved, 
use of these tests cannot be recommended in routine manage- 
ment, although they will continue to be of interest as investi- 
gational tools for specific risk-assessment protocols. 
Invasive Evaluation 
Coronary Angiography and Possible Percutaneous 




1. Patients with spontaneous episodes of myocardial isch- 
emia or episodes of myocardial ischemia provoked by minimal 
exertion during recovery from infarction. 
2. Before definitive therapy of a mechanical complication 
of infarction such as acute mitral regurgitation, VSD, pseudo- 
aneurysm, or LV aneurysm. 
3. Patients with persistent hemodynamic instability. 
Class IIa 
1. When MI is suspected to have occurred by a mechanism 
other than thrombotic occlusion at an atherosclerotic plaque. 
This would include coronary embolism, certain metabolic or 
hematological diseases, or coronary artery spasm. 
2. Survivors of acute MI with depressed LV systolic func- 
tion (LV ejection fraction less than or equal to 40%), CHF, 
prior revascularization, or malignant ventricular arrhyth- 
mias. 
3. Survivors of acute MI who had clinical heart failure 
during the acute episode but subsequently demonstrated 
well-preserved LV function. 
Class lib 
1. Coronary angiography performed in all patients after 
infarction to find persistently occluded infarct-related arteries 
in an attempt o revascularize the artery or identify patients 
with three-vessel disease. 
2. All patients after a non-Q wave MI. 
3. Recurrent VT or VF or both, despite antiarrhythmic 
therapy in patients without evidence of ongoing myocardial 
ischemia. 
Class III 
1. Routine use of coronary angiography and subsequent 
PTCA of the infarct.related artery within days after receiving 
thrombolytic therapy. 
2. Survivors of MI who are thought not to be candidates for 
coronary revascularization. 
This section discusses indications for coronary angiography 
and possible angioplasty (PTCA) in patients with acute MI. 
The use of emergency angiography and primary PTCA in 
evolving acute MI is considered separately from use of PTCA 
as an adjunct to thrombolytic therapy (see "Initial Recognition 
and Management in the Emergency Department"). 
Coronary Angiography in the Survivor of Myocardial 
Infarction Not Receiving Thrombolytic Therapy 
All survivors of MI who are candidates for revascularization 
therapy (irrespective of whether they were given thrombolytic 
therapy) with (1) postinfarction a gina, (2) objective vidence 
of ischemia on stress testing, or (3) noninvasive evidence of LV 
systolic dysfunction should be considered for coronary angiog- 
raphy, because PTCA or CABG may be considered in these 
patients if they are found to have significant coronary artery 
disease. 
Coronary Angiography and Possible Percutaneous 
Transluminal Coronary Angioplasty After 
Thrombolytic Therapy 
In the immediate period after intravenous administration f 
thrombolytic therapy, coronary angiography and PTCA have 
been proposed (1) to restore antegrade coronary flow in the 
patient in whom thrombolytic therapy isunsuccessful (adjuvant 
PTCA--a term preferred to "rescue") or (2) to reduce the 
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severity of the residual stenosis of the infarct-related artery in 
the person in whom thrombolytic therapy is successful. 
Adjuvant Percutaneous Transluminal 
Coronary Angioplasty 
Immediately After Failed Thrombolysis 
Intravenous thrombolytic therapy successfully restores an- 
tegrade coronary flow in 75% to 90% of patients with acute 
MI. 667 In those in whom it is unsuccessful, antegrade coronary 
flow can usually be restored with PTCA. Several studies have 
demonstrated the marked beneficial effect of infarct-related 
artery patency (obtained via endogenous, pharmacological, or
mechanical recanalization) on survival in patients with acute 
MI. 5°,~6s Survivors of infarction with a patent infarct-related 
artery demonstrated at 90 minutes after treatment have an 
improved long-term outcome when compared with those with 
an occluded infarct-related artery, even when LV systolic 
function is similar. 669,~'7° Therefore, in patients in whom throm- 
bolytic therapy fails to restore antegrade coronary flow, recan- 
alization of the infarct-related artery via PTCA has been 
advocated to (1) establish early infarct-related artery patency, 
(2) salvage ischemic (but viable) myocardium, and (3) improve 
long-term survival. Only one relatively small randomized 
trial 67~ has assessed the effects of early (performed immedi- 
ately after identification of failed thrombolysis) adjuvant 
PTCA on LV function, subsequent cardiac events, or mortal- 
ity. The results showed a trend favoring better outcomes in 
those assigned to adjuvant PTCA, but the high mortality rate 
associated with failed PTCA in this setting and the lack of 
statistical power of the study argue against its routine use. 
A major problem in adopting a strategy of adjuvant PTCA 
lies in the limitation of accurate identification of patients in 
whom thrombolytic therapy has not restored antegrade coro- 
nary flow, Unless unsuccessful thrombolysis recognized and 
corrected quickly (within 3 to 6 hours of onset of symptoms), 
salvage of ischemic myocardium is unlikely. Unfortunately, 
clinical markers of reperfusion, such as relief of ischemic-type 
chest discomfort, resolution of ST-segment elevation, and 
reperfusion arrhythmias, have limited predictive value in iden- 
tifying failure of thrombolysis. 672 Immediate catheterization f 
all patients following thrombolytic therapy to identify those 
with an occluded infarct-related artery is impractical, costly, 
and often associated with bleeding complications. 673,674 
Even in the patient with documented failure of thrombo- 
lysis, it is unknown if adjuvant PTCA should be attempted. 
First, because xtensive myocardial necrosis occurs when cor- 
onary occlusion has been present for more than 3 hours, 449 
PTCA may not salvage a substantial amount of myocardium, 
considering the time delay associated with presentation f the 
patient to the hospital after onset of symptoms, infusion of the 
thrombolytic agent, recognition of failed thrombolysis, and 
subsequent initiation of PTCA. Second, adjuvant PTCA fails 
to reestablish antegrade coronary flow in about 10% of pa- 
tients, and reocclusion of the infarct-related artery occurs in as 
many as 20% of the remainder. 675 Third, unsuccessful salvage 
PTCA is associated with a high mortality. -~37.23~ Finally, coro- 
nary reperfusion occurs over the subsequent hours in many 
patients with an infarct-related artery that occluded early after 
thrombolytic therapy. Although infarct-related artery patency 
is only 65% to 75% 90 minutes after thrombolytic therapy, it 
rises to 90% by 24 hoursJ '67 Such "late" reperfusion may 
improve survival without he risk of invasive procedures cou- 
pled with thrornbolytic therapy. 
Recent nonrandomized and retrospective studies have sug- 
gested that mechanical reperfusion of occluded coronary ar- 
teries may improve survival in patients with MI and cardio- 
genic shock. 238 Such patients have an in-hospital survival rate 
ranging from 20% to 50% when treated with intravenous 
thrombolytic therapy. 292 Mechanical restoration of antegrade 
coronary flow via PTCA can be associated with a hospital 
survival rate ranging from 40% to 70%. Multicenter, prospec- 
tive, randomized studies are currently under way to objectively 
test these promising observations. 
Hours to Days After Failed Thrombolysis 
Patency of the infarct-related artery is an important predic- 
tor of mortality in survivors of MI. 668,~'~'9 In comparison with 
those with a patent infarct-related artery, survivors of infarc- 
tion with an occluded artery have (1) increased LV dilata- 
tion/ '76 (2) a greater incidence of spontaneous and inducible 
ventricular arrhythmias, ~77 and (3) a poorer prognosis. 67s In 
survivors of infarction, infarct-related artery patency may favor- 
ably influence LV remodeling and electrical stability even if 
accomplished ata time when salvage of ischemic myocardium is 
unlikely (ie, hours to days after unsuccessful thrombolysis). The 
usefulness of PTCA of a persistently occluded infarct-related 
artery 7 to 48 hours after symptom onset was assessed in a 
relatively small number of patients (n=71) in the randomized 
TAMI-6 Study. ~'79 Angiography 6 months later revealed a high 
incidence of infarct-related artery patency in those who did not 
receive PTCA as well as a high incidence of reocclusion i those 
who did, so that infarct-related artery patency was similar in the 
two groups. Not surprisingly, the two groups had similar LV 
ejection fractions, incidence of reinfarction, hospital readmission, 
and mortality during follow-up. Although other studies in very 
small numbers of patients 6s° suggested that routine PTCA of 
occluded infarct-related arteries may improve LV performance, 
there are no convincing data to support the routine use of 
adjuvant PTCA within 48 hours of failed thrombolysis. 
Routine Coronary Angiography and Percutaneous 
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Class III 
1. Routine PTCA of the stenotic infarct-related artery 
immediately after thrombolytic therapy. 
2. Percutaneous transluminal coronary angioplasty of the 
stenotic infarct.related artery within 48 hours of receiving a 
thrombolytic agent in asymptomatic patients without evidence 
of ischemia. 
Occlusive coronary thrombus and subsequent MI occur 
when platelets and fibrin aggregate at sites of endothelial 
injury or atherosclerotic plaque rupture. For several days 
after successful fibrinolysis, platelet aggregation and 
thrombus formation may recur at the site of arterial injury 
and lead to reocclusion, especially if a severe residual stenosis 
is present. Hence, many physicians perform catheterization 
on all patients who have received thrombolysis with the 
intention of performing PTCA if a high-grade residual stenosis 
is present o prevent reocclusion, reinfarction, and death. 
This rationale has led to strategies that include performing 
PTCA immediately (within hours), early (within 48 hours), or 
late (up to 2 weeks) after thrombolytic therapy. A number of 
important clinical trials have addressed each of these strate- 
gies, and their findings merit special mention and careful 
consideration. 
Immediately After Successful Thrombolysis 
Three randomized, prospective trials have examined the 
efficacy and safety of immediate PTCA after thrombolysis. In
the TIMI-IIA study, o73 389 patients received r-TPA, after 
which they were randomly assigned to immediate (within 2 
hours) or delayed (18 to 48 hours) PTCA of the infarct-related 
artery. Left ventricular function, the primary end point of the 
study, was similar for the two groups at hospital discharge and 
6 weeks. The incidence of exercise-induced ischemia was similar 
for both groups. However, those who underwent immediate 
PTCA had an increased incidence of major adverse vents (death, 
recurrent infarction, emergency CABG surgery, or transfusion). 
In the TAMI study ~74 197 patients underwent routine PTCA of a 
stenotic infarct-related artery immediately (90 minutes) or 7 to 10 
days after thrombolytic therapy. Left ventricular ejection fraction 
at 1 week was similar for the two groups, as was incidence of 
reocclusion. Notably, 18% of the patients required a transfusion 
of 2 or more units of blood as a result of catheterization. A similar 
outcome was noted in the European Cooperative Study Group 
VI trial, ~,~ in which 367 patients who received thrombolytic 
therapy were randomly assigned to immediate PTCA or conser- 
vative management, with cardiac atheterization a d PTCA only 
for those with spontaneous or provokable ischemia. Immediate 
PTCA did not influence LV ejection fraction or the subsequent 
incidence of reinfarction. However, those who underwent imme- 
diate PTCA had a higher incidence of recurrent ischemia (17% 
versus 3%), bleeding complications (41% versus 23%), and 
transfusions (10% versus 4%). The study was prematurely termi- 
nated because those who underwent immediate PTCA had a 
higher early (2-week) mortality (7% versus 3%). At l year the 
differences inoutcome persisted. 
Taken together, these trials show no benefit of routine 
PTCA of the stenotic infarct-related artery immediately after 
thrombolytic therapy. Such a strategy does not appear to 
salvage myocardium or prevent reinfarction or death, and 
those subjected to this approach appear to have an increased 
incidence of adverse events, including bleeding, recurrent 
ischemia, emergency CABG, and death. 
Recent studies have provided insight into why routine 
PTCA immediately after thrombolysis may be deleterious. In
these patients, vascular complications at the site of catheter- 
ization account for most of the excessive bleeding and trans- 
fusion requirements. Furthermore, when PTCA is performed 
after thrombolytic therapy in a patent vessel with some ante- 
grade flow, there is more extensive hemorrhage into the vessel 
wall than when either treatment is used alone. 6~2 This may 
further compromise the lumen of the infarct-related artery and 
promote rethrombosis and reocclusion. 
Hours to Days After Successful Thrombolysis 
It has been suggested that elective PTCA of the stenotic 
infarct-related artery hours to days after thrombolysis may 
allow sufficient time for development of a more stable hemostatic 
milieu at the site of previous thrombotic occlusion. In this setting 
PTCA would be safer and more effective in reducing the inci- 
dence of reocclusion and improving survival. Two large random- 
ized, prospective trials have tested this hypothesis, with both 
concluding that (1) there are fewer complications if PTCA is 
delayed for several days after thrombolytic therapy, and (2) 
routine VFCA in the absence of spontaneous or provokable 
ischemia does not improve LV function or survival. In the British 
SWIFT (Should We Intervene Following Thrombolysis?) 
Study, ~3 800 patients with acute MI who received intravenous 
anistreplase were randomly assigned to PTCA within 2 to 7 
days or to conservative management with catheterization a d 
PTCA only for spontaneous or provokable ischemia. There 
was no difference between the two treatment s rategies with 
regard to LV function, incidence of reinfarction, in-hospital 
survival, or 1-year survival. The TIMI-IIB triaP °v randomly as- 
signed 3262 patients who had received r-TPA to routine cathe- 
terization and PTCA within 18 to 48 hours of thrombolysis or
conservative management. At the end of the 6-week follow-up 
period, the two groups had a similar mortality (5.2% versus 4.7%, 
respectively), incidence of nonfatal reinfarction (6.4% versus 
5.8%, respectively), and LV ejection fraction (0.50 versus 0.50, 
respectively). At 1 and 3 years, survival, anginal class, and 
frequency of bypass urgery were similar in the two groups .  684,685 
Thus, in unselected patients receiving thrombolytic therapy, 
PTCA of the stenotic infarct-related artery in the absence of 
evidence of recurrent ischemia within 48 hours does not appear to 
be beneficial. 
It is noteworthy that only recently have data been presented 
to support he policy of performing catheterization a d subse- 
quent revascularization for patients who do have spontaneous 
or inducible angina after MI. The Danish Acute Myocardial 
Infarction (DANAMI) Trial 327 randomly assigned 1008 survi- 
vors of a first acute MI treated with thrombolytic therapy within 
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12 hours of onset of symptoms tocatheterization a d subsequent 
revascularization r standard medical therapy if they showed 
evidence of spontaneous orinducible angina. Those who under- 
went revascularization had less unstable angina nd fewer nonfa- 
tal MIs during a 2 1/2-year period of follow-up compared with 
those patients randomly assigned to medical treatment only (18% 
and 5.6% versus 30% and 10.5%, respectively). 
Days to Weeks After Successful Thrombo!ysis 
Continued clot lysis and remodeling of the infarct-related 
artery stenosis occurs over the days to weeks after success- 
ful thrombolysis, making the underlying residual coronary 
stenosis more stable and less prone to rethrombosis and 
reocclusion. Thus, delaying PTCA for days to weeks after 
thrombolysis might improve survival, even though earlier 
routine PTCA does not. To date there have not been 
adequately sized trials to evaluate this treatment strategy. 
Barbash et a1686 randomly assigned 201 patients treated with 
tissue plasminogen activator to (1) catheterization a d PTCA 
of suitable lesions, including occluded vessels, more than 72 
hours after admission or (2) conservative management with 
revascularization ly for recurrent ischemia. At 10 months the 
groups had similar LV function, rates of reinfarction, and 
mortality. 
Ellis et al 6~7 also assessed late PTCA after thrombolytic 
therapy. Following intravenous thrombolysis, they randomly as- 
signed 87 asymptomatic patients to PTCA at 4 to 14 days or 
conservative management. Those with postinfarction angina or 
ischemia with provocative t sting were excluded. Although those 
having PTCA had less angina t I year, there was no difference in
survival in the two groups. Procedure-related infarction occurred 
in 9.5% of patients, which is similar to that observed when 
mechanical revascularization s attempted earlier in the postin- 
farction course. 6s~ In short, these relatively small studies have not 
suggested that routine PTCA in asymptomatic survivors of acute 
MI is beneficial. It remains to be established whether the more 
widespread use of IIb/IIIa antiplatelet drugs or intracoronary 
stents will alter this apparent lack of benefit. 
Periprocedural Myocardial Infarction 
A situation meriting special attention is the occurrence of 
myocardial necrosis in the setting of revascularization proce- 
dures. Early surgical iterature indicated that although eleva- 
tion of CK and CK-MB was common during bypass urgery and 
generally inconsequential, substantial e evations or the develop- 
ment of Q waves 6~9 have been associated with increased mortality 
and morbidity. Similarly, elevations of CK-MB are common after 
percutaneous revascularization procedures. Initial reports indi- 
cated no increase in adverse outcomes in patients with elevations 
less than 50 IU/L? ~ but subsequent reports have indicated a 
direct relation between CK-MB elevations and both short- and 
long-term adverse outcomes with no obvious threshold ef- 
fect. 691,692 A commonsense guideline based on currently available 
data is to treat patients with an increase in CK-MB more than 
fivefold in the same manner as any other patient with an MI. 
Patients with elevations less than threefold above the upper limit 
of normal may be discharged from the hospital in a routine 
manner, although careful follow-up is indicated because of the 
higher late event rate. Patients with elevations between three and 
five times normal are in an uncertain category; especially when 
the elevation isassociated with clinically apparent abrupt closure 
or side branch occlusion, careful monitoring and routine care for 
patients with myocardial necrosis would be a conservative route. 
This area needs considerable further esearch to determine if
enzyme levations have different meanings as a function of the 
device used and whether the currently observed adverse progno- 
sis is due to the enzyme levation itself or the underlying severity 
of illness of the patients. 
Secondary Prevention 
Management of Lipids 
Recommendations 
Class I
1. The AHA Step II diet, which is low in saturated fat and 
cholesterol (less than 7% of total calories as saturated fat and 
less than 200 mg/d cholesterol), should be instituted in all 
patients after recovery from acute MI. 
2. Patients with LDL cholesterol levels greater than 
125 mg/dL despite the AlIA Step II diet should be placed on 
drug therapy with the goal of reducing LDL to less than 
100 mg/dL. 
3. Patients with normal plasma cholesterol levels who have 
a high-density iipoprotein (HDL) cholesterol level less than 
35 mg/dL should receive nonpharmacological therapy (eg, 
exercise) designed to raise it. 
Class IIa 
1. Drug therapy may be added to diet in patients with LDL 
cholesterol evels less than 130 mg/dL but greater than 100 
mg/dL after an appropriate trial of the AHA Step II diet alone.* 
2. Patients with normal total cholesterol levels but HDL 
cholesterol ess than 35 mg/dL despite dietary and other 
nonpharmacological therapy may be started on drugs such as 
niacin to raise HDL levels. 
Class lib 
1. Drug therapy using either niacin or gemfibrozil may be 
added to diet regardless of LDL and HDL levels when 
triglyceride levels are greater than 400 mg/dL. 
Approximately 70% of coronary heart disease deaths and 
50% of MIs occur in patients who have previously established 
coronary artery disease/'~3 It is estimated that the likelihood of 
fatal and nonfatal MIs is four to seven times higher in patients 
with apparent coronary disease. Several years ago an overview 
*HmG CoA reductase drugs produce the greatest lowering of LDL choles- 
terol. Niacin is less effective in lowering LDL, although it is more effective in 
raising HDL levels. Resins arc rarely sutficiently effective to be used alone, but 
they may be used to supplement lowering LDL with either niacin or HmG CoA 
reductase drugs, See reference 693. 
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of secondary prevention trials using both drugs and diet to 
lower cholesterol demonstrated an approximate 25% reduc- 
tion in nonfatal and 14% in fatal MIs9  3 Recently the Scandi- 
navian Simvastatin Survival Study ~4 reported results in 4444 
men and women with coronary heart disease and moderate 
hypercholesterolemia observed over 5.4 years. Coronary heart 
disease mortality was reduced by 42% and total mortality by 
30% among those receiving simvastatin compared with pla- 
cebo. It is noteworthy that the relative risk reduction seen in 
this trial was similar among those with the lowest quartile 
compared with the highest quartile of serum LDL cholesterol. 
The Cholesterol and Recurrent events (CARE) trial was a similar 
study in a population of patients who had recovered from an 
earlier MI and whose total cholesterol (mean 209 mg/dL) and 
LDL cholesterol (mean 139 mg/dL) were essentially the same as 
the average for the general population. In this trial 4159 patients 
were randomly assigned to either 40 mg of pravastatin a day or 
placebo. After a median follow-up of 5 years, there was a 
significant 24% reduction in the primary end point of fatal 
coronary heart disease and nonfatal confirmed MIs in the prav- 
astatin cohort. 69-~ These results firmly establish the desirability of 
lowering atherogenic serum lipids among patients who have 
recovered from an acute MI. 
The effect of cholesterol lowering combined with low-intensity 
oral anticoagulation  late saphenous vein graft status was also 
recently reported. 69~ In an angiographic trial attempting toreduce 
atherosclerosis in saphenous vein grafts, post-coronary bypass 
graft, aggressive lowering of LDL to less than 100 mg/dL with 
lovastatin, 80 mg daily, in addition to a Step I AHA diet, achieved 
a significant 29% reduction in obstructive changes in the vein 
grafts at 4 to 5 years. There was no additional effect of low-dose 
warfarin in achieving further eduction. 
Approximately 25% of patients who have recovered from an 
MI demonstrate normal total cholesterol but a low HDL choles- 
terol fraction on a lipid profile. Low HDL cholesterol is an 
independent risk factor for development of coronary artery 
disease, 697 and therefore a rationale xists for attempting to raise 
HDL cholesterol when it is found to be low in the patient with 
coronary artery disease. The effect of hypertriglyceridemia is 
more obscure because in many cases the level varies inversely with 
HDL cholesterol levels. However, if moderate to severe hyper- 
triglyceridemia exists in a patient with established coronary 
disease, it is probably desirable to attempt to lower triglycerides. 
The National Cholesterol Education Panel II has recom- 
mended that a complete blood lipid profile be taken in all 
patients with established coronary heart disease. 69s In the 
infarct patient, this should be done at the time of admission or 
no later than the first 24 hours; othe~'ise, there is a minimum 
4-week waiting period after onset of the infarct to allow 
lipid fractions to stabilize and ensure accuracy. During this 
interim all patients hould be treated with a low-cholesterol, 
low-saturated fat diet such as the AHA Step II diet. If 
plasma LDL cholesterol concentrations remain greater than 
130 mg/dL, drug therapy should be initiated with the goal of 
achieving an LDL level less than 100 mg/dL. The drugs 
available for accomplishing this include HMG CoA reductase 
inhibitors, nicotinic acid, and bile acid sequestrants. The use of 
fibrates in patients with established coronary heart disease 
should be reserved for patients demonstrating moderate to 
marked elevations in serum triglycerides as well as low HDL 
cholesterol. In an adjunct study to the Helsinki Primary 
Prevention Trial, gemfibrozil given to patients with known or 
suspected coronary artery disease actually resulted in a trend 
toward more clinical events than in the control group at the 
end of 5 years. ~99 
Rehabilitation programs tressing nonpharmacological in- 
terventions have been shown to achieve significant reductions 
in total cholesterol levels and LDL, with increases in HDL 
levels. 7~ Exercise, weight management, dietary modification, 
stress management, and smoking cessation have all been 
shown to improve blood lipid levels, even without lipid- 
lowering medications. Because most programs are multifacto- 
rial, it is difficult to ascertain which of the treatments are most 
effective. There are data, however, that demonstrate that 
exercise and moderate consumption of alcohol can effectively 
raise HDL levels. 7°1-7°3 
According to a policy statement on lipids by the Council on 
Geriatric Cardiology (personal communication, W. Kannel, 
March 1996): 
Diet and drug treatments available for the correction of 
lipid abnormalities are as effective in the elderly as in the young. 
Clinical trials have shown that such treatment can reduce total 
mortality up to age 70 '~4 and the rate of recurrent coronary 
events up to the age 75. ~'5 In addition, to date, there have been 
no trials to test the value of lipid control for the prevention of 
initial coronary events in older persons. Such treatment appears 
reasonable, however, in those elderly who also have other isk 
factors uch as high blood pressure and diabetes, because their 
risk of a coronary attack is similar to that of persons who have 
already survived an attack. 
Smoking Cessation 
Smoking cessation is essential in patients with acute MI. 
Smoking triggers coronary spasm, reduces the anti-ischemic 
effects of /3-adrenoceptor blockers, and doubles mortality 
after acute MI. 7°4-7°6 Smoking cessation reduces rates of 
reinfarction and death within a year of quitting, but one third 
to one half of patients with acute MI relapse within 6 to 12 
months. 7o7 
Houston-Miller and Taylor 7~'~ advocate a stepped approach 
to smoking cessation: 
• Provide a firm, unequivocal message to quit smoking. 
• Determine if the patient is willing to quit. 
• Determine the best quitting method. 
• Plan for problems associated with withdrawal. 
• Set a quit date. 
• Help the patient cope with urges to smoke. 
• Provide additional help as needed. 
• Follow up by telephone call or visit, 
Nicotine gum and patches have been shown to mitigate 
symptoms of nicotine withdrawal in recovering patients. 7°~ 
These agents are not recommended uring hospitalization 
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due to the sympathomimetic effects of the active ingredient, 
nicotine. However, the dose of nicotine in gums and patches 
is significantly lower than that found in cigarettes and 
may be preferable to cigarette smoking if the patient is 
experiencing acute withdrawal. Clonidine has been shown to 
be effective in women but not menTm; the reason for this 
finding is unclear. Lobeline has not been shown to have 
any advantage over placebo 7~-7L~ but is again under investi- 
gation. 
Long-Term Use of Aspirin 
The long-term use of aspirin in the postinfarct patient also 
results in a significant reduction i  subsequent mortality. In six 
randomized, placebo-controlled trials in which patients were 
randomly selected between 1week and 7 years after the initial 
infarct, meta-analysis reveals a reduction in vascular mortality 
of 13% among those randomly assigned to aspirin with a 
reduction in nonfatal reinfarction of 31% and nonfatal stroke 
of 42%. 7~4 Although all of these trials involved the use of 
aspirin in doses ranging from 300 to 1500 mg/d, a recent rial 
of patients with chronic stable angina pectoris in which aspirin 
75 mg/d was used demonstrated a significant reduction of 34% 
in the primary end point of nonfatal MI and sudden death. 7~5 
This suggests long-term use of aspirin in the postinfarction 
patient in a dose as low as 75 mg/d can be effective, with the 
likelihood that side effects can be reduced. Other antiplatelet 
agents uch as sulfinpyrazone and dipyridamole have been 
used in the postinfarct patient, but there is no evidence from 
these clinical trials that they were any more elficacious than 
aspirin alone. 7j~,,717 Ticlopidine, an antiplatelet agent hat has 
been effectively used in unstable angina and cerebrovascular 
disease, has not been studied in major clinical trials involving 
patients with acute MI. 
Angiotensin Converting Enzyme Inhibitors 
The use of ACE inhibitors early in the acute phase of MI 
has been described earlier. Angiotensin converting enzyme 
inhibitors are also of value in selected patients who have 
recovered from an acute infarction through their ability to 
interfere with ventricular emodeling and thus attenuating 
ventricular dilatation over time. The clinical result is a lessened 
likelihood for development of CHF and death. In addition, the 
likelihood of a recurrent MI may also be reduced. 
The expression of tissue ACE within the heart probably 
arises from vascular endothelium. In the setting of myocardial 
necrosis and fibrosis, relatively high concentrations of ACE 
can be found in the myocardium compared with normal 
ventricular myocardium5 ~s These observations, coupled with 
experience in both the rat model of MI 7> and large random- 
ized clinical trials 72°-722 have established that use of ACE 
inhibitors begun after a patient has recovered from acute MI 
improves long-term survival, provided the infarct was large, 
and anterior in location and results in significant impairment of
LV contractility. Specifically, in the Survival and Ventricular 
Enlargement (SAVE) trial, patients received captopril at a 
mean 11 days after onset of infarction, resulting in an approx- 
imate 20% reduction in mortality? 2~ The Acute Infarction 
Ramipril Efficacy (AIRE) trial, in which patients who had been 
in clinical heart failure during the first day of their infarct and 
were then randomly assigned an average of 5 days after onset 
of infarction to either ramipril or placebo, resulted in an 
approximate risk reduction of 27% in all-cause mortality. 721 
Similarly, the Trandolapril Cardiac Evaluation (TRACE) trial, 
in which patients with LV dysfunction on echocardiogram were 
randomly assigned to receive either trandolapril or placebo a 
median 4 days after onset of infarction, demonstrated a 22% 
reduction in mortality. 722 
The Studies of Left Ventricular Dysfunction (SOLVD) trial 
evaluated the ACE inhibitor enalapril in 4228 asymptomatic 
patients with LV ejection fraction less than 0.35, 80% of whom 
had experienced a prior MI. 723 However, randomization was 
carried out considerably ater on the average than in the SAVE 
and AIRE trials. This prevention arm of the SOLVD trial 
revealed a trend toward improved mortality but not a statisti- 
cally significant difference. 724 On the other hand, SOLVD did 
demonstrate a significant risk reduction of 20% for the com- 
bined end points of death or development of CHF requiring 
hospitalization. 
In secondary analyses of the ACE inhibitor trials, the 
benefit of treatment appears to be primarily in patients with 
anterior infarctions or LV ejection fraction below 40%. Some 
rationale xists for the use of these drugs in all patients after 
MI, based on the observation in the SAVE trial that the 
likelihood of recurrent MI was reduced by approximately 25% 
in treated patients. ~'7° However, this finding is based on 
posthoc analysis and is currently being studied in prospective 
trials. There is also preliminary evidence that patients who 
express a homozygous deletional form of the ACE gene (dd) 
have an increased circulating ACE level and are more likely to 
develop MI than those with the II allele ACE gene. 725 This 
reasoning is also supported by recent observations that myo- 
cardial evels of ACE are also higher in patients expressing the 
dd gene. 72~' 
/3-Adrenoceptor Blockers 
Recommendations for Long-Term Therapy in 
Survivors of Myocardial Infarction 
Class I 
1. All but low-risk patients without a clear contraindica- 
tion to ~-adrenoceptor blocker therapy. Treatment should 
begin within a few days of the event (if not initiated acutely) 
and continue indefinitely. 
Class lla 
1. Low.risk patients without a clear contraindication to 
/3-adrenoceptor blocker therapy. 
Class III 
1. Patients with a contraindication to /3-adrenoceptor 
blocker therapy. 
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Several placebo-controlled trials, involving a total of more 
than 35 000 survivors of MI not receiving thrombolytic therapy, 
have shown that chronic/3-adrenoceptor bl cker therapy re- 
duces mortality through areduction i  incidence of sudden and 
nonsudden cardiac death. Of the available /3-adrenoceptor 
blockers, propranolol, 727 timolol, 72~ and metoprolo1729 have 
been shown to be efficacious in this regard. For example, in the 
Norwegian trial of timolol conducted in the late 1970s in 
survivors of infarction, mortality was reduced from 9.8% in 
those given placebo to 7.2% in those receiving timolol, 10 mg 
twice daily, over an average observation period of 25 months. 
Interestingly, the beneficial influence of timolol on survival was 
sustained for at least 6 years after initiation. 73o Propranolol, 
80 mg 3 times daily, and metoprolol, 100 mg twice daily, 
reduced mortality by 26% and 36%, respectively, in other 
studies.727.729 
The salutary effect of long-term /3-adrenoceptor blocker 
therapy isgreatest inhigh-risk patients, ie, those with evidence 
of large or anterior infarction, and there is continued ebate 
about whether low-risk subjects (ie, those without he follow- 
ing: previous infarction, anterior infarction, advanced age, com- 
plex ventricular ectopy, or hemodynamic evidence of LV systolic 
dysfunction) should be treated with /3-adrenoceptor blockers 
because their long-term prognosis extremely favorable irrespec- 
tive of such therapy. Although adverse ffects of/3-adrenoceptor 
blockers, such as fatigue, depression, sexual dysfunction, ight- 
mares, and difficulty with recognition of hypoglycemia n
diabetics are known to occur, the frequency and severity of 
these effects are sufficiently low to warrant heir use even in 
low-risk patients. Although no study has determined if
long-term/3-adrenoceptor blocker therapy should be admin- 
istered to survivors of MI who subsequently have success- 
fully undergone revascularization, there is no reason to 
believe that these agents act differently in coronary patients 
who have undergone revascularization. 
Antioxidants 
Earlier observational data from epidemiological studies 
suggest hat an increased intake of lipid-soluble antioxidant 
vitamins (vitamin E and beta carotene) is associated with 
reduced rates of cardiovascular events, including acute 
MI. 731-733 In support of these data, one randomized placebo 
control study of vitamin E treatment in 2002 patients with 
documented coronary disease indicated a 77% reduction in 
nonfatal MI but no effect on cardiovascular death or overall 
mortality.734 However, amid-study change in the vitamin E dose 
and some imbalance in the use of/3-adrenoceptor blockers in 
subjects receiving vitamin E make interpretation of that study 
problematic. A recent prospective cohort study of over 34 000 
postmenopausal women indicated that an increase in dietary 
vitamin E but not supplemental vitamin E was associated with 
decreased cardiovascular risk. 735 Regarding beta carotene, sev- 
eral prospective studies have convincingly shown a lack of bene- 
ficial effect on cardiovascular disease, 736-%~ and two studies have 
indicated an increase in lung cancer with beta-carotene treat- 
merit.736.737 
There is even less evidence to support he use of water- 
soluble enzymatic antioxidants for cardiovascular disease. Al- 
though one study suggested reduced cardiovascular risk in sub- 
jects on supplemental vitamin C, 739 the majority of other large 
epidemiological studies have not indicated abenefit, vBt-v33 Thus, 
routine use of vitamin C cannot be recommended. 
Despite promising experimental studies, recombinant su- 
peroxide dismutase failed to reduce infarct size in a well- 
controlled acute PTCA trial. 74o One small study showed a 
trend for reduced restenosis with vitamin E treatment follow- 
ing coronary angioplasty (restenosis rate 35.5% for treatment 
group versus 47.5% placebo; n= 100, P=.06). 741 A larger study 
evaluating the combination of vitamin E in association with 
w-3 fatty acids 2 weeks before elective PTCA showed no 
impact on the restenosis rate. 7~2 
Thus, there is no convincing evidence to support lipid- or 
water-soluble antioxidant supplementation n patients after MI 
or patients with or without established coronary disease. 
Because these agents are not harmless, the growing practice of 
recommending antioxidant supplements in these patients 
should be discouraged until the results of ongoing, well- 
controlled studies become available and unequivocally indicate 
a beneficial effect. 
Anticoagulants 
Recommendations for Long-Term Anticoagulation 
After Acute Myocardial Infarction 
Class I 
1. For secondary prevention of MI in post-MI patients 
unable to take daily aspirin.* 
2. Post-MI patients in persistent AF. 
3. Patients with LV thrombus. 
Class Ila 
1. Post-MI patients with extensive wall motion abnormal- 
ities. 
2. Patients with paroxysmal AF. 
Class lib 
1. Post-MI patients with severe LV systolic dysfunction 
with or without CHF. 
The indications for long-term anticoagulation after acute 
MI remain controversial. A series of studies comparing warfa- 
rin with conventional therapy has demonstrated a reduction in 
risk of death of 13% and reduction in relative risk of both 
stroke and reinfarction of41%.743 The lack of aspirin use in the 
control groups in these trials has made it difficult o assess the 
relative merits of aspirin alone versus warfarin alone. Although 
a cost-effectiveness analysis demonstrates that warfarin com- 
pared with standard therapy without aspirin meets the general 
criteria for cost-effective therapy, the more impressive cost- 
effectiveness of aspirin 744 makes aspirin alone the current 
*See section on "Aspirin, page 13,,14. 
JACC Vol. 28, No. 5 RYAN ET AL. 1399 
November 1, 1996:1328 428 MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
standard antithrombotic regimen for secondary prevention, 
Although an ample theoretical rationale can be developed for 
using aspirin and warfarin in combination as a secondary 
preventive strategy, inadequate mpirical information cur- 
rently exists to recommend it at this time. In a recent report 
evaluating 160 mg aspirin versus 80 mg aspirin plus 3 mg 
warfarin versus 80 mg aspirin plus 1 mg warfarin, there was no 
evidence that combined low-dose aspirin and warfarin reduced 
subsequent events in 8800 patients after MI. Thromboembolic 
stroke rates tended to be higher in low-dose warfarin-treated 
patients as well. 745 
The previous ACC/AHA guidelines trongly recommended 
the use of oral anticoagulants with an International Normal- 
ized Ratio (INR) ratio of 2.0 to 3.0 in patients with a 
ventricular mural thrombus or a large akinetic region of the 
left ventricle for at least 3 months. Despite a number of small 
observational studies demonstrating a higher isk of embolic 
stroke in patients with large anterior infarction and a better 
outcome in patients treated with warfarin after demonstration 
of LV murat thrombus by echocardiography, 746randomized 
controlled trials are not available to support his recommen- 
dation. Concern exists that patients at lower risk were treated 
in the observational studies, so that a firm recommendation 
based on empirical information cannot be made. Warfarin is 
indicated in patients with persistent AF after MI, based on 
results of multiple trials in other patients with AF. 
Calcium Channel Blockers 
Calcium channel blockers are not presently recommended 
for routine treatment or secondary prevention after acute MI. 
In general, calcium channel blockers should be reserved to 
treat the subset of patients with angina or hypertension 
inadequately controlled by other agents. If/3-adrenoceptor 
blockers are contraindicated or poorly tolerated, calcium 
antagonists that slow heart rate (such as verapamil or 
diltiazem) may be appropriate as an alternative for second- 
ary prevention in those patients with preserved LV func- 
tion.230.3~ 1.532,538,542,747 755 
that combining estrogen with a progestin 76° will ameliorate he 
potential beneficial effect of ERT on the lipid profile. 
In 1993 the American Heart Association and the American 
Fertility Society sponsored a consensus conference on post- 
menopausal hormone therapy and the cardiovascular sys- 
tem. 7~ This conference concluded that the limited data 
available would indicate that estrogen therapy did reduce 
mortality in women with moderate and severe coronary 
artery disease. 
Other factors must be considered in recommending ERT. 
These include beneficial effects on osteoporosis, exuality, 
skin tone, and psychological well-being. These must be 
weighed against he concern of the possible increase in 
breast cancer rates, although this is highly controver- 
sial. 7~2,763 A hypothetical population-based analysis by Gor- 
sky et a1764 concluded that there was a health benefit of ERT 
that exceeded any risk. 
The dose of estrogen for postmenopausal women who have 
had a hysterectomy is usually 0.625 mg oral conjugated estro- 
gen or its equivalent once a day. In postmenopausal women 
with a uterus, two dosing schedules are commonly used: 
0.625 mg conjugated estrogen or its equivalent once a day plus 
10 mg progestin (medroxy-progesterone) orally per day for 10 
to 14 days each month or 2.5 mg progestin orally every day. 
Screening procedures for women without a uterus who are 
taking estrogen are no different han for the nontreated 
population. If women receiving cyclic progestins develop 
bleeding other than at time of withdrawal, or women receiving 
continuous progestin develop either heavy, prolonged, fre- 
quent, or intermittent bleeding lasting longer than 10 months 
after the start of progestin, they should be evaluated for the 
bleeding. 7~5 
Given the overall uncertainty about he true benefit of ERT 
in a woman after MI, patient preference is the dominant factor 
in making any decision. Estrogen replacement therapy ismost 
likely of benefit in both primary and secondary prevention of 
coronary artery disease. 
Recommendation 
Estrogen Replacement Therapy and Myocardial Infarction 
The issue of estrogen replacement therapy (ERT) for 
cardiovascular disease in women is far from clear. Observa- 
tional studies 756,757 have been interpreted as indicating that 
oral unopposed estrogen is effective in primary prevention of 
cardiovascular disease. Confounding factors such as compli- 
ance 758 and baseline health in these studies make it difficult o 
be certain of the effect of ERT. 
Recent clinical trials have shown that estrogen given alone 
or in combination with progestin improves the lipid profile and 
lowers fibrinogen. 759 Favorable ffects of estrogen on the lipid 
profile would, theoretically, be expected to produce afavorable 
result in preventing coronary atherosclerosis. There is concern 
Class IIa 
1. All postmenopausal patients who have an MI should he 
carefully counseled about the potential beneficial effects of 
ERT and offered the option of ERT if they desire it. 
Antiarrhythmic Agents 
Given the risks of traditional (Class I) antiarrhythmic 
therapy as observed in CAST, a study that tested suppressive 
antiarrhythmic therapy targeted to patients with frequent and 
complex ventricular ectopy,: there is little support at present 
for the hypothesis that suppression of premature ventricular 
complexes in post-MI patients will lower mortality. Routine 
ambulatory (Holter) monitor ecordings to identify patients 
who should receive antiarrhythmic therapy at the time of 
discharge after an MI is therefore not presently indicated. 
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Amiodarone, a drug with Class III (as well as Class I, II, and IV 
action) has shown promise in some but not all post-MI pilot 
studies. 7~6-76~ These potential benefits of empiric therapy with 
amiodarone after MI were tested recently in two moderate-size 
randomized trials involving post-MI patients at high risk due to 
LV dysfunction (European Myocardial Infarction Amiodarone 
Trial [EMIAT]) or ventricular arrhythmias (Canadian Amio- 
darone Myocardial Infarction Arrhythmia Trial [CAMIAT]). 
In preliminary reports presented at the 1996 ACC Scientific 
Session, amiodarone appeared to reduce arrhythmia death and 
cardiac arrest, but effects on total mortality were not signifi- 
cant. Also, tolerance of long-term amiodarone was poor (40% 
dropout rate). Thus, amiodarone is safe to use after MI, if 
necessary for suppression of severe, symptomatic arrhythmias, 
but /3-adrenoceptor blocker therapy is preferred for general 
prophylaxis. 
VII. Long-Term Management 
The majority of patients need to modify their lifestyle after 
acute M1, Typical recommendations require a change in 
previous behavior, including exercise, diet, smoking cessation, 
stress management, and medication adherence. Achievement 
of these goals is often complicated by denial of the signifi- 
cance of the event, physical deconditioning that may reflect 
a lifelong history of sedentary behavior, and emotional 
distress. Achievement of treatment goals may be facilitated 
through participation in a formal cardiac rehabilitation 
program or home rehabilitation if the patient is sufficiently 
motivated. 
Cardiac Rehabilitation 
Cardiac rehabilitation combines prescriptive xercise train- 
ing with education about coronary risk factor modification 
techniques. Formal rehabilitation programs have been shown 
to effectively improve functional capacity, 7~ promote compli- 
ance, decrease emotional distress, improve quality of life, 
reduce cardiovascular mortality, 77° mitigate ischemic symp- 
toms, 771 promote reversal of atherosclerosis, 772 and reduce risk 
of subsequent coronary events. 773 Cardiac rehabilitation may 
decrease denial, which is known to have a repressive ffect and 
may discourage treatment compliance and recovery after dis- 
charge. 774 
Despite these benefits, only 15% of qualified patients 
participate incardiac rehabilitation, possibly because of lack of 
physician referral, poor motivation, logistical or financial con- 
straints, or a combination of these factorsS 5 Home exercise 
training programs have been shown to be beneficial in certain 
low-risk patient groups, v76 They offer the advantages of con- 
venience and low cost but lack the valuable elements of 
education and group interaction. 
Social integration and social support have been repeatedly 
shown to influence outcomes after acute MI. Social integration 
refers to existence of social ties (eg, spouse, close family 
members, or friends) and degree of participation i  group 
activities (eg, family gatherings, religious affiliations). Social 
support refers to the actual or perceived receipt of informa- 
tion, materials, and/or emotional support. 
Mortality from all causes, including ischemic heart disease, 
is lower in socially integrated individuals. 777 Recurrent cardiac 
events are also significantly lower among persons reporting 
high levels of social integration when compared with socially 
isolated persons. 778,v7~ 
The most effective social support interventions occur natu- 
rally. Family members should be told the importance of their 
support, including the observation that the need for support 
has been shown to last longer than most family members 
realize. 7~° The quality of the support provided is key; support 
has been shown to facilitate treatment compliance but only 
when "policing" is minimized. 7~ Telephone follow-up, cardiac 
rehabilitation, orother group events can be effective methods 
of support for socially isolated individuals. 7°s Family members 
should be offered the opportunity o learn CPR because most 
episodes of cardiac arrest occur within 18 months after hospital 
discharge for acute MI. 1~7 
Return to Prior Levels of Activity 
A significant percentage (14%) of the estimated $56 
billion cost to society of coronary artery disease in 1994 was 
due to lost productivity from temporary or permanent 
disability2 ~2 Return-to-work rates, which currently range 
from 63% vs3 to 94%, 7s4 are difficult to influence because 
they are confounded by factors such as job satisfaction, 
financial stability, and company policies. Return to prior 
levels of activity is a better outcome indicator than return to 
paid employment. 
The majority of patients who remain asymptomatic after an 
uncomplicated acute MI can very likely return to prior activi- 
ties safely within 2 weeks, although few data are available to 
guide this recommendation. I  PAMI-II a study of primary 
PTCA in low-risk patients with acute MI (ie, age less than 70 
years, ejection fraction greater than 45%, one- or two-vessel 
disease, good PTCA result), patients were encouraged to 
return to work at 2 weeks. The actual timing of return to 
work was not reported, but no adverse vents occurred as a 
result of this strategy. 7~5 In patients who desire to return 
to physically demanding activities early, the safety of activity 
can be determined by comparing performance on a graded 
exercise test with the MET level required for the desired 
activity. Table 12 presents energy levels, expressed in METs, 
required to perform a variety of common activities. This and 
similar tables can be helpful in translating a patient's perfor- 
mance on a graded exercise test into daily activities that may be 
undertaken with reasonable safety. 
The physician should provide explicit advice about when to 
return to previous levels of physical activity, sexual activity, and 
employment. Daily walking can be encouraged immediately. 786 
In stable patients without complications (Class I), sexual 
activity with the usual partner can be resumed within a week to 
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Table 12. Energy Levels Required to Perform Some Common Activities 
<3 METs 3-5 METs 5-7 METs 7-9 METs >9 METs 
Self-care 
Washing Cleaning windows Easy digging in garden Sawing wood 
Shaving Raking Level hand lawn mowing Heavy shoveling 
Dressing Power lawn mowing Climbing stairs (slowly) Climbing stairs 
Desk work Bedmaking/stripping Carrying objects (30-60 lb) (moderate speed) 
Washing dishes Carrying objects (15-30 lb) Digging vigorously Carrying objects (60-90 lb) 
Driving auto 
Light housekeeping 
Carrying loads upstairs 
(objects >90 lb) 
Climbing stairs (quickly) 
Shoveling heavy snow 
Occupational 
Sitting (clerical/assembly) Stocking shelves (light Carpentry (exterior) Digging ditches Lumber jack 
Typing objects) Shoveling dirt (pick and shovel) Heavy laborer 
Desk work Auto repair Sawing wood 
Standing (store clerk) Light welding/carpentry Operating pneumatic ools 
Recreational 
Golf (cart) Dancing (social) Badminton (competitive) Canoeing Handball 
Knitting Golf (walking) Tennis (singles) Mountain climbing Squash 
Hand sewing Sailing Snow skiing (downhill) Paddle ball Ski touring 
Tennis (doubles) Light backpacking Vigorous basketball 




Walking (2 mph) 
Stationary bike 
Very light calisthenics 
Level walking (3-4 mph) 
Level biking (6-8 mph) 
Light calisthenics 
Level walking (4.5-5.0 mph) 
Bicycling (9-10 mph) 
Swimming, breast stroke 
Level jogging (5 mph) 
Swimming (crawl stroke) 
Rowing machine 
Heavy calisthenics 
Bicycling (12 mph) 
Running (>6 mph) 
Bicycling (>13 mph) 
Rope jumping 
Walking uphill (5 mph) 
METs indicates metabolic equivalents. Adapted from Table 9.2, p 147. Rehabilitation f the coronary patient (Wenger NL, Hellerstein HK, eds). Haskell WL. 
Design and Implementation of Cardiac Conditioning Program. New York, NY: Churchill Livingstone; 1978. 
10 days. Driving can begin a week after discharge if the patient 
is judged to be in compliance with individual state laws. Each 
state's Department of Motor Vehicles or its equivalent has 
mandated certain criteria that vary from state to state and must 
be met before operation of a motor vehicle after serious 
illness. 7~7 These include such caveats as the need to be 
accompanied, to avoid stressful circumstances such as rush 
hour, inclement weather, night driving, heavy traffic, and high 
speeds. Because commercial aircraft are pressurized to only 
7500 to 8000 feet (personal communication, Federal Aviation 
Administration, February 14, 1996), air travel should be un- 
dertaken only by stable patients (without a fear of flying) 
within the first 2 weeks and then only as long as they travel with 
companions, carry sublingual nitroglycerin, and request airport 
transportation to avoid rushing. 
For patients who have experienced a complicated MI 
(requiring CPR, experiencing hypotension, serious arrhyth- 
rajas, high-degree block, or CHF), driving should be delayed 
2 to 3 weeks after symptoms have resolved. Unstable or symp- 
tomatic patients or patients with complications should also be 
stabilized for at least 2 weeks before commercial air travel 
because of the lowered oxygen tension experienced above 
5000 feet. 
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